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FOREWORD
This report presents the methodology and main findings of the trial of two
high titer measles vaccines conducted in Niakhar, Senegal from 1986 to 1990 by
ORSTOM , Unité de Recherche Population et Santé. This report has been published
as soon as possible after the end of the field work. It is a comprehensive report
aiming at making results available to policy makers and to vaccine producers as
quickly as possible, before formal publications are out.
The data and results are protected by the contract, reproduced in annex,
and by a copyright at the Library of congress, washington, OC, USA.
Further information can be obtained from the director of the study:
Michel Garenne, PhD
Associate Professor of Dernography
Harvard University
Center for Population and Development Studies
9 Bow street
Cambridge, MA 02138
USA.
Phone: 1-617-495-3012
Fax 1-617-495-5418
Bitnet: Michel at harvarda.harvard.edu
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SUMMARY OF MAIN FINDINGS
A randomized vaccine trial was conducted in a rural area of Senegal
(Niakhar) to study the safety, immunogenicity and efficacy of two high titer
measles vaccines given at five months of age: Edmonston-zagreb (EZ-HT) and
Schwarz (SW-HT). Results were compared to the performance of the Standard (low
titer Schwarz) vaccine given at 10 months.
The study was embedded in the national EPI program and based upon a
comprehensive demographic and epidemiologic surveillance system of a rural
population of about 25,000 people. New birth cohorts were recruited over time
and were included in the study when they reached the appropriate age at
vaccination. AlI children were prospectively fo1lowed for 16-39 additional
months. Two sets of birth cohorts were considered separately: cohorts 01-16
randomized in three groups (EZ-HT, SW-HT, Standard) and cohorts 17-24 randomized
in two groups (EZ-HT and Standard). The randomized groups were comparable in
various social, familial and health characteristics. Due to vaccinations and to
medical services provided during the study period, mortality of infants and
children was significantly reduced during the study period.
Efficacy: both high titer vaccines protected against clinical measles.
Efficacy was 89.9% for the EZ-HT vaccine (CI=74.7-95.9, p=1.lE-6) and 82.6% for
the SW-HT vaccine (CI=59.0-93.4, p=1.2E-4). However, rates of vaccine failure
were higher after high titer vaccines than after the Standard vaccine: 5.2 times
more vaccine failures after the EZ-HT vaccine and 8.3 times more vaccine failures
after the SW-HT vaccine. Results were confirmed by a case contact study and by
values of efficacy of the Standard vaccine for older cohorts.
Safety and adverse reactions: among the first 16 cohorts, child mortality
was significantly higher in the two groups vaccinated with high-titer measles
vaccines than in the group assigned to the Standard vaccine. Relative risk of
mortality was 1.80 (CI=1.18-2.74, p=0.007) in the EZ-HT group and 1.53 (CI=0.99-
2.37, p=0.056) in the SW-HT group. Most of the effect occurred in the second and
third year after vaccination and during the rainy season. There were no
significant differences in mortality by sex. The last 8 cohorts were followed
for a period too short to verify this effect. Morbidity was monitored only until
age 12 months and there were no significant differences between the groups. Mild
measles-like rashes occurred frequently after high-titer vaccines given at 5
months. Vaccination with high titer vaccines at 5 months was considered unsafe
in these circumstances.
Immunogenicity: both high titer vaccines were immunogenic at 5 months.
Among seronegative children, seroconversion rates were 98.6% with the EZ-HT
vaccine (CI=95.9-99.9, P=O.OOOl) and 85.5% with the SW-HT vaccine (CI=78.5-
93.2, P=O.OOOl). Immunogenicity of the EZ-HT vaccine was significantly greater
than immunogenicity of the SW-HT vaccine. There was a significant increase in
antibody titers among seropositive children after EZ-HT and SW-HT vaccine.
However, there was no clear evidence of seroconversion among children with high
levels of maternaI antibodies (1000+ miu) in any of the vaccine group.
Furthermore, the geometric mean titer of antibodies 5 months after the high titer
vaccines was lower than 5 months after the Standard vaccine.
Conclusion: in this situation, the use of high titer measles vaccines at
5 months of age does not seem to be justified and alternative strategies for
protecting children against measles at an early age should be investigated.
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RESUME EN FRANCAIS
Une étude randomisée a été conduite dans une zone rurale du Sénégal
(Niakhar) pour étudier l'efficacité, l' inocuité et l' immunogénicité de deux
vaccins à haut titre contre la rougeole administrés à 5 mois: le vaccin
Edmonston-Zagreb (EZ-HT) et le vaccin Schwarz (SW-HT). Les résultats ont été
comparés aux performances du vaccin standard (un vaccin Schwarz à bas titre)
administré à l'âge de la mois.
L'étude a été réalisée dans le cadre du PEV national. Elle était basée sur
un système de surveillance démographique et épidémiologique exhaustif d'une
population rurale d'environ 25.000 habitants. Les cohortes de naissances étaient
recrutées au fur et à mesure et inclues dans l'étude lorsqu'elles atteignaient
l'âge de la vaccination. Tous les enfants étaient suivis prospectivement pendant
une période allant de 16 à 39 mois. Deux groupes de cohortes de naissances
étaient considérés séparément: les cohortes l à 16, randomisées selon trois
groupes (EZ-HT, SW-HT, Standard) et les cohortes 17 à 24 randomisées selon deux
groupes (EZ-HT and standard). Les groupes randomisés avaient les mêmes
caractéristiques socio-économiques et sanitaires. Du fait des vaccinations et
des services médicaux fournis au cours de l'étude, la mortalité des enfants a
été significativement réduite.
Efficacité: les deux vaccins à haut titre ont protégé contre la rougeole
clinique. L'efficacité a été estimée à 89.9% pour le vaccin EZ-HT (CI=74.7-
95.9, p=1.1E-6) et à 82.6% pour le vaccin SW-HT (CI=59.0-93.4, p=1.2E-4).
Cependant, les taux d'échecs des vaccins à haut titre ont été supérieurs à ceux
du vaccin Standard: 5.2 fois plus d'échecs vaccinaux après le vaccin EZ-HT et
8.3 plus après le vaccin SW-HT. Les résultats ont été confirmés par une étude
cas-contact et par l'efficacité du vaccin Standard administré antérieurement à
des enfants plus âgés.
Inocuité et effets indésirables: parmi les 16 premières cohortes, la
mortalité a été significativement plus élevée dans les groupes ayant reçu les
vaccins à haut titre que dans le groupe qui a reçu le vaccin Standard. Les
risques relatifs de mortalité ont été estimés à 1.80 (CI=1.18-2. 74, p=O. 007) dans
le groupe EZ-HT et 1.53 (CI=0.99-2.37, p=0.056) dans le groupe SW-HT. L'essentiel
de la surmortalité est survenue au cours de la seconde et troisième année après
la vaccination et a été concentrée au cours de la saison des pluies. Il n'y a
pas eu de différence de mortalité selon le sexe. Les 8 dernières cohortes ont
été suivies pendant une période trop courte pour vérifier cet effet. La
morbidité, qui a été suivie jusqu'à l'âge de 12 mois, a été la même dans les
trois groupes. Des éruptions similaires à celle de la rougeole ont été
fréquemment observées après les vaccins à haut titre. La vaccination à 5 mois
avec des vaccins à haut titre ne peut pas être considérée comme sans danger.
Immunoaénicité: les deux vaccins à haut titre ont été immunogéniques à
5 mois. Parmi les enfants séronégatifs, les taux de séroconversion ont été de
98.6% avec le vaccin EZ-HT (CI=95.9-99.9, P=O.OOOO) et 85.5% avec le vaccin SW-
HT (CI=78.5-93.2, P=O.OOOO). L'immunogénicité du vaccin EZ-HT a été
significativement plus élevée que celle du vaccin SW-HT. Les titres d'anticorps
ont été significativement plus élevés même chez les enfants séropositifs.
Cependant, aucune séroconversion au sens strict n'a été observée après les
vaccins à haut titre chez les enfants ayant des titres élevés d'anticorps
maternels (1000+ miu). De plus, le niveau d'anticorps 5 mois aprés la vaccination
a été plus faible chez les enfants ayant reçu les vaccins à haut titre que chez
les enfants ayant reçu le vaccin standard.
Conclusion: dans ces circonstances, l'utilisation des vaccins à haut titre
à l'âge de 5 mois ne semble pas justifiée et d'autres stratégies devront être
recherchées pour protéger les enfants avant 9 mois.
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En Afrique de l'OUest, comme dans les autres régions du monde, un nom
précis est donné à la rougeole, maladie habituellement bien identifiée par la
population et distinguée des autres maladies éruptives. Cette facilité par
rapport à d'autres pathologies permet des études fiables de la morbidité et la
mortalité par rougeole au niveau des populations.
En Afrique de l'OUest, cette maladie s'est ainsi révélée comme une cause
majeure de morbidité et de mortalité. Sa gravité y est probablement plus élevée
qu'elle ne l'était autrefois en Europe. La population était consciente de la
gravité, considérant comme un permis de survie le fait d'avoir passé le cap de
la rougeole. Les milieux médicaux aussi: par exemple en 1930, la rougeole était
signalée comme un grave problème parmi les Touaregs. Dans les années 50, les
rapports des services de santé du Burkina Faso, rassemblant les informations des
Circonscriptions Médicales, signalaient "chaque année un lourd tribu est payé
par la rougeole".
Mais le poids n'en était pas mesuré. En effet les statistiques du Service
de Santé renseignent sur les causes de décès survenues à l'hôpital, mais ne
représentent pas la mortalité du milieu rural. La maladie se passant à la maison,
peu de cas étaient présentés à l 'hôpital, et relativement peu de décès y
survenaient, de sorte que la gravité était mal perçue des responsables du Service
de Santé.
La mesure a été possible grâce à des enquêtes représentatives recueillant
les déclarations des familles, et se limitant à certaines causes évidentes,
notamment la rougeole.
L'enquête démographique de la Vallée du Sénégal en 1957-1958 a permis
d'avoir pour la première fois un taux de mortalité par rougeole en milieu rural
en Afrique. Devant son importance, la réaction de certains pédiatres a été de
contester le fait, avec l'argument que "si c'était vrai, ça se saurait"!
Mais la confirmation fut apportée par l'enquête du Burkina-Faso en 1960
et au Nigéria. A ce moment, le vaccin nouvellement mis au point devenait
disponible. Et à la demande du Ministre de la Santé du Burkina-Faso, des études
préliminaires eurent lieu dans ce pays en 1961, avec le vaccin Edmonston B. Elles
ont été suivies d'une campagne de masse de vaccination contre la rougeole au
Burkina-Faso en 1962.
Le vaccin a été proposé au Sénégal en même temps qu'aux autres états de
l'OCCGE. Après quoi, il a été administré au Sénégal en 1963 dans la région du
Sine-Saloum, à Niakhar et à Tattaguine. Mais son inocuité n'ayant pas été jugée
suffisante, le Ministère de la Santé y renonça d'autant plus qu'un nouveau
vaccin, issu de la souche Schwarz, venait d'être mis au point. Une étude en fut
réalisée dès 1965, limitée à la zone pilote de Khombole; puis en 1966, la zone
d'enquête démographique du Sine-Saloum bénéficia d'une petite campagne de
vaccination, précédant la première campagne de masse au Sénégal en 1967.
L'effet de ces premières campagnes a été spectaculaire, arrêtant les cours
des épidémies et faisant chuter l'incidence de la maladie qui s'est traduit par
une baisse de la proportion de consultations par rougeole dans les dispensaires.
Mais c'est seulement au Sénégal qu'a été mesuré l'impact de la vaccination, non
seulement sur la baisse de la mortalité du moment, mais aussi sur la survie des
cohortes. La vaccination, en supprimant la maladie, a permis de montrer que
l'impact de la rougeole était encore plus élevé que si l'on tenait seulement
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compte des décès qui lui sont directement attribués. Il a été ainsi démontré
qu'une action de santé de ce genre peut être décisive pour la baisse de la
mortalité. Et ceci avec une seule vaccination qui assure une protection durable,
en principe toute la vie. De plus, l'avènement de la vaccination contre la
rougeole a changé la nature des déterminants de la maladie et de sa gravité.
Les notions de transmission et de prévention existaient-elle? Au Sénégal,
à Khombole, on a constaté qu'une quarantaine était pratiquée spontanément par
les familles lorsque l'épidémie survenait, afin d'isoler les enfants de la
contagion. Cette mesure a pour conséquence de retarder l'âge de la maladie, et
l'on sait que l'enfant devient relativement moins vulnérable à mesure qu'il
avance en âge après 2 ou 3 ans. En milieu urbain, cette pratique étant plus
difficile à appliquer, les risques de contage sont plus fréquents, d'où
l'atteinte plus précoce de la rougeole.
Quant aux facteurs de gravité, ils portaient sur
associations avec d'autres pathologies, la notion de cas
primaires, et enfin le traitement et les soins traditionnels.
l'âge, sur
secondaires/
les
cas
Depuis la vaccination, le seul déterminant est d'assurer cette
intervention. En général, dès que la vaccination contre la rougeole a été
proposée pour la première fois à une population en Afrique, elle a été acceptée
sans réserve, car au niveau des mères comme de la communauté, tous en avaient
vécu la gravité. Au constat de son efficacité; la vaccination a été considérée
comme un nouveau pouvoir protecteur, à l'instar des protecteurs traditionnels,
et sans doute plus puissants.
Mais, après la première campagne, le système de santé n'a pas pris les
moyens de maintenir une couverture vaccinale suffisante an quantité et surtout
en qualité dans les nouvelles générations. Au Sénégal, le résultat a été qu'après
une période de quatre ans environ, la mortalité est revenue à son niveau
antérieur. L'enquête de santé du Sine Saloum en 1982 l'a confirmé, de même que
dans la zone d'étude du Sine, pendant la période 1983-1984. Cette évolution a
été à peu près la même dans les autres pays d'Afrique Occidentale.
Le nouveau programme de vaccination, entrepris depuis 1986 sous l'égide
de l'UNICEF, a connu un succès analogue aux premières campagnes vingt ans
auparavant; c'est encore la série du Sine qui permit à nouveau de confirmer la
chute de la mortalité par rougeole, ainsi que la série de l'état civil de la
ville de Saint Louis. La question est maintenant de poursuivre de façon
permanente le programme et le système mis en place va dans ce sens.
Mais l'étape décisive dans la lutte contre cette affection, sera
l'éradication à l'échelle mondiale, comme il en a été pour la variole, dont le
dernier cas a été relevé en 1979. C'est dans cette perspective qu'a été réalisée
l'étude des vaccins précoces décrite dans les pages suivantes.
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INTRODUCTION
O. 1 KEASLBS VACCINE RESEARCH IH WEST AFRICA
Historical background
Measles was known for centuries as a major cause of death among children
throughout the world. In tropical Africa, measles was ignored for a long time
by colonial physicians. In their bibliography on population and health in the
Senegambia region, Collignon and Becker (1989) identified only 3 references on
measles prior to 1960, as compared to 151 references on Yellow-Fever. P.
Cantrelle (1959) was among the first to draw attention to measles as a major
cause of death among children in West Africa. Since then, measles has been
recognized as a major public health problem in this region of the world and many
efforts have been devoted to control measles mortality. However, measles
mortality remains very high in West Africa for a variety of reasons.
The discovery of the measles virus by Enders in 1954 and the production
of the first measles vaccines in 1963 resulted in several vaccine trials in West
Africa. In Senegal, the first trial of the so-called Edmonston,B vaccine was
conducted as early as 1963 in Tattaguine, a small town of central Senegal. This
was a collaborative study between the Ministry of Public Bealth (service des
Grandes Endémies), the Faculty of Medicine, Service des Maladies Infectieuses,
Fann Hospital in Dakar and ORSTOM. That same year, a large vaccine trial was
conducted in Burkina-Faso (Upper Volta at that time) in collaboration with the
local Ministry of Public Health and the Centers for Disease Control (CCC).
Results of these trials were disappointing: the Edmonston,B vaccine, a killed
vaccine, was not safe. Adverse reactions were numerous, and the vaccine was
producing severe clinica1 measles in a number of cases.
Chart 0.1 : Attenuation history of sorne measles vaccines
EDMONSTON
HK/24
HA/28
HA/12
Plaque cloning
SK(33°C)/17
CEF(33°C)/12
Clonal isolate
CE(Lam. )/6
CEF(37°C)/13
CEF(36°C)/17
CEF(32"C)/40
WI-38(37°C)/19
Plaqued 3X
SCHWARZ MORATEN EDMONSTON-ZAGREB
Source: WHO/EPI/GEN/88.11. Abbreviations: HK=human kidney, HA=human amnion,
SK=sheep kidney, CE (Lam. )=chick embryo (intraamniotic cavity), CEF=chick embryo
fibroblast, WI-38=human diploid cell line.
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Two new vaccines, live and further attenuated, were produced a few years
later the Schwarz vaccine (1965) and the Moraten vaccine (1968) (see chart 0.1).
They were also tried in Senegal for the first time in 1966, in Niakhar and in
nearby Khombo1e. Again this was a joint project of the Ministry of Public Health,
the Faculty of Medicine and ORSTOM. This time the trial was successful. The
further attenuated vaccines were found to be safe and effective.
Various estimates of measles vaccine efficacy were done at that time. The
Khombole study showed a high efficacy of measles vaccines in a vaccinated village
as compared with neighboring unvaccinated villages; furthermore measles
vaccination was reducing child mortality by 26% when measles deaths accounted
for only 16% of deaths (Garenne and Cantrelle, 1985).
The Schwarz vaccine was also tested in a variety of situations. Chart 0.2
displays measles vaccine trials that were conducted in West Africa over the last
30 years.
The window problem
Infants rarely contract measles before 4 months of age, because they are
usually protected by transplacentally-acquired maternal antibodies. In less
developed countries (LDCs), most infants become susceptible shortly after the
age of 4 months. Measles case-fatality rates (CFR) are highest at younger ages,
particularly between 4 and 12 months.
In developed countries low-titer, live, attenuated measles vaccines are
safe, immunogenic, and effective when given in the second year of life. In LOCs,
the profile of maternal antibodies is somewhat different (Black et al., 1986)
and it is usually recommended that children be vaccinated at the age of 9 months
(WHO, 1982). However, this strategy leaves open a window of high risk of death
from measles between the ages of 4 and 9 months.
The Edmonston-Zagreb vaccine, a live measles vaccine from the Edmonston-
B strain produced by the Institute of Immunology in zagreb, Yugoslavia (Ikic et
al., 1972) was found to produce a better immunologie response than standard
vaccines even when given as early as 4 months of age (Whittle et al., 1984;
1988a, 1988b). Two possible explanations for the performance of this vaccine were
proposed: the strain and the titer, often 10-100 times higher than that of
standard vaccines. A series of recent vaccine trials compared the immunologie
response and the adverse reactions after low, medium, and high titer Edmonston-
Zagreb vaccines with those of other measles vaccines of the sarne titers (Aaby
et al., 1988a; 1988b; Khanum et al., 1987; Gendrel et al., 1988; Tidjani et al.,
1989; Markowitz et al., 1990; Halseyet al., 1991).
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Chart 0.2 Estimates of immunogenicity and adverse reactions in Africa
Country Author Year Strain Titer Age N % Sero- Safety and
loglO (mo) conversion Adverse reactions
Burkina Meyer 1962 EB 4.0 T 5-54 260 50-98 H Fever+Rash
Burkina Kalabus 1965 EB 2.6-2.9 T 9-60 379 97-100 H Rash 7 %
+646
Cameroon Guyer 1975
Cameroun Mouchon 1989 SW 3.0 T 6-10 89+85 84-90 H
Gabon Gendrel 1986 SW 3.4-4.5 T 3-7 52+37 29-45 H
Gambia Whittle 1984 EZ 3.5-4.1 P 73-100 H
" " 85-87 EZ 3.8-4.6 P 111
85-87 SW 4.0-4.6 P 105 79 H
Gambia Teller
G.Bissau Aaby 1985 EZ 4.6 P 234
SW 3.8 P 235
Ivory Co. Lhuillier 1988 SW 3.0 T 6-9 61+85 96-100 H
Kenya Machakos 74-81 SW
Kenya WHO 74-75 SW 3.3 T 4-11 60-100 H
Nigeria Ifekwun. 1980
Nigeria Morley 1962 EB 19 100 H Rash 10 %
SW 21 100 H + deaths?
Nigeria Ruben 1973 SW 3.5 T 6-24 64-89 H
Nigeria Sherman 1967 EB 3.0 T 6-36 88-93 H
BK 3.0 T
Rwanda Ndikuyeze 1987 SW 3.0 T 8-19 63-90 E Rash 2.5%
Sudan omer 1986 SW 3.0 T 3-30 149 42-100 H
Tanzania WHO 1977 SW 3.0 4-60 17-83 H
Tanzania Kimati 1981 6-21 44-91 H
Togo Budd 1965 EB 154 96 fi Rash 29.4%
Togo Tidjani 1988 EZ 5.0 T 4-5 296 96 H
" " AK 3.7 T 4-5 289 94 fi
" SW 5.0 T 4-5 285 50 H
" SW 3.9 T 8-10 117 69 H
" AK 3.7 T 8-10 66 87 H
Zaire Kasongo 74-77
Note: EB=Edmonston-B, SW=Schwarz, EZ=Edmonston-Zagreb, AK=AIK-C, BK=Beckenham.
T= TCIDso ' P=PFU, E=Elisa, H=HI.
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O. 2 MEASLES VACCINATION IN SENEGAL
After conclusive results of the 1966 studies, a major national measles
vaccine campaign was conducted in 1967-1969 in Senegal (phase d'attaque).
According to official records 682,901 children were vaccinated, representing
74.8% of the estimated 1 to 7-year-old population in 1968 (Cantrelle et al.
1985). Measles vaccination was later continued nationwide. Official publications
suggest a high vaccination coverage. However, these figures are to be interpreted
with caution. First they are not necessari1y accurate, since some reports are
missing from certain health posts; second, they mostly concern the urban areas
and western Senegal; third, the size of the susceptible population that was
vaccinated is unknown: chi1dren between ages 0 to 14 years were vaccinated,
including children who already had measles and children who were already
vaccinated once. Therefore, reliable estimates of vaccine coverage could not be
computed direct1y from these data. Routine measles vaccination (phase
d'entretien) was maintained at a relatively high level after 1970, with the
potential of covering at least 75% of the susceptible population.
Measles vaccination was later included in the national Expanded Programme
on Immunization (EPI) in 1978, together with other EPI vaccines (DPT, Polio,
BCG, Yellow-Fever). Mass measles vaccination resumed in Many places with the
start of the "Primary Health Care" program. During the Mid 1980's vaccination
coverage dropped again, especially in rural areas.
A new EPI program began in October 1986, sponsored by UNICEF. This program
was based on fixed post and mobile teams and a strong social mobilization during
national weeks of vaccinations (opérations coup de poing). Measles vaccine
coverage for the target population was estimated in July 1987 at 70% (children
born from July 1, 1985 to June 30 1986). Since then, it is possible that
vaccination coverage has dropped again, especially in rural areas, but reliable
estimates are not available for comparison.
The declaration of measles cases is compulsory in Senegal. The quality of
the registration of measles cases was probably not constant over time. However
it gives a rough idea of disease incidence at the national level (Garenne et
al. 1985). During the years following mass vaccination campaigns (1967-1969),
measles had a much lower incidence: in 1970 the number of measles cases declared
had dropped by 67.3 % of the Mean number for the 5 years preceding the campaign
(1962-1966). However, in the 5 years preceding the start of Primary Health Care
(1973-1977) measles incidence was back at a level comparable to prevaccination
years. After the 1978-1979 campaign, the number of reported cases had dropped
again but only by 23.1%.
0.3 THE NIAIœAR STUDY AREA
There was also a long tradition of demographic research in Senega1 in
collaboration with the Bureau National du Recensement (BNR) and ORSTOM. Most of
this research was conducted in the central part of Senegal and was associated
with measles and measles vaccination studies. Outside of its participation in
the Khombole demographic surveillance (1963-1969), ORSTOM was running prospective
community studies (also called population laboratories) since December 1962, one
in the department of Fatick, the other in the department of Nioro du Rip. The
size of the population under study varied over time: three main periods can be
considered, 1963-1966, 1967-1982, 1983-1989: they are summarized in the chart
0.3.
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Chart 0.3 ORSTOM Prospective Community Studies in Senegal
Fatick
(North West)
Nioro du Rip
(South East)
Phase l : Sine-Saloum : December 1962 - February 1966
all Niakhar arrondissement
65 villages
35,187 people in 1966
1/2 Paos-Koto arrondissement
135 villages
18,988 people in 1966
Phase II : Ndemene-Ngayokheme : December 1962 - February 1983
all secco Ngayokheme
8 villages
about 5,000 people
subsample of previous area
all secco Ndemene
30 villages
about 6,000 people
subsample of previous area
Phase III Niakhar March 1983 - ongoing
CR Ngayokheme + 1/2 CR Diarere
30 villages
about 25,000 people
extension of previous area
18 villages from phase l
8 villages. from phase II
18
(terminated)
Figure 0.1 Location of ORSTOM studies in senegal
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Figure 0.2 Map of the study area.
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Administrative divisions have changed over time in Senegal. They are based
on: Regions (Région), Departments (Département) and Districts (Arrondissements).
From independence until 1983 there were 8 regions. In 1984 two new regions were
created within the former Sine-Saloum: Fatick and Kaolack. Fatick ia the head
of the Fatick region and of the Fatick department. The North West areas were
always located in the department of Fatick, which was part of the Sine-Saloum
Region until 1983 and is now part of Fatick region. The South East area was
always located in the department of Nioro-du-Rip, which was part of the Sine-
Saloum Region until 1983 and is now part of the Kaolack region.
Below district (arrondissement, a unit of 5000 ta 50000 people) was
"Seccos" before 1974. The second phase was based on the seccos of Ndemene and
Ngayokheme, which were sub-samples of the former area. In 1974 "Communautés
rurales" were created. The third study was based on an extension of the
Ngayokheme area, encompassing the rural community of Ngayokheme and half of the
rural community of Diarere.
Measles and measles vaccine information is available in all study areas.
However, is it matchable with current files (Niakhar) only for the 8 villages
of Ngayokheme since December 1962.
0.4 MKASLBS INCIDENCE ABD VACCINATION IN NGAYOKHEME 1963-1989
Data on measles incidence and measles vaccination were nearly complete for
the 8 villages of the Ngayokheme area. They were not fully representative of
the whole area since pilot vaccinations were conducted in the 8 villages in 1966
and special measles vaccination were conducted in 1981, 1982, 1983 again in the
sarne 8 villages within the Dutch Primary Health Care Prograrn with the help of
the ORSTOM tearn. However they can be considered as an upper limit for vaccine
coverage and a lower limit for measles incidence for the area as a whole.
Vaccines delivered and measles cases reported in the Ngayokheme study area
are displayed in table 0.1 and in table 0.2. Vaccine coverage varied strongly
with time. Birth cohorts best vaccinated were those vaccinated in 1966 (1963-1964
cohorts), in 1979-1983 (1978-1981 cohorts) and recently the 1985-1988 cohorts.
These data do not fu11y ref1ect the effort of vaccination in cohorts, because
they do not integrate the competing risks of contracting measles and of dying
prior to vaccination.
Despite the relatively important effort of measles vaccination in this
population, 41.2 , of the 0-14 population was still susceptible to measles in
1987-1989, not counting vaccine failures, and 49.2 , were protected by
vaccination. A few other people age 15-29 years were also susceptible: this will
be seen later when analyzing the age pattern of measles incidence, which ranges
from age 4 months until age 29 years.
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CHAPTER 1
METHOOOLOGY
1. 1 GENESIS OF THE PROJECT
This study had its origin in a series of circumstances. First, in the
beginning of 1986, the Ministry of Public Health was preparing, with the help
of UNICEF, a major push to the national EPI, in a peor shape at that time.
Second, the ORSTOM team of "UR population et Santé" based in Dakar (Michel
Garenne, Oliver Fontaine, Jean-Pierre Beau and Odile Leory) was looking for a
new major research project in Niakhar: the former project on malnutrition and
mortality was ending in 1986 and there was an interest in vaccine efficacy and
in the impact of measles vaccines on child survival. Third, there were contacts
with Peter Aaby and Hilton Whittle who were getting the first results on the
Edmonston-Zagreb vaccine in the Gambia and in Guinea-Bissau. P. Aaby had
collaborated in a recent study on the epidemiology of measles in Niakhar [Garenne
and Aaby, 1990]. It was felt desirable to undertake a forma1 vaccine trial based
on large numbers, and the demographic and epidemiologic surveillance system
already in place in Niakhar was considered particularly appropriate. Fourth, the
Task Force for Child Survival sent a mission to Senegal, in April 1986, with CDC
and APMP experts (Roger Bernier, Mr Giordano and Jacques Drucker) to look for
a field site for a measles vaccine trial on high titer measles vaccines.
At that time, the efficacy of measles vaccines was debated and two factors
were discussed: the strain and the titer. The CDC had gathered a recent meeting
in Atlanta in 1986 to investigate the Edmonston-Zagreb vaccine as well as other
vaccines unknown in the European and North American countries (Leningrad 16, AIK-
C etc ••• ). Among open issues, were the following:
a) does the strain matter for immunogenicity and efficacy? in particular was the
Edmonston-Zagreb vaccine better than standard Schwarz or Moraten vaccines when
given at the same titer?
b) does the titer of the vaccine matter for immunogenicity and efficacy?
c) are measles vaccines safe at a titer as high as 5.0 10g10 TCIDso ' such as the
Edmonston-Zagreb vaccine? WHO recommendations were at least 3. a 10g10 and current
usage was around 3.6 10g10?
Contacts between the Task Force for Chi1d Survival (TFCS), the Faculty of
Medicine and ORSTOM, UR Population et Santé, were taken in Dakar and in May 1986
a first draft protocol was sent for review to the TFCS. The idea of the first
protocol was to compare the efficacy of the Edmonston-Zagreb vaccine administered
at 5 months against the efficacy of a standard Schwarz vaccine administered at
la months. After in depth discussions with CDC experts it was decided:
a) to have 3 groups: Edmonston-Zagreb at 5 months, a Schwarz vaccine at the same
titer as the Edmonston-Zagreb vaccine, also given at 5 months and a standard
Schwarz at la months; furthermore a placebo should be given at 5 months in the
third group to ensure a blind trial.
b) to add an immunogenicity study: this was considered safer in case there were
not enough measles cases; this would also permit quicker results and a comparison
of the two vaccines. The immunogenicity study was supposed to cover the first
5 cohorte.
c) to have a comprehensive safety study built into the protocol.
The final protocol was written and approved at a meeting of the
investigators and TFCS experts (the Scientific Committee) in November, 1986 in
Dakar. It was then submitted to the Ministry of Health for approbation.
Approbation was delivered on July 26, 1987.
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1.2 ORIGINAL RESEARCB PROTOCOL
The main pointa of the reaearch protoco1 are explained here brief1y. The
protocol waa to be fully integrated into the national EPI and implemented in
the 30 villagea of the Niakhar atudy area. From the beginning of the project,
the vaccination team waa in charge of the national EPI in the three local
diapenaariea of Ngayokheme, Toucar and Diohine, covering the whole population
of the 30 villagea. For the Miniatry of Public Health the team waa a mobile
vaccination team (équipe mobile") although vaccinationa were alwaya conducted
in a fixed poat.
Objectives
The primary objective of the study was to evaluate the efficacy between age
5 and 10 months of the EZ-HT vaccine and of the SW-HT vaccine when administered
at age 5 months.
The secondary objectives of the project were:
- to assess the adverse reactions to the injection of high titer measles live
vaccines when administered at age 5 months.
- to evaluate the immunogenicity after high titer measles vaccination at 5
months.
The study was also deaigned to provide information for evaluating the impact
of a new schedule of the EPI on survival of young children and on their morbidity
and nutritional status, as weil as information on the duration of the clinical
protection after early vaccination with high titer vaccines.
Methodology
The study was designed as a randomized blind controlled clinical trial.
Children were randomly allocated at birth to one of the three groups, by a micro-
computer random generator: Group A, received the EZ-HT vaccine at 5 months,
Group B received the SW-HT vaccine at age 5 months and Group C received a placebo
at 5 months and a Standard low titer measles vaccine at age 10 months.
Inveatigators and field workers did not know the type of vaccine each child
received until the code was broken (June 1989).
Children were recruited at birth by the demographic surveillance system.
They were vaccinated at age 3, 5 and 10 months. Vaccinations occurred once a
month and children were grouped by monthly birth cohorts. For instance, a child
born in January was vaccinated in April, June and November and so on. Age was
computed in difference of months between month of vaccination and month of birth.
This is not exact demographic age in months. Children in the 5 months group were
in fact exact age 4.5 to 5.5 months old, since vaccination occurred usually in
the middle of the month. Clinical efficacy was to be aasessed through a
comprehensive surveillance of ail measles cases.
The study. of adverse reactiona was conceived at first as a record of ail
morbid epiaodes aa they were declared by the family. In addition a full record
of mortality was conducted, including the unvaccinated group. Later, a proper
clinical examination by a physician of children vaccinated at 5 months waa
conducted, with emphasis on post vaccination rashes (see below).
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Immunogenicity data were first scheduled to be obtained on the first 5
cohorts only. They were later collected on all cohorts (see below). Blood samples
were routinely taken at the time of the 5 months and the 10 months sessions from
children participating in the trial, except if the family objected. Additional
immunogenicity data were to be obtained at the end of the study on all children
who participated in the study. The data monitoring and safety committee evaluated
the immunogenicity data of the first Bevan cohorts to determine whether
sero-conversion rates were adequate or whether subjects needed to be revaccinated
at approximately 10 months of age.
Parents were informed of the objectives and methods of the study and of
their right to refuse to participate in the trial, and therefore to receive only
the standard EPI vaccines; a few people refused any vaccination (see below 3.1).
OUtside of the EZ-HT and of the SW-HT vaccine, all other vaccines were those
routinely administered in the National EPI: BCG, DPTP (Diphtheria, Pertussis,
Tetanus, Inactivated Polio) and YF (Yellow fever).
1.3 CBAHGBS ro TBB ORIGINAL PROTOCOL
1.3.1 Vaccine delivery
Four major changes were made to the original protocol following the advice
of the Data Monitoring and Safety Committee. The first change was in vaccine
delivery and in duration of the study. A first analysis of data was conducted
in August 1988 and presented at a WHO meeting in Washington in September 1988.
Results showed that the EZ-HT vaccine produced a better serological response than
the SW-HT vaccine. These results corresponded to the results of the seven other
studies presented at the meeting. The Data Monitoring and Safety Committee met
in Dakar in OCtober 1988 and recommended dropping the SW-HT vaccine (the B
group). The Data Monitoring and Safety Committee met again in Dakar on June 28-
30, 1989. In reviewing the available data, it recommended stopping the trial,
after only 24 cohorts instead of 28 originally planned. However, vaccination of
the population would continue with the EZ-HT vaccine at 5 months, when possible,
and with the Standard vaccine at 10 months or more in other cases.
Chart 1.1 Vaccine schedule, according to birth cohort (project children)
Group 3 months 5 months 10 months
l Cohorts 01-16
A DPTP-l + BCG DPTP-2 + EZ-HT DPTP-3 + YF
B DPTP-1 + BCG DPTP-2 + SW-HT DPTP-3 + YF
C DPTP-l + BCG DPTP-2 + placebo DPTP-3 + YF + Measles
II- Cohorts 17-24
A DPTP-l + BCG DPTP-2 + EZ-HT DPTP-3 + YF
C DPTP-l + BCG DPTP-2 + placebo DPTP-3 + YF + Measles
NB the 3 months session was conducted at 8 months for the first 2 cohorts.
(see table 3.6 for details).
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Therefore, the effective vaccination protocol was (chart 1.1):
- for the first 16 cohorts (01-16), vaccinated at 5 months from August 87
until October 88 : 3 groups (A, B, C)
- for the next 8 cohorts (17-24), vaccinated at 5 months from November 88
until June 1989 : 2 groups (A, C)
- the last 5 cohorts (25-29), did not participate in the trial, although they
were vaccinated during the last 5 months of the study; cohorts 26-29 were
vaccinated at 5 months with the EZ-HT vaccine. Cohort 25 (children born in
February 1989) did not receive the EZ-HT vaccine at 5 months in July 1989; it
received the Standard vaccine at la months.
1.3.2 Revaccination of seronegative children
At the second meeting of the Data Monitoring and Safety Committee it was
also felt that children belonging to groups A and B, who had received a high
titer measles vaccine at 5 months and who did not have detectable levels of
measles antibodies at la months should be re-vaccinated. All children from the
first 16 cohorts who had no detectable antibodies at la months were then re-
vaccinated in April 1989. They were randomly assigned to a group: either the EZ-
HT vaccine or the Standard measles vaccine. A blood sample was taken at time of
re-vaccination and 28 days later (see below 5.5).
1.3.3 Decay of antibodies
The third change in the protocol was the study of decay in measles
antibodies after vaccination. At the second meeting of the Data Monitoring and
Safety Committee it was felt that measles incidence was low (only 28 cases of
all ages had been recorded at that time) and that more data on decay of
antibodies over time was needed. consequently, all children in the first 16
cohorts who were incompletely vaccinated and who came to at 1east one of the 5
or la months sessions were called back: their vaccines were completed (eg a third
DPTP) and an additional b100d sample was taken. Cohorts 01-04 were called in May
1989 (at age 24-27 months), cohorts 05-08 were called in June 1989 (21-24
months), cohorts 09-12 were called in July 1989 (18-21 months) and cohorts 13-16
were called in August 1989 (15-21 months). Among them, there were children
vaccinated with one of the three measles vaccines and unvaccinated children. A
1ast blood sample was taken at that time for the study of the decay of measles
antibodies.
1.3.4 Adverse reactions
The fourth change in the protocol was for the study of adverse reactions.
At the first meeting of the Data Monitoring and Safety Committee it was felt that
the recording of morbidity from family declaration, although interesting, was
not enough to document small adverse reactions such as post vaccination rashes.
Hence, after each vaccination session following this meeting (sessions la to
24) the project physician was assigned a group of 15 children randomly selected
among those vaccinated at 5 months. Each of these children were visited 5 times
from day 1 to 28 after vaccination and carefully examined (see below 4.3).
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1.4 THE DEMOGRAPHIe SURVEILLANCE SYSTEM
The whole study was based on the demographic surveillance system. In fact,
official vital registration in the area was virtua11y use1ess: 1ess than one
third of births and less than 10 % of deaths were registered in Niakhar;
furthermore, dates of birth or death were often wrong since the registration may
have occurred months or even years after the event.
The demographic surveillance system existed in the new study area since
March 1983 and in the old area since december 1962. Before this study, it was
mainly basad on a yearly census. Since January 1987, it has been based on weekly
visits to households. Risks of missing events were extremely low during the
weekly visits and furthermore censuses were conducted over the periode In
December 1986 a formal census of the whole area was taken. In June of 1987 and
1988 light control censuses were taken by updating the list of residents and
maternity histories for women. A formal census was again conducted in July 1989.
The study area was dispatched in 11 enumeration areas of about the sarne
size. Each area was covered by one field worker. Each week, the 11 field workers
visited each of the 1770 compounds of the study area and recorded all new
demographic events: births, deaths, migration, changes in marital status as well
as weaning. In addition they asked about any case of suspected measles and
pertussis. Each suspected case was immediately reported to the physician. All
events detected during the weekly visits were properly recorded on an event forme
There was a special form for each category of event. Each of the field workers
had the right to take a month of vacation each year. This was done month after
month (first going in January, second going in February etc.). The twelfth field
worker was utilized to replace his colleague on leave. He went on vacation the
twelfth month. The demographic surveillance with weekly visits to households
was continued over the 36 months of the project for the whole area, from January
1, 1987 until December 31 1989, without any discontinuity except for the few
official holidays.
In addition, field workers routine1y recorded the absences and the morbidity
of all study children as reported by the mother or the family, from the first
vaccination date (the 3 months session) until their first annual birthday (age
12 months).
The two supervisors had two weekly contacts with their field workers. They
checked the work of the last 3 days, collected the event forms and randomly
reinterviewed 2 compounds per field worker per week. Events forms were sent each
week to Dakar, on Friday afternoon. They were checked again and coded prior to
entry into the micro computer. Hence the population file was continuously updated
in the computer and served as a basis for calling new birth cohorts for
vaccination.
The key for the enrollment in the project was the early detection of live
births. This was done systematically by following up pregnancies for women who
were resident for a long period and by systematic questioning for women who
recently settled, e.g. new wives. All together, for the 24 monthly birth cohorts,
live births were reported to Dakar headquarters within a month in 96.4 % of
cases, an additional 1.5 % the second month, and 1.0 % the third and fourth
month. The 27 others (1.1%) were already too old to be enrolled in the project
when notified. They were added to the statistics as children absent at the 5
months session.
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1.5 EPIDEMIOLOGIe AND CLINICAL INVESTIGATION
As mentioned above, the field workers notified the field physician of all
suspected cases of measles. In addition, strict monitoring of the dispensaries
was also conducted at least once a week and almost every day in the case of an
outbreak. Once a case was suspected, the physician went to the compound for a
comprehensive clinical and epidemiological investigation.
At the first visit by the physician, an investigation was conducted in six
steps:
a) the children age 0-14 living in the compound were listed, including residents
temporarily absent and visitors; this was done systematically by asking all women
living in the compound and later by matching with the field worker's list;
b) the history of contamination of the index case or cases was reconstructed,
by questioning the mother or other family members. In general it was possible
to find out where the index case was most likely infected. Secondary cases were
usually found during next visits;
c) a clinical examination of all cases was conducted at time of the first visit
as well as a clinical examination of all susceptibles (who never had measles).
d) a blood sample was taken for all cases and susceptibles;
e) all sick children were treated;
f) neighboring compounds with social contacts with infected children were visited
in hope of early detection of new cases.
Infected compounds were revisited twice a week until the last case was fully
cured, ie until desquamation had finished. Revisiting infected compounds implied:
a) updating the list of cases.
b) monitoring the clinical signa among cases not yet cured.
c) taking a blood sample for all cases about 28 days after onset of first
symptoms.
d) treating sick children.
1.6 INFORMATION OF THE POPULATION
Prior to the vaccine trial, all governmental and health authorities as well
as traditional authorities of the study area were visited and the methodology
of the study was explained by the investigators. Then, all villages were visited
by the field physician, who was often accompanied by one of the investigators.
Meetings were organized with men and women under the authority of the head of
the village. The aims of the study and the right to refuse or to withdraw at any
time were explained to the people in words easy for them to understand. In
addition, field workers had to explain again individua11y to a11 mothers the aims
of the study and their rights at the time of vaccination. Mothers had to give
an oral informed consent prior to having their children vaccinated. As it will
be sean below (see 3.1) a relatively high proportion of mothers refused to
participate in the trial (about 20 \).
1.7 MEDICAL SERVICES PROVIDED TO THE POPULATION
During the duration of the project, a special effort was made to provide
the population with appropriate medical services, to the extent personnel and
financial means permitted (chart 1.2). Medical services were integrated into the
local system of primary health care as much as possible. systematic use and
promotion of essential drugs was continued during the study period. A list of
these is provided in annex A-3. A separate study of use of medicines in the
population was conducted in 1988.
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A) Vaccinations
Free vaccination was provided not only to project children but also to
aIl other children age and to adults who came on vaccination day to one of the
three dispensaries. Free tetanus toxoid immunization was provided to aIl pregnant
women who came for antenatal care as weIl as to aIl other persons who came for
this purpose.
The vaccination sessions were conducted in the local dispensaries and
vaccines were administered by the local nurses (infirmier) under the strict
supervision of the vaccination team. This did not change the vaccination habits
of the people and the standard national EPI program could continue after the end
of the project without any disruption. During the vaccination sessions, free
medical services were provided to the project children. In addition, standard
fee consultations was provided to aIl sick people of aIl ages who came to the
dispensary (see below).
B) Home visits
During his visits to the infected compounds, the physician treated free of
charge aIl persons of any age who needed treatment. When required, people were
referred to the nearest hospital, in general to Fatick, sometimes to Kaolack or
to Dakar when necessary.
C) Dispensary consultations and antenatal care
In addition to their work in the field, the physicians provided
consultations in collaboration with the local nurse once a week in each
dispensary of the study area: Tuesday in Ngayokheme, Wednesday in Toucar and
Thursday in Diohine. AlI people were properly treated when possible, others were
referred to the nearest hospital. Sporadic antenatal care with a physician, about
once a month, started in 1986. During the project antenatal services were
provided regularly, on a weekly basis after 1987. From January 1987 there was
one full time physician in Niakhar. In April 1988 he was assisted by a second
physician who was in charge of pertussis cases investigation. In March 1989 a
third physician joined who was in charge of the follow-up of pregnant women and
tetanus toxoid immunization, and later participated in a study on AIDS and
sexually transmitted diseases. A list of physicians who participated in the
study is provided in annex A-S.
D) Detection and treatment of malnourished children
Malnourished children were systematically screened during vaccination
sessions, home visits and dispensary consultations. In 1987 and early 1988 they
were referred to Pikine (near Dakar) where ORSTOM UR Population et Santé runs
a center for nutritional rehabilitation (Dr Jean-Pierre Beau). In August 1988
a small unit was opened in Toucar dispensary; the unit was closed in December
1988 and after this date children were either referred to Fatick where a new unit
(CREN) was opened or to Dakar when needed.
E) Malaria treatment and prophylaxis
In order to facilitate the early treatment of malaria, anti-malaria pills
(chloroquine) were given in small quantities (10 pills of 100 mg) to aIl mothers
who brought a child for vaccination. Mothers received the necessary advice about
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how to use the pills. Children with measles were also systematically given anti-
malaria prophylaxis. All children or adults who were found to be sick during a
home visit or in a dispensary were offered anti-malaria treatment. In addition,
large quantities of chloroquine were distributed in the local dispensaries when
there was a shortage of this drug. Sorne 80,000 chloroquine pills were distributed
during the course of the project.
1.8 ORGAHIGRAH
The project was a collaborative project with several institutions and
researchers. The list of researchers and advisers is provided in annex A-S.
Scientific committee
The scientific committee (SC) met once in November 1986 to discuss and
approve the protocol. A list of members who participated in the committee is
provided in annex A-S.
Data monitoring and safety committee
The Data Monitoring and Safety Committee (DMSC) met four times at about
9 months intervals after the start of the project: in January 19-21, 1988,
October 25-27, 1988, in June 28-30, 1989 and in June 1990. The DMSC was composed
of representatives from participating institutions. A list of members is given
in annex A-S.
Technical committee
The Technical Committee (TC) met every week during the entire period of
the study, usually on Friday afternoon from 4 to 6 PM.
1.9 TIMBTABLB
A timetable of the project is presented in chart 1.3. The study per-se
lasted almost exactly 3 years in the field, from December 1986 until December
1989. However, the efficacy study was prolonged until August 1990, after the end
of the third measles outbreak. The mortality study was prolonged until OCtober
1990, after the last check during the third rainy season. About 5 years elapsed
between the first draft protocol and the final report.
Most of the analysis refers to the period between August 1987 and December
1989: tables are labelled "Niakhar, 1987-1989". Mortality tables relating to the
period from August 1987 to October 1990 are labelled "Niakhar , 1987-1990" •
Efficacy tables relating to the period from August 1987 to August 1990 are also
labelled "Niakhar, 1987-1990".
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Research Council based in Fajarah, the Garnbia, provided laboratory facilities,
supplies and personnel throughout the project.
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Chart 1.2
Date
Medical services provided to the study population during the
course of the project (in addition to the normal activity of
the three dispensaries)
Medical services and personnel
l Medical Services
December 86-April 87 - free vaccination of children 0-23 months
(national EPI campaign).
August 87-December 89 (duringvaccination sessions)
- free vaccination of new cohorts, born after
February l, 1987;
- free vaccination of other children and adults;
- free tetanus toxoid immunization of pregnant women
or any person who needed one.
January 87-December 89 (in dispensaries, 3 times a week)
- fixed fee consultation in dispensaries;
- fixed fee antenatal visit+care;
- free essential drugs when needed;
- free medical care+drugs during home visits;
- free referral to hospital when needed;
- free referral+fixed fee treatment for malnourished
children.
- antenatal visits
August 86-December 87 - sporadic antenatal clinic
January 88-December 89 - systematic antenatal clinic,
with TT immunization.
II Medical personnel
January 87-March 88
-
1 full time physician + 1 part time physician
April 88 - February 89
- 2 full time physicians + 1 part time physician
March 89 - August 89
- 3 full time physicians + 1 part time physician
September 89
- Dec 89
- 3 full time physicians + 1 full time midwife
NB Fixed fee consultation was the self financing of the primary health care;
the team provided drugs for free and gave the money to the local
"comité de gestion".
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Chart 1.3 Timetable of the project
- April 1986 : first contacts between ORSTOM, the Ministry of Health,
the Faculty of Medicine and the Task Force for Child Survival.
- June 1986 : first draft protocol.
- OCtober 1986 discussion of the draft protocol in Atlanta;
- November 1986 meeting of the scientific committee; approval of the
protocol.
- December 1986 : baseline census.
- January 1987 : composition of the team; full time physician arrives in
Niakhar; the demographic and epidemiologic surveillance
systems with weekly visits installed.
- February 1987 : registration of the first birth cohort.
- March 1987 : high titer measles vaccines received in Dakar.
- July 1987 : formaI approval of the Ministry of Public Health.
- August 1987 : first 5 months vaccinations (cohort 01 and 02).
- January 1988 : first meeting of the Data Monitoring and safety Committee
- September 1988 : WHO meeting on the EZ vaccine in Washington;
first results on seroconversion presented (cohorts 01-07)
- OCtober 1988 : second meeting of the DMSC;
decision to drop the high titer Schwarz group made;
Lmplementation started in November 1988.
- June 1989 third meeting of the DMSC;
the code is broken; first results on efficacy presented;
decision to stop the trial is made;
decision to continue supporting the vaccination of the last
cohorts until aIl children had their la months vaccination.
- september 1989 : expatriate physician (O. Leroy) leaves;
field work and vaccination continued until December 31, 1989;
a new team arrived for the Pertussis trial.
- November 1989 : last vaccination at la months (cohort 24);
Principal Investigator (M. Garenne) leaves Senegal.
- December 1989 : Pertussis project started;
Measles Surveillance and ascertainment will continue for 4
more years, supported by WHO.
- April 1990 demographic data for the 1989 period entered;
laboratory work completed for the vaccinated children.
- May 1990 : demographic data cleaning.
- July 1990 : end of the third measles outbreak.
- October 1990 : check on deaths among project children.
- February 1991 : mortality data presented at WHO, Geneva.
- March 1991 : census performed; a few errors in deaths detected.
- May 1991 : last corrections on deaths made.
- June 1991 : final report presented.
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CHAPTER 2
STUDY POPULATION
This chapter briefly introduces the study population and the basic features
of population dynamics which were the basis for the recruitment of birth cohorts
and for the study of survival after vaccination. Details of the computations of
age and person-years which are a key for most rates computed thereafter are
provided in annex A-4. Most of demographic data were up-dated in April 1990,
before the final results of the 1991 census were known.
2.1 DEFINITION OF THE RESIDENT POPULATIOH
The population under study was the resident population of the 30 villages
listed in annex A-6. The details of the demographic surveillance system as weIl
as the definitions used for the study are listed in the manual of instructions
ta the field workers. The definition of residence was the same as during the
former study on malnutrition and mortality, 1983-1986: this period was used as
a "baseline" for comparison of various demographic variables during the 1987-
1989 period. The definition of residence was based on usual residence and the
"6 months and rainy season" rule: people who moved out for more than 6 months
and did not spend the last rainy season were considered as outmigrant; people
who stayed for more than 6 months and stayed during the rainy season were
considered as immigrant. Precise definitions are always arbitrary but various
checks showed that the total population of the study area was known within a
margin of approximately ± 1%.
2.2 POPULATION DYRAMICS
The period for the study of population dynamics covered three years, from
January l, 1987 ta December 31, 1989. The resident population of the 30 villages
of the study area accounted for 24,202 resident of aIl ages on January l, 1987,
just after the December 1986 census and for 26,356 resident of aIl ages on
January l, 1990. The total person-years lived was 75,342, that is an average
population of 25,114 people.
Population growth was 28/1000 person-years over the study period which
was more than during the baseline period (15/1000). Table 2.1 displays basic
demographic rates and events over the 1983-1989 period. Over the three years of
the study, there were 3713 live births, 1291 deaths, 2956 immigrants and 3224
outmigrants. The crude birth rate was on the average slightly lower than during
the previous period 1984-1986. The crude death rate showed a marked decrease
between 1984-1986 and 1987-1989. During the study period, immigration was higher
and outmigration lower than before. A more thorough analysis of fertility and
mortality is presented hereafter.
The age pyramid (figure 2.1) revealed the high fertility-high mortality
situation. Most of the irregularities among the young adults of bath sexes in
the pyramid are genuine and due ta a strong age specific pattern of migration.
There were marked seasonal variations in birth, death and migration rates
(table 2.2). There were more births and deaths during the rainy season (July ta
October) and more in and out-migration at the end of the dry season which is the
season during which marriages occur.
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Figure 2.1
AGE STRUCTURE
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2 • 3 FERTILITY AND THE RECRUITMENT Ol!' BIRTH COHORTS
Fertility is best assessed by computing the Total Fertility Rate (TFR),
which gives a measure of fertility independent of the age composition of the
population. This was done separately for males (fathers) and females (mothers)
(table 2.3). Female age specifie fertility rates were computed directly by
dividing the number of live births to women in each age group by the person-
years spent by the women in the same age group. TFR is the suro of the age
specifie fertility rates. Live births are counted here if and only if the mother
was resident at time of birth.
Computations for male fertility raised a question of residence. The mother,
and therefore the birth, could be resident but the father might not necessarily
be resident; conversely a father who was resident couId have children from a
woman living outside of the study area. Here, the live births to non resident
fathers (11.0 \ of aIl live births) were allocated proportionately to the ages
of other resident fathers; this compensated for births outside of the study area
to fathers who were resident. After this correction, computation of male TFR
was the sarne as for female TFR.
The three years of the study pariod were compared to the 1984-1986 period
considered as a baseline. Both female and male fertility were markedly stable
(figures 2.2 and 2.3): the female TFR fluctuated around 7.9 children par woman
over life time, with a small variation of ± 2\; the male TFR fluctuated with
the sarne variations around 13.0 children per man over life time. These
fluctuations were smaller than those of the crude births rates, which means that
a large part of the yearly fluctuations in the number of births was due to
fluctuations in the number of susceptible adults. In any case, the yearly
variations of the number of births were small and the reliability of the
recording system remained stable over time.
Seasonal variations were far more pronounced. The number of live births
par month, which determined the size of vaccination cohorts, varied from a low
71 (June 88) to a high 154 (November 88). The mean number of live births per
month was 103 with a random standard deviation of 20 and an interval of
confidence of [83-123]. other fluctuations were not random and there were
significant seasonal variations, with a peak at the end of the rainy season
(September, October) and a low at the end of the dry season and beginning of
the rainy season (June, July).
The sex ratio of live births was 104.6 (CI=100 .1-109.2) , which is
consistent with former values of 105 found in this population as weIl as in
other populations throughout the world. There was a ratio of 1/68 of twin
deliveries and 1/4343 of triplet deliveries, which are also values consistent
with other populations (table 2.4). 8.2\ of aIl deliveries were still births.
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Figure 2.2
AGE SPECIFIC FEMALE FERTILlIY RATES
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2.4 HORTALITY DBCLlNE
Mortality was lower during the 3 years of the study (1987-1989) than during
the 3 preceding years (1984-1986). An abridged life table was computed for each
sex (table 2.5). The life table was computed using standard formulae (Chiang,
1984). The starting point was age specifie death rates (ASDR), computed directly
by dividing deaths in each age group by person-years at risk.
Probably for the first time in the history of these villages, life
expectancy exceeded 50 years for a significant period of time (51.9 for males
and 52.5 for females). Infant mortality was 97.7/1000 for males and 108.3/1000
for females and child mortality age 1 to 5 was 135.0 for males and 141.2 for
females.
When compared to the baseline period 1984-1986, mortality dec1ine was
noticeable at all ages (table 2.6 and figure 2.4). The crude death rate (COR)
in 1989 was 49% lower than the COR in 84-86, i.e. mortality was reduced by half
over the course of the study. Largest gains were obtained among children below
age 5 years. This indicates that care provided by the project physicians was
efficient. In fact mortality decline was more pronounced in 1988 than 1987 and
greatest in 1989. This effect could be matched with the number of full time
physicians in the study area: approximately 1 physician in 1987, 2 in 1988 and
3 in 1989 (see chart 1.2 for details of interventions). Although the ratio of
people to physicians remained low by developed countries standards (8574
persons/physician in 1989) it was definitely higher than over the 84-86 period
where only 1 physician was taking care of the whole department of Fatick which
covers about 200,000 people.
Changes in mortality were significant in all age groups of infancy and
childhood and virtually for all causes of death (table 2.7 and figure 2.4). In
the neonatal period there was a reduction of 26%, probably due to better care
and treatment of the newborn. The decline in neonatal tetanus mortality was not
as marked as it could have been. This was probably due to two factors: 1)
systematic vaccination of pregnant women started in 1987 only and was generalized
in 1988 and therefore could not have a large effect on births before 1989; 2)
it seems that tetanus mortality was lower than normal in 84-85 because of a
marked drought in 83-84; this tended to diminish the overall effect of a marked
neonatal tetanus mortality decline from 1987 to 1989 (- 55.1%). A significant
effect of the rainy season on neonatal mortality has been documented elsewhere
(Leroy and Garenne, 1988; Leroy and Garenne, 1990). A comprehensive studyof
neonatal tetanus is in process and will be published separately.
Decline in mortality due to other diseases preventable by vaccinations
was close to full control. Decline in measles mortality was 100% for the post-
neonatal period and 85.8% for children 1-4 years. Decline in pertussis mortality
was 100% in all age groups. Better control of diarrhea and ARI mortality was
achieved through systematic use of Oral Rehydration Therapy (aRT) and through
the use of selected and appropriate antibiotics.
Maternal mortality was also reduced by half and other adult causes of
death were reduced mostly through a good referral system to hospitals and help
in treatment when necessary. A more detailed analysis of the control of morta1ity
will be published separately.
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Figure 2.4
CHANGES IN MORTALITY
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2.5 MIGRATION FLOWS
Migratory movements were difficult to compare with precision to previous
periods since the method of data collection was not strictly the same, although
the definitions were identical. Before this study, migration data were collected
only once a year, at the time of the yearly census; hence all small term
migration movements in and out between two censuses had no chance of being
recorded, whereas this became possible with the weekly visits. However migration
flows fluctuated between 108.9 and 156.3/1000 over the study period, a range of
variation similar to that of the 1984-1986 period (104.8 to 150.4/1000).
Migration played a relatively important ro1e in the efficacy study and in the
morta1ity study. In each case, the exact period of exposure to risk was computed
to discount for the effects of migration.
2.6 PROJECT CBILDRBH
Chi1dren e1igib1e for the study, ca11ed project chi1dren, were those born
to mothers resident in the study area, from February l, 1987 unti1 January 31,
1989 (24 month1y birth cohorts). Chi1dren cou1d be born outside of the study
area, in Dakar for instance, but the mother had to meet the residence criteria
at time of de1ivery. Chi1dren born within the study area but whose mother was
not resident, were not counted as e1igib1e for the study: they were considered
as visitorsJ if they matched the residence criteria 1ater on, they were counted
as immigrants.
Table 2.8 disp1ays the situation of each birth cohort on December 31, 1989.
Chi1dren of the first cohort (01) were already 34 months old at that time and
children of the last cohort (24) were 11 months old. On the average 14.2\ of a11
live births had died by December 31, 1989 and 7.5\ had emigrated.
Morta1ity of project children was compared to mortality of corresponding
previous birth cohorts, born between February 1983 and January 1985 (table 2.9
and figure 2.5). These cohorts were not affected by this study between age 0 and
2 years since a11 of them were a1ready two years old when the study started.
Cohorts born between February 1985 and January 1987 were not considered for the
comparison Binee they benefited from the study as we11 (they were less than 2
years old at start) and from the national EPI program for December 86 to March
87.
Results of the camparison of cohort mortality were as striking as those
of period morta1ity. Probabi1ities of dying from 1 month to 36 months were
reduced fram 23.2\ to 65.1\ depending on the age group. Largest gains were at
12-23 months. However, this was not the case for neonata1 morta1ity for the
reasons mentioned above.
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Figure 2.5
SURVIVAL OF BlRTHS COHORTS AGE 1-36 MONTHS
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2.7 SUMKARY OF KAIN FINDINGS
Fertility was stable over the period, with marked seasonal and random
variations. The average size of the monthly birth cohorts was 103 children,
which was close to the value predicted by the protocol.
Mortality was reduced by 49% over the study period, when compared to the
1983-1986 baseline periode The most striking decline occurred for children below
age 5 years, outside of the neonatal period, and for the diseases that were the
target of the vaccination project, measles and pertussis. pertussis mortality
was under total control and measles mortality close to total control. The decline
in other causes was attributed to the efficient work of the study physicians who
provided high quality care, and were available about 5 days a week. The decline
was proportionate to the number of physicians working full time in the study
area. Strong improvement in child survival over those three years was a major
achievement of this study.
Migration flows during the study period were comparable to those of the
baseline periode
42
43
CHAPTER 3
VACCINATION
3.1 VACCINES
Vaccine batches
Vaccines other than the trial vaccines were provided by the Ministry of
Public Health. Most of them were donated by UNICEF. They were collected from the
regional pharmacy in Kaolack about twice a year. Details of batch numbers and
dates of acquisition are provided in annex A-2. Trial vaccines were provided
directly by the producers: the Institute of Immunology, Zagreb, Yugoslavia, for
the EZ-HT vaccine and Institut Mérieux, Lyon, France, for the SW-HT, the Standard
measles vaccine and the placebo. The trial vaccines were identical to the ones
used in the Mexico trial (Markowitz et al., 1990).
Two batches of the EZ-HT vaccine were received directly from Zagreb. The
first batch (81/3) was received in February 1987 and the second (137) in January
1989. The first batch was used for cohorts 01 to 21 and the second batch for
cohorts 22 to 24 and 26 to 29; cohort 25 did not receive it because of a
confusion in the batch numbers: after checking in early July 89, we thought that
we had a low titer vaccine, and we did not use it at the July 1989 session; but
this proved to be incorrect and the batch was used at the August session for
cohort 26 and thereafter until November 1990, when the excess mortality effect
was detected.
One batch of SW-HT vaccine was received directly from Lyon, in March 1987.
The use of the SW-HT was discontinued after OCtober 1988 when the immunogenicity
of the vaccine was found to be too low. Two batches of Schwarz standard vaccines
and two batches of placebo were received in March 1987 and in March 1989. The
first batches were used until the April session of 1989 and the second batches
thereafter. The placebo was a standard vaccine preparation without the active
particles. It was also produced by Institut Mérieux, France. All trial vaccines
and the placebo were single dose vaccines. They were in similar containers with
a standard label on them: A, B, C and D.
Vaccine storage
Vaccines were stored in a cold room at 4·C, at ORANA, Dakar. This room was
checked regularly, once a month, bythe manufacturer. There was no evidence of
any change in temperature over the 30 months. Vaccines were transported in UNICEF
large cold boxes from Dakar to the field station in Niakhar, once a month, on
the Monday of the vaccination week. Vaccines were taken in supplies larger than
needed and vials that were not used were taken back on the Friday of the
vaccination week in the same conditions. At the Niakhar field station, vaccines
were stored in the solar refrigerator which had an outside thermometer and a
permanent registration of internal temperature. For the vaccination days,
vaccines were taken in small UNICEF cold boxes. Trial vaccines were in individual
vials. other vaccines came in 10 or 20 doses vials. Live vaccines were
reconstituted at time of use. Individual vials of reconstituted measles vaccine
were never kept for more than a few minutes. other vials of reconstituted
vaccines (10 or 20 doses) were kept cold for about one hour.
44
Vaccine potency
After each vaccination session a sample of each measles vaccine was brought
back to Dakar, deep frozen and then sent to Fajarah M.R.C. laboratory for
analysis of potency. various analyses were performed over time, including plaque
formation and tissue culture infection. Hence results are expressed in PFU or
in TCID50 and are not strictly comparable. A conversion rate can be applied for
converting PFU in TCID50 depending on the vaccine strain according to the
following chart 3.1:
Chart 3.1 Conversion factors, according to method of potency determination
Vaccine strain
Moraten
Schwarz
Schwarz
Edmonston-Zagreb
Edmonston-Zagreb
Adsorption method
PFU / TCIDso
theoretical
S / S
P / P
P / S
P / P
P / S
Ratio
PFU / TCIDso
0.69
0.60
2.5
10.0
1.0
17.0
Source : Institut Pasteur-Mêrieux.
P virus adsorbed onto performed monolayers
S = virus adsorbed in dilute cell suspension.
Furthermore the tissue culture techniques were changed over time and later
results were not directly comparable to others. In any case, results showed that
there was no decrease in potency of any vaccine, even after 24 months of storage
at 4"C (see annex A-7). Mean values for the EZ-HT vaccine averaged consistently
5.4 10g10 pfu, the SW-HT vaccine 5.4 10glo pfu and the Standard vaccine 3.7 10g10
pfu. Very high values for the EZ-HT vaccine at the beginning were probably due
to excessive sensitivity of the cultures to the EZ virus.
Vaccine administration
Vaccinations for the trial were fully integrated in the national EPI.
Vaccines were given at the local dispensaries by the local nurse, using the
tools provided in late 1986 by UNICEF for the mass vaccination campaigns.
Syringes and needles were reusable and sterilized in UNICEF pressure cookers.
Measles vaccines were injected subcutaneously in the left upper arme BCG
was given intra-dermatically in the right upper arme DPTP vaccines were given
deep subcutaneously in the left thigh. Children who did not come at the 5 months
session but came at the 10 months session or later received measles and
yellow-fever mixed in the same syringe. Children who came at the 5 months session
(project children) received measles and yellow-fever separately, even in the
placebo group that received measles and yellow-fever vaccines the same day; in
this case yellow-fever was injected in the right thigh.
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3.2 VACCINATION SESSIONS
Vaccination sessions were organized each month, usually in the week closest
to the 15 of the month, sometimes a week earlier or later for convenience such
as avoiding a holiday or a local festival. The vaccination team and the vaccines
came from Dakar to Niakhar on Monday. There were three vaccination days: Tuesday
in Ngayokheme, Wednesday in Toucar and Thursday in Diohine. The unused vaccines
and the blood samples were kept cold and taken back on Friday to Dakar.
Calling infants
Two weeks before each vaccination session a list of children eligible for
vaccination was printed by the computer. Two copies of the lists were given to
the field workers. The first list was used by the field worker as a reminder.
The second list was eut in small pieces used to convoke children (convocation),
one for each child. The week before the vaccination session, at the time of the
weekly visit, the field workers gave the convocation. Therefore, the family knew
a few days in advance that the child was to be vaccinated, which day and in which
dispensary. People were asked to come on their own if they could. Days of
vaccination were chosen in agreement with market days. Tuesday was a market day
in Ngayokheme, Wednesday was a market day in Toucar and Thursday was a market
day in a village north of Diohine, Mbafaye. For each vaccination day people had
many opportunities of finding a cart for transportation. If they did not come
on their own, a car was sent from the dispensary to pick them up at home. This
was done systematically for villages more than 4 kilometers away from the
dispensary. Two or three cars were used for picking-up children, depending on
the number of eligible children. There were 50 to 150 children vaccinated at each
session day, depending on the dispensary, the number of cohorts eligible and the
number of children who showed up although not convoked. The vaccination day
started early in the morning and lasted until late at night, with about 30
minutes for lunch in the middle of the day.
The line of flow
Two other copies of the list of eligible children were also printed: one
for the supervisor and one for the drivers. On vaccination day, the team arrived
at the dispensary early in the morning. A line of flow was organized. First the
mother had to check-in at the registration desk. One of the supervisors was
sitting at that desk with his own list of eligible children. He had the tasks
of registering the attendants, preparing the vaccination card, keeping the
driver's list updated and sending the driver to pick-up missing infants village
by village. Usually people came with their own convocation; in case they did not,
the supervisor had to cheCk the name and identification in his own register.
Children not convoked were also welcome and identified the same way. These were
older children, visitors or children who had missed an earlier session. After
the first desk all infants were properly identified and all had a national
vaccination card prePared. Children who participated in the project had a stamp
put on their health cardo The stamp warned that the child was in a vaccine trial
and that he was not supposed to be re-vaccinated outside of the trial until July
l, 1989. However, a few children were vaccinated elsewhere (see below 3.4).
Anthropometrv
The second desk in the line of flow was anthropometry. All children were
weighted on a SECA la grams precision scale, measured on a locally constructed
length board (2 mm precision) and had their arm circumference measured with an
insertion tape (Talc, UK) with a 2 mm precision. Anthropometrie measurement was
written on a separate sheet, in the order in which children came in the
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dispensary. Weight was also written on the national vaccination card and on the
growth chart.
Clinical examination
The third desk was the clinical exarnination. A comprehensive clinical
examination was conducted for each child. Emphasis was on any contra-indication
to vaccination, any disease to be treated and malnutrition. Contra-indications
were any evolving systemic infection for live vaccines and any history of seizure
for DPTP. At each session, there were a few cases of contra-indication, usually
high fever from various origin, malaria, pneumonia or other diseases of infancy.
History of seizure was rare at that age. Sick children were treated when possible
and brought back home or referred when necessary. Most common cases of sickness
were: diarrhea, eye infection (conjunctivitis), ear infection (otitis media) and
skin diseases. These were treated for free. Cases of severe malnutrition were
referred to the nutritional rehabilitation center that ORSTOM "UR Population et
Santé" was running in Pikine near Dakar at the beginning of the trial; after
August 1988 children were referred to the centers that were opened in Toucar and
in Fatick; mothers whose children were mildly malnourished were given feeding
advice with the help of a local interpreter.
Vaccine identification
The fourth desk in the line of flow was the vaccine identification. This
desk was manned either by the Bioforce or by one of the investigators. A register
similar to that of the registration desk was available, printed by the computer
with the vaccines that the child should receive. For measles vaccines, when the
child was eligible, a letter was printed on the register, A, B, C or D. For other
vaccines, the narne of the vaccine was also written (BCG, DPTP, YF). The computer
also printed whether the child was to have a blood sample taken or note The name
of the child was checked again at that time by calling his name to the mother
to avoid any error, especially in the case of twins. However, a few mistakes were
made: 5 cases of errors in identification were found at this point, out of 1606
children vaccinated at 5 months, usually because mothers mixed their cards after
their arrival at the admission desk.
Blood sample
Blood samples were taken at this time from eligible children, usually the
5 and la month-old (fifth desk). Detachable stickers were used and the sarne
number was stuck on the microtainer and in the register. Over the 24 sessions,
a small proportion of women (5.0%) refused to have the blood sample taken. Most
of them accepted the vaccination but a few decided at that time they did not
accept it and left.
Vaccination
The last desk of the line of flow was the vaccination desk. Vaccines other
than measles vaccines for the project carne in la or 20 doses vials, prepared in
advance and ready to use. Measles vaccines for the project came in individual
vials. They were prepared by the person in charge of the vaccine identification
desk which was close to both the blood sampling desk and the vaccination desk.
The vaccine to be given, A, B, C or D, was given with the infant health card to
the nurse in charge of the vaccination. Errors were very unlikely, although we
noticed 3 cases of mixing vaccines over the 2965 children who came at 5 or la
months. project vaccines, A, B, C and D, were counted day by day: with the
exception of the above noted cases, the count was correct. This does guarantee
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a high degree of certainty to have administered the proper vaccines. However,
it would have been easier to have had each measles vaccine vial given a
sequential number and have written down the number on the register for later
cross-checking.
Sometimes, a woman started the line of flow and later disappeared, usually
after anthropometry where the waiting list was longer, or because she was afraid
of the blood sampling she could see from the open door. These were called
"évadées" (escaped) and usually identified at night when matching the admission
register with the vaccine register.
All vaccinations performed by the team were transcribed into the dispensary
register and a monthly report was sent to the Fatick Circonscription Médicale.
3.3 ATTBRDARCB AT VACCINATION SESSIONS
Attendance at vaccination sessions was first classified by residence and
participation in the study. Persons who were not resident in the study area were
not counted. They appeared only in the dispensary register and statistics.
Children belonging to the 24 cohorts, called "Project Children" were classified
into "convoked" that is called for the 3, S, la months vaccination sessions or
for the later revaccination session and "not convoked" that is children who came
by themselves outside of the scheduled sessions. other children or persons who
were vaccinated were classified as "other".
Project children whose age matched the vaccination session (3, S, la
months) could be resident, dead or emigrated at time of the session. If resident,
they could be present at the session, absent from the village or present in the
village but refused to come (refusal), whatever the reason for not coming.
Children who came at the session but were not vaccinated because of
contra-indication were treated as present. Children who did not complete the line
of flow but registered at the registration desk (évadés) were treated as refusal.
Children who were not convoked were separated into project children and others.
Mortality and migration of project children was discussed earlier (see chapter
2) •
Over the 29 sessions the proportion of refusal (refusal / refusal + present)
averaged 19.9%. This proportion was lower at the beginning: 4.6% for the first
3 sessions, increased sharply after to peak at the eighth session (32.4%) and
later stabilized around 20% (table 3.1; figure 3.1). There were three main
reasons for refusal to attend the vaccination session when mother and child were
in the village. The first reason was refusal to participate in the study,
sometimes associated with systematic refusal of blood sampling and of any
vaccination. A second reason was personal inconvenience, usually a family
ceremony at home or within the village, often a funeral ceremony. A third and
important reason was rumors against the project. These rumors were investigated
during the first year of the project. They were based on irrational ideas,
usually coming from one person, often associated with blood sampling (they are
selling the blood of our children; they aresending the blood to cure old
Europeans who are sick etc.). Rumors spread mostly within the extended family,
first in the same village but also among other members of the family living in
other villages. Rumors dissipated as fast as they started and there was no case
of systematic refusal of the study over the 26 sessions, except in a few families
in two neighboring villages, Sob and Diokoul. These were villages were the ORSTOM
team has been known for the longest period and where we had several friends.
However these were also villages where blood was taken in bad circumstances in
1968 for a nutrition study and it seems that the memory of these regrettable
events was retained over the years.
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Figure 3.1
Proportion refusai to vaccination sessions
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Villages which were included in another vaccine trial againat hepatitis
B in 1978-1979 also had bad memoriea of blood sampling. However, the fact that
we took only small amount of blood (0.5 ml) and that thia was done openly in a
room where everybody could see what was going on, greatly helped to overcome
apprehension.
Among children who were not convoked, who accounted for 11.9% of the total
number of vaccinated children, the majority (52%) were project children who were
coming late (rattrapage); others (48%) were older children or adults who needed
their vaccination series to be completed or visitors who took the opportunity
to be vaccinated. .
Attendance at the 5 months vaccination session was even higher than the
average: 82% (table 3.2). Among cohorts 01-16, 1015 children participated in the
study, 336 in the EZ-HT group, .322 in the SW-HT group and 357 in the Standard
group; among cohorts 17-24, 576 chi1dren participated in the study, 292 in the
EZ-HT group and 281 in the Standard group (table 3.3). Among children who came
at 5 months, a majority came back at 10 months and therefore could participate
in the immunogenicity study: 67.9 % among cohorts 01-16 and 78.0% among cohorts
17-24 (table 3.4). By December 1989,80.8 % of resident children were vaccinated
against measles, 82.9% among cohorts 01-16 and 79.6% among cohorts 17-24 (table
3.5) •
3.4 AGE AT VACCINATION
In the regular schedule, children were to be vaccinated at 3, 5 and 10
months. The 3 month session was delayed at 8 months for the first 2 cohorts. In
fact the trial started in August 1987, with the first 2 cohorts eligible for the
5 months vaccination session already too old for the 3 months session (table
3.6). They were vaccinated in OCtober and November 87, at 8 months instead of
3 months and received BCG and DPTP-2. Cohort 03 was vaccinated at 4 months
instead of 3. All other cohorts 04-24 were vaccinated at 9-17 weeks, or 3.0
months on the average (standard deviation: sd=0.36).
To be included in the project, a child had to attend the 5 months session.
OUtside of the first cohort which was vaccinated at 6 months in August 1987, all
the others were vaccinated at 5 months, age being counted in difference of
months. 5 months, in difference of months, was roughly equivalent to 20-24 weeks
of age. However some were vaccinated earlier and some later. Table 3.6 displays
the distribution of age at the 5 months vaccination session by birth cohort. Ages
lower than 20 weeks were those born late in the month who were vaccinated in a
session set up early in the month; ages higher than 24 weeks were those born
early in the month who were vaccinated in a session set up late in the month.
For cohorts 02 to 24, 89.7% of the children were vaccinated between 20 and 24
weeks, 7.4% before 20 weeks and 2.9% at 25 weeks; the first cohort was vaccinated
at 24-28 weeks. This rather smal1 age range was important to consider since the
level of maternal antibodies decreased rapid1y over this period and 20 weeks was
the threshold be10w which vaccines have a much lower uptake. This point is
discussed further below (see 5.8). For cohorts 02-24, the mean age at vaccination
was 5.0 months (sd=0.35); for cohort 01 the mean age at vaccination was 6.0
(sd=0.30).
The 10 month session was conducted as scheduled for all cohorts, in general
between 41 and 46 weeks of age. The mean age at vaccination was 10.0 months
(sd=0.35). Project children who were not convoked could receive their measles
vaccine at any age after 10 months.
The interval between the 5 months and the 10 months sessions also had a
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small range (table 3.7). This interval is important for the study of
immunogenicity since antibodies decay with time, as well as for the study of
efficacy since not all children were exposed to the exact sarne length between
the two sessions. Except for the first cohort for which it was 3.7 months (16
weeks), the interval between the 5 months and the 10 months sessions was 5.0
months (sd=0.26) with a range from 20 to 24 weeks. There was no difference arnong
the vaccination groups.
3 • 5 INCLUSION ABD EXCLUSION RULES
To be included in the study a child must:
- have been born to a resident mother between February l, 1987 and January 31,
1989;
- have attended the clinic at 5 months for vaccination and have parental
agreement to participate;
- not have had any contra-indication to measles vaccination, i.e. evolving
infectious disease, history of convulsion, previous measles infection or previous
measles vaccination;
- not have been revaccinated with another measles vaccine between 5 and 10
months.
Children who accidentally did not receive the scheduled vaccine were also
excluded (chart 3.2).
Chart 3.2 : Cases of exclusion arnong 2470 children of the 24 birth cohorts
No longer resident (dead or outmigrated):
Not present (absent or refusal) :
Contraindications to vaccination :
Errors in identification (5), vaccine (2)
Participants
Total
3.6 RBVACCIBATION
277
587
11
7
1588
2470
(11.2 %)
(23.8 %)
( 0.4 %)
( 0.3 %)
(64.3 %)
(100 %)
In two separate instances, children were called back after the 10 months
session to be revaccinated. In the first instance, children who were vaccinated
with one of the high titer vaccines who were seronegative at 10 months were
revaccinated with either the EZ-HT vaccine or with the Standard vaccine. There
were 49 children for whom this was the case, of whom 37 carne for revaccination
(session 22). Children were randomly allocated to a group: 14 received the EZ-
HT vaccine and 23 received the Standard vaccine (chart 3.3).
Chart 3.3 : status of seronegative children called at session 22
for revaccination with a measles vaccine (cohorts 01-16)
Residence
status
Previous vaccine at 5 months
EZ-HT SW-HT
Emigrated/dead
Absent/refusal
Present : EZ-HT
Standard
o
2
1
4
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4
6
13
19
All children of cohorte 01-16 who were incompletely vaccinated after the
10 months session, were also called back systematically, by groups of 4 cohorts,
from session 23 to session 26 (chart 3.4). other children were revaccinated in
May 1990.
Chart 3.4 Calendar of cohorts called back for completing EPI vaccination
Age range
Cohorts Session (in difference N
of months)
01-04 23 24-27 79
05-08 24 21-24 51
09-12 25 18-21 45
13-16 26 15-18 48
3 • 7 SOMMARY OP MAIN POINTS
Attendance at vaccination sessions was high: 80.1 % of present children.
Pew women refused the blood sample at time of vaccination (5.0 %). OUtside of
firm refusal to participate in the study, cases of refusal were often due to
personal inconvenience; others were due to fears of vaccines based on various
rumors circulating in the study area.
Altogether, 1589 children of the 24 births cohorts were vaccinated at age
5 months and therefore could participate in the study.
Age at vaccination was kept within a narrow range (sd=0.35 months) around
3.0, 5.0 and 10.0 months, with the exception of the first 3 cohorts.
Randomization between the three groups was fair and there was no evidence
of any bias at this level.
37 children from cohorts 01-16, who were seronegative at age 10 months,
were revaccinated with either the EZ-HT or the Standard vaccine.
223 children from cohorts 01-16, who were incompletely vaccinated after
the 10 months session, were revaccinated at sessions 23 to 26.
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CHAPTER 4
SAFETY
The safety of the high titer measles vaccines was investigated with three
indicators: mortality, morbidity and specific adverse reactions. Therefore, this
chapter is divided into three independent parts. Mortality was investigated until
OCtober 1990. Morbidity and adverse reactions were investigated until December
1989. The analysis of nutritional status was integrated into the morbidity part.
PART I: : HORTALI:TY
The study of mortality after early vaccination with high titer vaccines was
part of the original protocol. It was expected that early vaccination against
measles would prevent deaths and therefore improve child survival. In addition,
mortality was considered as a safety check because cases of severe measles were
reported after earliest vaccinations in the 60's with the Edmonston-B vaccine,
even though this was a killed vaccine. When first results of mortality
differences were found significant, in the Spring of 1990, it was decided to do
further checks on the data: one was done in the Fall of 1990 and another one at
the time of the 1991 Census. Results presented here integrate all deaths reported
at the 1991 Census that occurred prior to OCtober 1990.
4. 1 LI:FB TABLE RBSOLTS
Computations
Mortality was computed separately and differently in the various age groups.
From birth until the 5 months vaccination session and between the 5 months and
the la months vaccination sessions information on child survival was complete:
whether the child was alive or dead at the exact day of the scheduled session
was known. Therefore, probabilities of dying were computed directly by dividing
the number of children dead at the date of the vaccination session by the total
number of children at risk at the beginning of interval in the same cohorts.
After la months, the survival of the child was known only until the end
of observation, at which children's age ranged from 21 to 44 months. In this
case, computations were done by computing a monthly life table. Cases were
removed from analysis (censored) when they outmigrated or when they reached the
end of the study.
Comparisons between vaccine groups
Three kinds of comparisons could be made according to vaccine group:
1) From birth to 5 months, according to the 3 groups randomized at birth.
2) From 5 to la months or from 5 months until the end of the study, according
to the three randomized groups that received the EZ-HT, the SW-HT and the placebo
at 5 months; children who did not participate in the study were counted
separately.
3) From la months until the end of the study, according to the three randomized
groups that received the EZ-HT, the SW-HT and the Standard at la months; other
children were counted separately, even when they received a Standard vaccine
after la months.
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The four children who accidentally received a vaccine that was not
scheduled were excluded from the analysis. There were no deaths among them.
Mortality from birth to 5 months
Since vaccination groups were allocated at time of birth, it was possible
to compute mortality by vaccination group although children were not yet
vaccinated. This was done to check whether randomization was fair, that is if
there was no selection bias associated with vaccination groups.
Results appear in table 4.1. For the 24 cohorts participating in the study,
mortality from birth until the 5 months session averaged 81.4/1000, 64.4/1000
in the neonatal period (0 to 27 days) and 18.2/1000 from 28 days until the day
of the 5 month session. There were no significant differences between the three
groups, which indicates that randomization was equitable.
Mortality from 5 to 10 months
For mortality between 5 and 10 months, results were less homogenous (table
4.2). The EZ-HT group consistently had the lowest mortality (23.8/1000 for
cohorts 01-16 and 6.8/1000 for cohorts 17-24). The SW-HT had the highest
mortality among cohorts 01-16 (46.4/1000). However, none of those differences
was significant, even when the 24 cohorts were cumulated. The non-participant
group had a mortality similar to the placebo group.
There was also no evidence of any clustering of deaths within the 6 weeks
after the vaccination at 5 months in any group. Among the causes of death of
children who died within 6 weeks after the 5 months vaccination session, there
were in the EZ-HT group: 1 diarrhea, 1 hydrocephaly, 1 unknown; in the SW-HT
group: 1 diarrhea, 1 unknown; in the Placebo group 2 cases of diarrhea; in the
non-participant group 1 pneumonia. Here also no pattern emerged.
Chart 4.1 : Cumulated mortality after 10 months, by group and cohort.
Vaccine group Death rate RR 95 % CI T P
/ 1000 (2 tail)
Cohorts 01-16
EZ-HT 147.7 2.50 1.52 - 4.13 3.537 0.0004
SW-HT 102.1 1. 73 1.00 - 2.98 1.915 0.0560
standard 59.0 1.00 (ref)
Not participant 89.6 1.52 (NS)
Cohorts 01-24
EZ-HT 127.8 1.94 1.26 - 2.99 2.847 0.0044
Standard 65.8 1.00 (ref)
Not participant 90.6 1.38 (NS)
55
Figure 4.1
Cumulated mortality after 10 months
Niakhar 1987-1990, cohorts 01-16
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Figure 4.2
Cumulated mortality after 5 months
Niakhar 1987-1990, cohorts 01-16
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Mortality after 10 months
Results of the life table analysis of mortality after 10 months are
presented in table 4.3 and summarized in chart 4.1. There was a marked excess
of deaths between 10 months and the end of the study in the two groups that
received high titer vaccines at 5 months (figure 4.1). For cohorts 01-16, the
EZ-HT group had a 2.50 higher mortality than the Standard group (CI=1.52-4.13,
P=0.0004) and the SW-HT group had a 1. 73 higher mortality (CI=1.00-2.98,
P=0.0560). Even when results were grouped with cohorts 17-24 there was still a
highly significant excess mortality in the EZ-HT group: RR=1.94, CI=1.26-2.99,
P=0.0044. Mortality in the non-participant group was not significantly different
from mortality in the standard group.
Mortality after 5 months
The life table analysis was repeated starting at 5 months for the three
randomized groups, whether or not children in the Placebo group at 5 months
received the Standard vaccine at 10 months. Results are displayed in table 4.4
and figure 4.2 and summarized in the following chart 4.2. Here again, the two
groups receiving the high titer vaccines had an excess mortality when compared
to the Standard group: RR=1.80, CI=1.18-2.74, P=0.0070 in the EZ-HT group;
RR=1.53, CI=0.99-2.37, P=0.0564 in the SW-HT group. The group that did not
participate had a mortality similar to that of the standard group. When grouped
with the last 8 cohorts, mortality was higher in the EZ-HT group (RR=1.41), but
the difference was no longer significant (P=0.0756).
Chart 4.2 : Cumulative mortality after 5 months, by group and cohort.
Vaccine group Death rate RR 95 " CI T P
/ 1000 (2 taU)
Cohorts 01-16
EZ-HT 168.2 1.80 1.18 - 2.74 2.706 0.0070
SW-HT 144.0 1.53 0.99 - 2.37 1.911 0.0564
Standard 94.0 1.00 (ref)
Not participant 96.2 1.02 (NS)
Cohorts 01-24
EZ-HT 141.8 1.41 0.97 - 2.05 1.778 0.0756
Standard 100.5 1.00 (ref)
Not participant 95.0 0.95 (NS)
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Figure 4.3
Age specifie death rates
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4.2 AHALYSIS OF BICBSS HORTALITY
Since all excess mortality was concentrated at older ages and therefore
among the first 16 cohorts, this analysis focuses on factors of mortality among
cohorts 01-16.
Randomization
Analyses were undertaken to determine whether the vaccine groups were
comparable (table 4.5). The 3 groups were similar with respect to the following
variables: age of mother, mother's literacy, size of residential compound,
distance to dispensary, past mortality of older children of the same mother,
proportion of outmigrants, overall death rate in compound during the study
period, and mortality in the randomized groups from birth to 4 months. Children
in the non-participant group were from families with a similar background, but
they lived in compounds with a higher overall death rate.
In addition, average age at vaccination, weight, height, and circumference
of the mid-left-upper-arm of children from the 3 vaccine groups were similar at
age 5 months (table 4.6).
Clustering of deaths
To verify whether any unexpected event could have accounted for the excess
mortality, such as an undetected epidemic, deaths were distributed by month and
village (table 4.7). There was no evidence of unexpected clustering of deaths
according to date or place of residence. There was a marked excess of deaths in
the rainy season (July to October) in all groups and in the large villages (V6,
V19, V21, V22).
Causes of death
The demographic survey routinely recorded information on causes of death,
that were later interpreted in "probable causes of death", using the so-called
"verbal autopsy technique". The method has been presented elsewhere (Garenne and
Fontaine, 1986). Children apparently died of common diseases of childhood (table
4.8). In the EZ-HT vaccine group, there was a high number of deaths attributed
to kwashiorkor (9 cases) and to viral diseases other than measles (5 cases). Five
out of 6 dysentery deaths and 8 out of 10 deaths due to acute respiratory
infections were in the SW-HT group. The only accidental death and the only death
attributed to measles were among the non-participants. The frequency of other
diseases and unknown causes of death was similar in the four groups.
Age Pattern
The number of deaths was comparable arnong the three groups during the first
year after vaccination (table 4.9). It becarne higher in the groups that received
the high titer vaccines only in the second and third years (figure 4.3). Relative
risks of death after 17 months were 2.76 in the EZ-HT group (CI=1.40-s.42) and
1.90 in the SW-HT group (CI=0.92-3.91).
Earlier data from the sarne population showed that 17 to 41 months of age
was a period of high risk for chi1dren, in part associated with a peak of severe
malnutrition (Cantre1le, 1974; Garenne, 1981; Garenne, 1982; Garenne et al.
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1987) •
Sex differences
There was no significant difference in mortality by sex in any of the
groups: the relative risk of death (females/males) was 1.20 in the EZ-HT group
(CI=0.68-2.10, P=0.497), 1.14 in the SW-HT group (CI=0.62-2.10, P=0.636), 0.64
in the standard group (CI=0.31-1.31, P=0.195), and 1.16 (CI=0.60-2.24) among
the non participants (P=0.640). Baseline data, going back to 1963 in the same
population, showed no difference in mortality by sex beyond the neonatal period.
However, most of the effect of excess mortality between the high titer vaccine
groups and the Standard group was among the females (the differences between the
male groups were not significant). This could be explained by the random
fluctuations in the sex ratio of deaths among the groups, none of which was
significant: due to random fluctuations, there were more female deaths in the
high titer vaccine groups and less in the Standard group.
Seasonality
Mortality had a strong seasonal component, death rates being much higher
during the rainy season (table 4.9). Most of the excess mortality was
concentrated in the rainy season. Relative risks of deaths in the rainy season,
as compared to the dry season were 7.67 in the EZ-HT group (CI=3.73-15.78), 3.90
in the SW-HT group (CI=2.03-7.50), 2.56 in the Standard group (CI=1.26-5.18) and
2.89 (CI=1.46-5.59) in the Non-participant group.
The pattern of deaths according to the season of vaccination was more
mixed. There was an excess of deaths among children vaccinated in the rainy
season in the EZ-HT group and in the corresponding cohorts of the non participant
group; on the contrary, there was an excess of deaths in the SW-HT group and in
the corresponding cohorts of the Standard group. Although these differences were
statistically significant, we could not find a reasonable explanation for these
inconsistencies and these differences were considered to be due to random
fluctuations.
Multivariate analysis
To simultaneously analyze the net effect of these different variables, two
types of multivariate analyses were carried out. The first procedure was a Cox
proportional hazard model. This model assumes that the relative risk of deaths
among the groups remains constant over time. This assumption was not fulfilled
because of the strong seasonality of deaths: a child vaccinated at 5 months in
January did not have the sarne risk of death at 12 months, in the middle of the
rainy season, than a child vaccinated in August. Note that the magnitude of the
perturbation, from 2.5 to 7.7 largely exceeds the magnitude of the relative risks
investigated (1.5 to 1.8). Despite the fact that the fit was poor, results were
consistent with the univariate analysis (table 4.10). The EZ-HT group had a
relative risk of death of 1. 70 (P=0.0204) and the SW-HT group had a relative risk
of death of 1.51 (P=0.0778). Other variables (sex, season of vaccination, age
at vaccination) had no significant impact. Due to the structure of the model,
age and season could not be introduced as covariates.
A second model was developed to include the age and season effects. Periods
of exposure to mortality were decomposed into periods of 4 months corresponding
to the 3 seasons of the year: July to October (rainy), November to February (dry-
cool), and March to June (dry-hot). Separate models were tested for each vaccine
group. Results of the effect of the vaccines remained stable when controlling
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for other variables: age, sex, age at vaccination, season, season of vaccination,
measles antibody titer at 5 months, and seroconversion between 5 and 10 months
of age. The EZ-HT vaccinehad an odds ratio of 1.53 (P=0.0204) and the SW-HT
vaccine an odds ratio of 1.49 (P=0.0778) (table 4.11). The coefficient of the
rainy season was always high and significant and was greater in the two
vaccinated groups. Sex, level of antibodies at 5 months, and seroconversion
between 5 and 10 months of age were not significant in any group.
Conducting the same multivariate analyses by vaccine group revealed that
the coefficient of age in the EZ-HT group was close to zero, whereas it was
significantly negative in the other groups. This finding indicates that mortality
remained consistently high in the second and third year after the EZ-HT vaccine,
whereas in other groups death rates declined with age as expected. The failure
ofmortality rates to decline as is customary with aging of children is an area
of future concern.
Simulations
The logistic model did not simultaneously integrate all the information
on survival. Although both the Cox model and the Logistic model gave similar
results with different hypotheses, it was felt important to directly evaluate
the effect of any possible bias in the sarnples and to obtain testing procedures
that could at the sarne time control for age, period, cohort and sex effects. This
was done by developing a Monte Carlo simu~ation model. The mortality experience
of each child was simulated directly beginning at 5 months until the end of the
study. Hypotheses were the following:
a) the monthly probability of dying declined with age;
b) mortality was the sarne in each vaccine group;
c) mortality was 3.1 higher during the rainy season;
d) there were no sex differences in mortality.
1000 samples for each vaccination group were generated on a personal
computer. Results (table 4.12a) revea1ed that by the mere effect of differences
in the composition of the groups one could expect 6.7% less deaths in the EZ-
HT group and 10.4% less deaths in the SW-HT group than in the Standard group:
biases in the sarnple would tend to diminish actual differences in the mortality.
Testing directly the differences between the logarithms of the observed and
expected deaths in the EZ-HT group produced again consistent estimates of the
relative risk: RR=1.65, CI=1.14-2.39, p=0.008; in the SW-HT group, estimates of
the relative risk were: RR=1.48, CI=1.02-2.15, p=0.041.
The simulations also a110wed direct testing of various events (table
4.12b). In particular, sex differences were again found to be not significant.
The only significant event, other than the total number of deaths, was the high
proportion of deaths in the rainy season in the EZ-HT group (P=0.012).
4.3 DISCUSSIOR
Comparison of statistical procedures
Differential mortality between the groups was tested by eight different
statistical procedures: life table, death rate, probability of death, age
standardized death rates, linear logistic regression, proportional hazards, log-
rank tests and simulations (table 4.13a and b). They showed a consistent level
of significance of mortality differences with respect to the standard vaccine
group (p=0.007 to 0.024 for the EZ-HT group and p=0.041 to 0.094 for the SW-HT
group) •
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Consistency of the data
The consistency of the data, both in the groups vaccinated with high titer
vaccines and in the groups not given the high titer vaccines was striking. The
probability of concurrent occurrence of at least 50 deaths in the EZ-HT group
and at least 42 deaths in the SW-HT was very low (P<0.0001). Sinee the high titer
vaccines produced by two different companies had similar effects, it is unlikely
that the excess mortality was due to a production defect such as contamination.
Level of mortality in the Standard group
The possibility of abnormally low mortality in the Standard group was
considered but ruled out by the data analysis. Since 1963, there has been a long
term trend of declining mortality at age 5 to 41 months. Because of medical
services provided during the project, overall morta1ity was reduced between 1987
and 1989. Extension of the trends predicts a mortality of 91/1000 during the
study period, versus the empirical value of 93/1000 found in the standard vaccine
group. Furthermore, the level of mortality among the non-participants was similar
to the 1evel of mortality in the Standard group.
Measles incidence
The finding of an excess mortality in the vaccinated groups was possible
because 1) the incidence of measles was low during the study period (68 cases
among the study children), 2) the measles case fatality rate was also low as a
result of intensive medical care provided during the project. The only child who
died from measles was away from the study area and was a non-participant in the
study.
Effect of censoring outmigrants
The fact that chi1dren who migrated out of the study area were counted as
removed (censored) at the time of their move did not affect the results. An
attempt to find those who died after outmigration indicated that including them
would not have affected the results. There were 11 deaths: 3 in the EZ-HT group,
none in the SW-HT group, 1 in the standard group, and 7 in the non-participant
group, which included most of the outmigrants. The difference between the EZ-
HT and the standard group would have been even larger (20 deaths) if deaths among
migrants had been included.
Other cohorts
Later cohorts also were vaccinated with the EZ-HT vaccine at 5 months:
cohorts born between June 1988 and January 1989 were randomized and cohorts born
between March 1989 and May 1990 were not randomized. It is too early to judge
the mortality of those cohorts, but mortality in the EZ-HT group, although lower
than in previous cohorts, thus far has not declined with age.
Prevalence of HIV
The prevalence of HIV infection was low in the study area: only 2 out of
401 project children sampled at age 3 months were found to have HIV antibodies
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and none of them died. A sero-prevalence of 0.5\ was found among pregnant mothers
of the study area. Thus HIV infections could not have played a role in this
study.
Biological plausibility
short terIn effects of live virus vaccines on child immunity have been
observed, but their association with mortality has not been documented (Gandra
and Scrimshaw, 1961; Baer et al. 1981; Hirsh et al. 1981). In a recent study in
the Niakhar area, a low response to yellow-fever vaccination was found when
given in association with the EZ-HT vaccine (personal communication of Dr
Gonzalês). A measles vaccine was found to have an effect on weight in India
(Kielman, 1977).
The wild measles virus has severe adverse short terIn effects on immunity
and nutritional status of children, in particular on nitrogen metabolism (Wilson
et al. 1961) and vitamin A (Oomen, 1958). In addition, the wild measles virus
can have long-terIn effects, such as subacute sclerosing panencephalitis (Choppin,
1981).
There was no reason to suspect excess mortality after measles vaccination
in the study area: earlier findings in the study area and in a nearby area showed
that survival was better among children vaccinated with a standard measles
vaccine, even when given before 6 months of age (Garenne and Cantrelle, 1986).
Therefore we suspected the high titer to be primarily responsible for the effect.
Excess mortality became significant for the first time in the Spring of
1990, several months after the last chiId completed the vaccination series.
However, children who participated in the study had a mortality not higher than
preceding cohorts and children who did not receive the high titer vaccines had
a better chance of survival than preceding cohorts (table 4.14). Overal1, the
population benefitted from the project in terms of survival.
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PART II MORBIDITY, HUTRITIONAL STATUS AND ADVBRSB REACTIONS
4.4 HORBIDITY
Morbidity was recorded routinely by the field workers from the date of the
first convocation (the 3 months session) until the first birthday. Signs and
symptoms were recorded on a morbidity sheet and then coded at the end of each
episode. All morbid episodes reported by the mother for children present in the
study area were registered and coded, whatever their nature.
Computations
The main parameter used in this analysis is "incidence", the ratio of new
episodes to person-years at risk. Periods at risk were computed by discounting
periods during which a child was not present in the compound and during which
no morbidity record could be made, usually when the child travelled outside of
the study area for a couple of weeks. Details of computations appear in table
4.15. Children spent on the average 4.8% of their time outside of the study area,
which induces a minor correction in estimates of incidence.
Morbidity is more difficult ta record than mortality. This can easily be
shown by comparing the number of episodes recorded by each field worker (table
4.16). The two most productive field workers (1 1,2) recorded 2 ta 3 times more
episodes than the two least productive (1 10,11), and 28% more than the average.
This gives a magnitude of the inaccuracy of the data, in lieu of which correcting
for absences appears ta be of minor importance.
A list of major morbid episodes appears in table 4.17, with their frequency
expressed as the number of episodes per person-years at risk for 3 age groups:
3-5 months, 5-10 months and 10-12 months. Here again 3, 5 and la are the exact
dates of the vaccination session and 12 months is the exact birthday. The
analysis by group will emphasize diarrhea, fever, cough and skin rashes since
these are the most sensible symptoms for our purpose.
There were no difference in any of the 4 major symptoms between the
vaccination groups. The study was restricted to the first 16 cohorts (table
4.17, table 4.18). A more detailed study of the frequency of morbid episodes
within 21 days after the 5 months and after the la months vaccination session
did not reveal any significant difference either. The ana1ysis was pursued by
sex (table 4.19) but again no c1ear pattern emerged that could match the
mortality findings.
4.5 REPORTS OP CONVULSIONS
Lastly, all mother' s reports of convulsions were investigated, with special
attention to the four weeks after vaccination. Again, no clear pattern emerged.
Most convulsions within 28 days after vaccination were after the la months
session (table 4.20). There was a high number of convulsions after 28 days after
the 5 months vaccination, both in the EZ-HT and in the placebo group.
A case of severe encephalitis of unknown origin was reported and treated
in Dakar, at Fann and Le Dantec hospital. This was the case of a 12 months old
boy who received the EZ-HT vaccine at 5 months. He had a series of convulsions
for several days unti1 he was sean for the first time by a physician and referred
ta Dakar. He went blind for about 8 months, after which he recovered gradually
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part of his sight.
Another case of severe convulsions leading to death was reported. A girl,
was vaccinated at 5 months with the EZ-HT vaccine. She developed high fever 2
days after vaccination and convulsions of unknown origin 6 days after
vaccination. She was seen once by a physician, but left the study area the
following day and died 11 days after vaccination. The cause of death was unknown.
4.6 HOTRITIONAL S~S
The nutritional status of chi1dren was assessed at each vaccination
session, using measures of weight, height and arm circumference. A comparison
of the anthropometric measurements of children who died after the EZ-HT vaccine
with those of other children did not reveal any association (table 4.21). This
indicates that there was no evidence of an interaction of the EZ-HT vaccine with
nutritional status, either at time of vaccination, or at la months. However,
children who died a(ter the SW-HT vaccine was administered to them had a
consistently lower anthropometry than the mean population, at 3, 5 and la months.
The difference was significant only for one measurement at 3 months. Although
this effect would require a thorough examination, it suggests that there may have
been a selection of malnourished children among the ones who later died after
receiving the SW-HT vaccine.
4. 7 ADVERSB REACTIONS
After the second meeting of the Data Monitoring and Safety Committee it
was agreed that the recording of morbidity from mother' s declaration was
insufficient and that a specific examination by a physician of a sample of
children within the next two weeks after vaccination should be conducted. This
was done for birth cohorts la to 24 (April 88 to June 89).
A double sampling procedure was used for this procedure. The first step was
to prepare a random list of eligible children, by dispensary. This was done by
computer before the vaccination session. All eligible children were assigned a
random number, then ranked. The second step occurred after the vaccination: the
first 5 children effectively vaccinated on each dispensary list were selected,
a total of 15 children. Then, each of these children were seen 5 times, on the
next 3 Fridays and 2 Mondays after the vaccination session. Since vaccination
sessions were conducted on three different days, chi1dren vaccinated on Tuesday
were seen on day 1,4,8,11 and 15, children vaccinated on Wednesday were seen
on day 2,5,9,12 and 16, children vaccinated on Thursday were seen on day
3,6,10,13 and 17. Most of the days after vaccination were covered except day 7
and 14. Children who still had a rash after the last day were seen for a longer
period, until the end of the rash.
Emphasis was put on rashes. Children have many skin rashes at this age.
There is a high incidence of 2.6\ episodes within 15 days reported by the mothers
and of 9.8\ episodes seen by the physician, or 3.8 times more (table 4.22a). The
physician may have missed short episodes since he came only every 3 or 4 days.
One of the most common skin rashes was miliaria. Miliaria bears some similarity
with mild measles rashes: it is a papular generalized rash often starting on the
face and followed by desquamation. Measles rash in natural measles occurs 8 to
16 days after contamination. Hence all measles like rashes which occurred during
the second week after vaccination could be interpreted by the physician as
measles-like rashes. The physician was blind to the type of vaccine received,
therefore it was possible for him to interpret a mi1iaria as a measles-1ike rash
in the placebo group if by chance it occurred at the right time. And in fact this
did happen.
66
Post vaccination measles like rashes were defined as a papular rash, which
occurred about 8 to 16 days after vaccination, started on the face, invaded
symmetrically all or most of the child body within a few days and followed by
desquamation. 22 measles-like rashes were found in thesample of 224 children
examined by the physician, 10 out of 87 children in the EZ-HT group (11.4%), 6
out of 35 children in the SW-HT group (17.1%) and 6 out of 102 children in the
placebo group (5.8%). There were more rashes classified as measles-like in the
SW-HT (P=0.0420) and in the EZ-HT group, although the difference was not
significant (P=0.1672) than in the placebo group (table 4.22b).
We propose to interpret this result the following way. Measles like rashes
were a genuine effect of high titer measles vaccine given at 5 months since the
incidence was higher in the vaccinated groups than in the placebo. But among
these, there was a proportion of rashes which were in fact miliaria rashes
occurring at the expected time and which did not have anything to do with
measles. If this is true there was a proportion of 5.8% false observations in
each group (this is the figure from the placebo group), which corresponded to
the true incidence of skin rashes in this population over a 8 days periode Hence,
we estimated the proportion of adverse reactions to be: 11.3% (=17.1-5.8) in the
SW-HT group and 5.6% (=11.4-5.8) in the EZ-HT group. These results roughly match
the results from the Mexico study (Markowitz et al. 1990).
In addition, the physician also examined any episode of diarrhea or fever
during the five visits. There were no significant differences between the three
groups, as was the case for the incidence of the same diseases reported by the
mothers.
4.8 SOMMARY OF HAIN FIBDIHGS
Vaccination with the EZ-HT and with the SW-HT vaccines at 5 months does not
appear to be safe. There was an excess of mortality among children who received
high titer vaccines when compared to those who did note
Most of the excess mortality was concentrated in the second and third year
after vaccination between ages 17 and 41 months, which are also ages of peak
mortality in this population. The excess mortality was also concentrated in the
rainy season which is also a high risk periode
There were no significant differences by sex, by age at vaccination or
seroconversion status.
The recording of morbid episodes by the field workers, as reported by
mothers was poor. No pattern of differences between vaccination groups emerged
from the analysis.
According to available data and to our interpretations, the EZ-HT vaccine
given at 5 months seemed to produce a measles like rash in about 5% of cases and
the SW-HT in about 10% of cases. These rashes were mild, they occurred within
the second week after vaccination and lasted for a few days; they were followed
by a mild desquamation. These rashes were usually not noticed by the mother or
if noticed they were not attributed to vaccination since they were similar to
common skin rashes of young children of the sarne age.
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CHAPTERS
IMMUNOGENICI'l'Y
Immunogenicity was not a main objective of the study at first, but its
importance became greater over time when measles incidence remained abnormally
low in the general population. In the original protocol, only the first 5 cohorts
were supposed to be part of the immunogenicity study, but in fact all 24 cohorts
had blood taken at the 5 and la months vaccination session and all of the first
16 cohorts were fully analyzed for comparison of the two vaccines.
5 • 1 BLOOD SAHPL:IBG
Blood was drawn fram children just before vaccination atthe 5 and la months
sessions for all children of the 24 cohorts. In addition, blood was drawn at the
3 months session for volunteer children of three cohorts (05, 06 and 07) and at
the 8 months session for the first 2 cohorts (01, 02). Blood was also taken from
project children of other ages when coming for other vaccinations, whatever the
antigen they received. In particular, this was the case for children of the first
16 cohorts who were called back from May to August 1989 to complete their
vaccination series. A specific study of seroconversion was conducted for children
of the first 16 cohorts who did not have detectable antibodies at la months after
vaccination at 5 months of age and who were revaccinated in April 1989 (see below
5.7). Altogether 3409 blood samples were taken at the time of vaccination, 125
before 5 months, 1513 at 5 months, 157 between 5 and la months, 1270 at la months
and 344 after la months. The following chart (5.1) summarizes the main points
of the blood sampling strategy at the time of vaccinations:
Chart 5.1 : Blood sampling strategy at time of vaccination
Date of sarnpling Cohorts involved
August 1987 - November 1989 Cohorts al to 24, at 5 and la months;
project children if not convoked, any age
September - November 1987 Cohorts 05, 06, 07 at 3 months (volunteers)
October - November 1987 Cohorts 01, 02 at 8 months (volunteers)
April 1989 Cohorts 01-16, if seronegative at la months
(prior to revaccination)
May 1989 - August 1989 Cohorts 01-16, called back for vaccination
Oral inforrned consent was obtained from aIl mothers before blood was drawn.
A small proportion of mothers refused to have their child's blood taken at the
time of vaccination: 6.3 % for the 24 cohorts called at either the 5 months or
the la months sessions. Their children received the sarne care and the sarne
vaccines as the others. This proportion varied slightly over time with a peak
for cohorts 09-12 and 17-20 (table 5.1). There were marked differences between
villages and dispensaries. In Ngayokheme, a dispensary where 9 villages were
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vaccinated the refusal rate was 19.8%; in Toucar, where 10 villages were
vaccinated, the refusal rate was 5.6\; in Diohine where the remaining 11 villages
were vaccinated, the refusal rate was low: 0.9%. The villages where the highest
rates of refusal were registered were also those that had some former bad
experience with blood drawing (see above 3.3).
Blood samples were taken by a laboratory assistant with several years of
experience in Senegal. He was of Sereer origin and was able to communicate
amicably with mothers to make them feel at ease. Blood was drawn from the left
hand mid finger, using a sterile lancet. Blood was kept in a siliconed separator
microtainer (Microtainer inc.). About 0.5 ml of blood was taken each time, less
if the child was crying too much or if the mother complained. Microtainers were
centrifuged the same night at the Niakhar field station for about 10 minutes at
7000 t/mn. They were later frozen in the solar powered freezer at about -14·C.
They were brought back to Dakar frozen and stored at -14· C until they were
shipped to MRC laboratory in Fajarah, every other month or so.
5.2 LABORATORY PROClmORE
42 batches of b100d samples were analyzed between August 1987 and April
1990 (table 5.2). The delay between blood sampling and serum analysis averaged
80 days with minimum and maximum values of 18 to 579 days (standard deviation=72
days). There was no correlation between the level of antibodies and the delay
between blood samp1ing and serum ana1ysis, which indicates that the samples were
properly stored and frozen. Details of the laboratory procedure are explained
in annex A-7.
5.3 INTERPRETATION Ol!" BI AHTlBODY TITBRS
Among the 3409 blood samples taken at time of vaccination, 165 were
analyzed twice (4.8%): 59 samples from the first cohort were reanalyzed because
they showed a low titer; 28 placebos meeting the criteria for seroconversion were
reanalyzed and 78 others for various reasons.
Except for the case of the first cohort, there was a high correlation
between the two analyses: 0.707 to 0.837 (table 5.3). There was, however, a
systematic bias of close to one dilution (0.896) between the two analyses, with
a tendency of higher titers at second analysis. The study of the 106 samples
other than the first cohort showed that in only 66\ of cases, titers were
equivalent, that is no more than one dilution off the previous value (table
5.4). This standard error, normally found with the HI method, must be taken into
account in the interpretation of any study of seroconversion. One way of handling
the problem is to add the variance due to the method to the sampling variance
using the formula:
Total variance Method Variance + Sampling Variance
The case of the first cohort was puzzling: there was no correlation between
the two analyses and reeults from the firet two cohorts, sampled and analyzed
at the same time, were discarded. This is why most tables are based on cohorts
03-16 only.
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Figure 5.1
NATURAL DECAY OF MEASLES ANTIBODIES BY AGE
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Figure 5.2
PROPORTION WITHOUT DETECTABLE MEASLES ANTIBODIES
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5.4 RATURAI. DBCAY OF HATBRRAL AHTlBODIES
The natural decay of maternal antibodies could be studied cross-sectionally
by comparing the Geometric Mean Titers (GMT) by age at time of blood sample.
Although this was not a longitudinal study, results revealed a strong pattern
(table 5.5 and figures 5.1 and 5.2). The GMT averaged 490 miu at 10-13 weeks and
declined rapidly until the first birthday. The proportion of children without
detectable antibodies increased rapidly from 6.1\ at 10-13 weeks to about 70\
at age 9 months. The GMT among the seropositive children had a more complex
pattern with decreasing titer from 10 to 33 weeks which then increased
significantly. This was probably due to a selection of fewer children with higher
titers. In any case it seemed that a small proportion of children had a
significant level of measles antibodies for quite a long time beyond age 12
months. Therefore, vaccine failure could be expected in this population, even
when children were vaccinated around their first birthday. At 5 months
vaccination (18-25 weeks), 68.8\ of children had a detectable level of measles
antibodies, with a GMT of 356 miu.
5.5 IMKUNOGBHICITY OF VACCnœS
The serological response to vaccines was studied by comparing the levels
of measles antibodies between the vaccines and the placebo, and directly between
the vaccines. Results were based on 535 children who came to the 5 and 10 months
sessions, who were immunized with the EZ-HT vaccine or the SW-HT vaccine or
received the placebo at 5 months, who belonged to cohorts 03-16 and who had not
had measles prior to age 10 months and were not known to have been exposed to
measles in a compound of the study area (table 5.6).
Proportions of children with a detectable level of antibodies and GMT were
comparable among the three groups at age 5 months, which indicates that
randomization was fair. At age 10 months, both vaccine groups had significantly
higher titers and a lower proportion of seronegative children than the placebo
group. Furthermore, the EZ-HT vaccine had significantly higher titer (P=3.0E-
06) and a lower proportion of seronegative children(P=3.7E-06) than the SW-HT
vaccine.
Three definitions of the serological response to vaccines were compared:
- sero-positivity, defined as at least 125 miu at 10 months
- sero-response, defined as at least the same titer, if >=125 at 5 months,
or >=125 miu, if <125 at 5 months.
- sero-conversion, defined as at least a four fold increase in GMT if >=125
or >=250 miu, if <125 at 5 months.
In the three cases, the EZ-HT vaccine performed far better than the SW-
HT vaccine, and results were highly significant (see figures 5.3, 5.4 and
following chart 5.2). The proportion of children without detectable antibodies
at age 10 months was 5.9 times greater in the SW-HT group, and the proportion
of children who did not meet the seroconversion definition was close to 50\ as
compared to 29\ in the EZ-HT group. Even the GMT among seropositive children
was higher in the EZ-HT group.
High titers (above 16,000 miu) were found in the two vaccine groups (table
5.7). This may be part1y due to a strong response and partly to the standard
error due to the method. In the earlier analysis of the method error it was found
that the same samp1e was tittered once 512,000 and once 16,000 miu.
71
Figure 5.3 comparison of immunogenicity of HT vaccines
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Figure 5.4 comparison of definitions of immunogenicity
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Chart 5.2 Statistical tests for the comparison of the immunogenicity of
the EZ-HT to that of the SW-HT vaccine.
GMT at 10 months T = 4.599 P = 6.0E-06 *
GMT if >=125 at 10 months T = 1.969 P = 5.0E-02 *
Sero-positivity Z = 4.951 P = 7.4E-07 *
Sero-response Z = 4.546 p ::0 5.4E-06 *Sero-conversion Z ::0 3.837 P ::0 1.2E-04 *
A small proportion (13.2%) of children who received the placebo at age 5
months had an apparent increase in titer which met the criteria for sero-
conversion. This could again be easily explained by the method error. Among the
106 samp1es analyzed twice, 33 (31.1%) would fall into this category, although
they were exactly the same samples.
5.6 AHALYSIS OF :IHMONOGBRICITY
Level of antibodies at age 5 months
Among the main factors of immunogenicity was the 1evel of antibodies at
time of vaccination. Table 5.8 compares the immunogenicity of the vaccines
according to the level of antibodies at age 5 months. For children with less than
250 miu at 5 months, seroconversion was 98.6% in the EZ-HT group and 85.5% in
the SW-HT group. For children with 250-999 miu at 5 months, seroconversion was
61. 6% in the EZ-HT group and 26.4% in the SW-HT group. There was no clear
evidence of aeroconveraion after high titer vaccines when the level of antibodies
was above 1000 miu. However, the percentage of seropositive children at age 10
months was significant1y higher than in the placebo group.
Factors of immunogenicity
Several other factors could account for differences in immunogenicity, in
particular age per se (in weeks, between 18 and 25), sex and nutritiona1 status.
Furthermore, to check if any trend in the potency of the vaccine was visible,
a variable "cohort" was introduced; a control was a1so estab1ished on the season
at which the child was vaccinated. Immunogenicity was studied using a
"Mu1tinomial Logit Regression" when the dependent variable was dichotomous (e.g.
sero-positivity, sero-conversion, sero-response) or a standard "Multinomial
Regression" when the dependent variable was the Log(GMT).
Extensive computations were performed using various models as well as
other variables. No effect of sex or nutritional status at either age 5 or 9
months was found significant; various interactions among significant variables
were also tried without success. Only significant results are presented here.
The effect of the vaccine and of the level of antibodies at 5 months
appeared overwhelming in the three main models (table 5.9). In addition, there
was a small aignificant independent effect of age at vaccination for aero-
conversion and sero-poaitivity, but not for sero-response.
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Comparison of the two vaccines
The behavior of the two vaccines was analyzed separately in other models.
For sero-positivity, the EZ-HT vaccine seemed to be more sensitive to the level
of antibodies than the SW-HT vaccine; however the SW-HT vaccine was more
sensitive to age when controlling for level of antibodies (table 5.10). When GMT
was used as the depandent variable, the EZ-HT vaccine seemed more robust to
changes in age at vaccination and in level of antibodies (table 5.11). In this
case, the EZ-HT vaccine group revealed a significant positive effect of cohort.
This suggests that the immunogenicity of the vaccine did not diminish over time,
although it remained for nearly two years. In addition, there was a significant
effect of season in the EZ-HT group only: the GMT was lower for children
vaccinated during the rainy season. This last observation requires further
research on the possible interaction between the vaccine and general immunity,
which is poor during the rainy season.
Decay of antibodies after vaccination
At the time this analysis was performed, only 104 blood samples from
children above the age of la months were available, 41 in the EZ-HT group, 32
in the SW-HT group and 31 in the Standard group (table 5.12). Another 166 samples
had already been taken but not yet tittered. This is, however, enough information
to perform a first comparison of the decay of antibodies after the three
vaccines. Most of the samples were taken around age 16 months, before a
revaccination (children who were revaccinated because they were sero-negative
at la months were not included here). The GMT in the EZ-HT group (1402 miu) was
still higher than in the SW-HT group (859), but the decline in levels of
antibodies seemed more pronounced and the proportion without detectable
antibodies increased to 19.5\. There was virtually no decline in GMT in the SW-
HT group between 10 and 16 months.
Children who were vaccinated with the Standard vaccine at age la months
had much higher levels of antibodies 6 months after vaccination (4090 miu) than
any other group, and also much higher than the EZ-HT or the SW-HT group at age
la months (figure 5.5). A similar result was recently reported (Whittle et al.,
1988). This raises seriQue questions concerning the value of the immunogenicity
of high titer vaccines given at 5 months.
5.7 RESPOHSE Al1'TER REVACClNATIOH OF SERO-HEGATIVE CHILDREH
Among children vaccinated at age 5 months with either the EZ-HT or the SW-
HT vaccine, 49 children did not have a significant level of antibodies at first
analysis. They were called back for re-vaccination in April 1989. At the second
meeting to the DMSC it was decided to randomize these children and to revaccinate
them with either the EZ-HT or the Standard vaccine.
Among the 49 children, 4 were dead or had outmigrated, 8 refused to come
or were absent and 37 participated. They were revaccinated according to the
schema displayed in chart 3.2. Results of the revaccination were not yet
available when this report was completed.
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Figure 5.5
MEASLES ANTIBODIES AFTER VACCINATION
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5.8 MORTALITY ABD SBRO-CONVBRSION
In an earlier article, Aabyet al. (1988) found that children who did not
seroconvert after measles vaccination had a higher risk of dying than others.
This was not the case in this study. Deaths among the 535 who entered in the
seroconversion study were broken-down by vaccine, sero-conversion, sex and age
at death. There was no significant difference between children who died and
survivors (table 5.13). Extensive survival analysis was conducted on the sarne
children, but nothing else of significance was learned except what was shown
earlier (see 4.1), i.e. the EZ-HT group had a higher mortality.
5.9 OPTIHAL AGE FOR VACCINATION
Estimates of the optimal age for vaccination could be derived by comparing
the expected proportion of children who would seroconvert or serorespond, by age
at vaccination. This was done by multiplying the expected rates and
seroconversion and seroresponse for each level of antibodies (from table 5.8)
by the distribution of antibodies at this age (from table 5.5). The expected
immunogenicity increased sharply with age from age 3 to 6 months and reached a
plateau after age 7 months (table 5.14, figure 5.6). These results indicate that
the optimal age for vaccination with high titer vaccines would be 6-7 months,
and not 5 as was chosen for this study.
5.10 DISCUSSION
We found very difficult to compare the values of seroconversion after high
titer vaccines with the results of earlier studies (chart 0.2). Seroconversion
varies very much with age, titer and strain, as well as with the definition used,
in particular with the laboratory method and the threshold used. Our results for
the EZ-HT compare well with results of the Mexico and Togo trials.
5.11 SOMMARY OP' HAIN P'IRDINGS
- Both the EZ-HT and the SW-HT vaccines were immunogenic when given at 5 months.
- The EZ-HT vaccine induced a higher response than the SW-HT vaccine. Differences
between the two vaccines were highly significant. For instance there were only
3.7% of children with no detectable antibodies at 10 months in the EZ-HT group,
as compared with 22.0% in the SW-HT group and to 67.6% in the placebo group.
- The evidence that the EZ-HT vaccine passed the barrier of high levels of
maternal antibodies (e.g. 1000+ miu) was poor.
- None of the high titer vaccines given at age 5 months seemed to produce a level
of antibody response comparable to the Standard vaccine given at 10 months.
- levels of antibodies present after the EZ-HT vaccine seemed to decline faster
than after the SW-HT vaccine; but this effect would require confirmation with
more data and at various points after vaccination.
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Figure 5.6
Optimal age for vaccination, Niakhar
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CHAPTER 6
HEASLES: EPIDEHIOLOGY AND CASE DEFINITION
This chapter is devoted to the case definition of measles. The case
definition is based on all epidemiological, clinical and serological evidence
that was gathered during the course of the study. The chapter is divided into
3 main sections: epidemiology, clinic and serology. Cases were investigated each
time there was a suspicion of a clinical case in a family. There was no
systematic attempt to investigate subclinical measles, although some observations
were made during the course of the study (see below). Therefore, estimates of
sensitivity and specificity of clinical and serological criteria are dependent
upon parental recognition and upon suspicion of clinical measles in a family by
the investigators.
Two analyses were performed separately: one in early 1990, which included
cases until December 1989. Tables referring to this period were labelled 1987-
1989. other cases were found in the first part of 1990. They were included in
some of the analyses. Tables referring to that period were labelled 1987-1990.
PART I : BPlDBHI:OLOGY or MEASLBS
6. 1 RESIDENCE CRITERIA
Residence
Residence criteria for the general demographic surveillance are detailed
in the manual for field workers. They were based on the following main ru1es.
Were considered as outmigrant:
- people who left the study area without intending to return;
- people who left the study area for more than 6 months or who did not spend
the previous rainy season in the study area, even if they intended to return;
Were considered as immigrant:
- people who came tothe study area with the intention of staying;
- people who spent more than 6 months in the study area or who spent the last
rainy season in the study area, even if they had no intention of staying.
Special rules for visiting husbands, seasonal workers and students were given
to the field workers.
Presence
People who spent the previous night in the compound were considered present
in the compound on a given day. Herders, usually young boys age 8 to 14, who
received their meals from the compound but who lived and slept in the bush with
the animals were considered as residents but considered separately. others were
considered absent. For measles investigation, only presence status at time of
first investigation in the compound was recorded. This slightly biases the case-
contact ratio: a child could be exposed to the index child but no longer be
present a few days later when the first investigation was conducted, and
therefore not counted as a contact; conversely, a child could be absent at the
first investigation and could return later and become infected by secondary cases
and therefore be counted as a case. However these cases were rare.
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In addition to these standard rules of residence and absence, various
provisions were made for the efficacy study and for the case contact study (see
chapter 7 for details).
Project children
Project children were those born between February 1, 1987 and January 31,
1989 to a mother resident in the study area at time of birth. Project children
were considered outmigrating if their mother or the person in charge of them
outmigrated after the birth. Once outmigrated, project children were not re-
inserted into the file used for the efficacy analysis even if they returnedi
they were however reinserted in the general demographic file. There were no cases
of children who left and returned prior to the 10 months vaccination session.
Children entered the file at time of birth, they entered the study at time of
the 5 months vaccination session and they left the study either at the end of
the study, or at death if they died during the study, or at time of outmigration
if they outmigrated before the end of the study.
Residence status for measles cases and contacts
AlI measles cases that occurred in the resident population within and
outside the study area and cases that occurred in visitors within the study area
were considered. Measles cases and contacts can have three residence statuses:
1) Resident, Present in the study area (RP): these are cases and contacts among
the resident population who were present in the study area at time of the
outbreak;
2) Resident, Absent from the study area (RA): these are cases among the resident
population, who were absent from the study area at time of the rashi they were
usually contaminated during travel outside the study area or during a stay in
another village or city;
3) Visitor, Present in the study area (VP): these are cases and contacts among
the non resident population who were present in a compound of the study area at
time of the outbreak.
For the efficacy study, aIl residents were considered. Residents could
have only two possible residence statuses at time of a measles outbreak in a
compound: Present (within study area) or Absent (outside study area). For the
case-contact study, only those present were considered for cases and contacts,
since knowledge of their exposure status was needed (table 6.1). Residents absent
at time of an outbreak in the compound were discounted from the contacts.
Therefore, depending upon the residence and the presence statuses, and the
infection, five situations were considered for the analysis. They are summarized
in the following chart 6.1:
Chart 6.1 Residence statuses
Residence status
Resident, present
Resident, absent
Visitor, present
Efficacy study
Case/contact study
cases
RP
RA
VP
RP+RA
RP+VP
81
contacts
RP+VP
6.2 MBASLBS OUTBREAXS DI TBB STODY ABEA
Before the vaccine trial
Prior to the 1987 mass vaccination campaign, short breaks of measles lasting
a few months occurred every year in the study area. The national mass vaccination
campaign ran from OCtober 1986 to April 1987. At that time an outbreak of measles
was in course in the study area; it continued throughout the dry season and the
last case of this outbreak occurred on May 24, 1987. This was the last case for
almost a year. However, four other cases occurred between June 87 and April 88
among resident children absent from the study area: they occurred in Dakar on
August 2 and 15, November 15 and December 4, 1987.
During the vaccine trial
The first vaccinations of the project started on August 11, 1987, about
10 weeks after the last case of the previous outbreak was recorded in May 1987.
From August 1987 until August 1990 three measles outbreaks occurred in the study
area; in addition, isolated cases occurred among residents absent from the area.
The reason cases outside of the study area occurred at about the same time ,as
the cases inside the area was because index cases in an outbreak were always
imported from outside, usually from Dakar. It was epidemics in Dakar or other
cities in the country that produced outbreaks in the study area: there was no
continuous transmission of measles within the study area (table 6.2).
First outbreak
The first outbreak began on May 2, 1988 in Godel-Mbelpil, a small hamlet
in the Western part of the study area. The index case was a 5 year old girl who
had been to a wedding ceramony on April 18 in Thiadiaye, a nearby town. Only 5
compounds in the same village and 19 cases were infected and the last case
occurred on August 3, 1988. In addition, there were 8 other cases among residents
outside of the study area during the same period and another isolated case in
another village: Toucar.
Second outbreak
Then, measles transmission ceased until November 6, 1988, when a case
occurred in Ngangarlame-Pindalang: this was an 11 year-old child for whom no
certain source of contamination could be found. Transmission resumed and lasted
until June 26, 1989, at which time it stopped again; in addition another compound
was infected from outside on July 7, 1989. Altogether, 20 villages, 48 compounds
and 122 cases were infected in the study area during the second outbreak. Measles
was present throughout the country and 39 resident children were infected
elsewhere, mostly in Dakar, during the same period.
Third outbreak
Transmission resumed on August 19 and 21, 1989 in two different villages
simultaneously: a 4 year old girl living in Gadiak-Dafeme was infected in a
nearby hamlet (Ngassiak) and a 20 month-old girl from Ngangarlame-Khakhal, coming
from Dakar where she slept in the same bed as another girl with measles. The
outbreak spread to 11 neighboring villages and peaked in November when it hit
the school of Gadiak. 119 compounds and 407 cases were infected and the third
outbreak lasted until July 14, 1990.
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Exposure periods
Since the code was broken in June 1989, computations before opening the
code included roughly the first two outbreaks (a few cases occurred after the
code was broken). Exposure to measles after vaccination at 5 months ran from
August 25, 1987 (14 days after the first vaccination with high titer vaccines)
to August 15, 1990, a month after the last case of the third outbreak. Most
tables in this chapter refer to these three years.
Pattern of disease transmission in outbreaks
The pattern of disease transmission was rather atypical when compared to
previous years. Firstly, the size of the first two outbreaks was small: previous
outbreaks during the 1983-1986 period accounted for 300 to 600 cases; this was
obviously the effect of the vaccine coverage. Secondly, the seasonality was
rather different from previous years: the dry season peak was less pronounced,
because the transmission of measles was seriously disrupted by the 1987
vaccination campaign. Thirdly and most surprising, the secondary attack rate in
compounds was low (54.8' versus close to 100' in previous epidemics). The
identification of the reasons for this pattern would require further
investigation that is beyond the scope of this report.
6.3 PATTBlUf OF TRANSMISSION
Measles transmission has a standard pattern that has been well described
for centuries. The length of the incubation period averages 12±3 days. The child
may transmit the virus from 2 or 3 days before rash to 1 or 2 days after the
rash. The delay between a source case and an infected case averages 12.5±5.5 days
(7 to 18). In this study, when a case was followed by another case occurring 7
to 18 days later, with evidence of social contact during the susceptible
transmission period, the first case was considered the source case of the later.
Incubation period * Onset * Rash * Desquamation
Day -18 -12 -7 -2 1 +3 8 42
** Contact **
(source case)
index
** Transmission **
(infected child)
secondary
Transmission within the study area
Measles transmission within the study area was carefully monitored at the
village and compound level. In most compounds the source of contamination of
the index case was identified with a good degree of likelihood since usually
only a few possibilities existed and among them one was likely and the others
were unlikely in the normal interval of incubation. This was due in particular
to low incidence of the disease. Furthermore, people were often able to infer
the source of contamination since they pay a great attention to disease
transmission. However their information was always checked for consistency
because they had a tendency to consider first the closest contact, even when
the interval was too short or too long.
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Figure 6.1 Measles transmission in a large compound.
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Over the 1987-1989 period, 48.9\ of the index cases in a compound were
infected in the village, during games with other infected children or exposure
during a visit or a ceramony in another compound; in addition 20.0\ were infected
during short term travel outside of the study area, 12.2\ in school and 5.6\ at
a local dispensary; in 4.4\ of cases the source of contamination was unknown
(table 6.3).
Transmission within compounds: generations
The pattern of disease transmission within the compound was also closely
monitored, as exposed elsewhere (Garenne and Aaby, 1990). An index child can
infect up to 20 other children living in the same compound. During the first
two outbreaks a maximum of 14 children infected was recorded in the same
compound. In large compounds, transmission was complex and usually there were
several generations of cases. An example of a very large compound of 95
residents in which 14 measles cases occurred between December 12, 1988 and
February 27, 1989 is displayed in figure 6.1: 6 generations of cases could be
distinguished: the index case, a 3 year old boy who was a visitor from Bambey,
a nearby town, infected 6 other children in the same kitchen (second generation),
who in turn infected 4 other children again in the same kitchen (third
generation). Later, there were three other generations of one child each, in
another kitchen at about 13 to 14 days interval each.
In ail compounds investigated during the study period, details were
obtained on living patterns and disease transmission. Each case was classified
according to the kitchen (Ngak) he was eating from and to the hut he was sleeping
in. An index of intensity of exposure which measured the social proximity to the
source case was defined as: (1) if the source and the infected cases did not live
in the same compound, (2) if in the same compound but not in the same kitchen,
(3) if in the kitchen but not the same hut, (4) if in the sarne hut. The source
case was identified as the "most likely" in the previous generation, ie the child
with the highest social proximity in the previous generation. The interval
between two successive generations was 7 to 18 days, 12.2 on the average. This
was due to the variance in the duration of the incubation period and in the
period of infectivity of a child (table 6.4 and 6.5).
There was little doubt that successive generations were properly identified
because most of the time there was a time lag of about la days between two
successive generations; 7-18 days seems to be a good eut-off to separate the same
generation from successive generations. OUr definition of the source case may
have sorne arbitrary component in extreme situations, but even comparing the date
of onset of a secondary case with the date of onset of the first and the last
case in the previous generation did not change the general picture and extreme
situations «7 or >18 days between secondary case and first or last case of the
previous generation) could be explained differently (same generation or three
different generations).
There were on the average 1.10 cases in the first generation (10\ of co-
index cases), 2. 08 cases in the second generation and 1.90 in the third
generation. Only three compounds had more than 3 generations, with 1 case in each
of the generation of rank higher than 3. The secondary attack rate diminished
with the rank of the generation. This is probably due to a selection of large
compounds, in which the secondary attack rate is lower because social proximity
is lower.
Altogether, secondary cases accounted for 60.8% of ail cases, a typical
feature of measles transmission in West Africa. This pattern has given the team
the opportunity to investigate clinical measles at the onset of the disease in
most secondary cases.
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6. 4 DBMOGRAPBY OF MBASLBS
Incidence, age and sex pattern
Incidence of measles was relatively low over the study period: on the
average 10.5/1000 person-years lived by children age 0-14. It was highest in the
5-9 years age group (the unvaccinated population) and below 10 months, before
vaccination of all groups (table 6.6, figure 6.2). These figures did not take
into account the exact time spent at risk, ie they did not discount for
vaccinated children and for children who already had measles. The age pattern
of measles incidence was strongly influenced by the vaccinations and was markedly
different from previous years. Incidence was slightly higher for females, as was
observed earlier on, although vaccine coverage was the sarne for males and
females.
case fatality
Mortality from measles was markedly low over the study period and much
lower than during previous years (figure 6.3). Only 5 deaths were recorded, four
girls, age 22 months, 23 months, 5 years and 6 years and one boy who was 20
months old. There were no deaths below age 1 year, whereas in previous years this
age group had the highest Case Fatality Ratios (CFR). The CFR for all ages was
15.8/1000 in 1988-1989, Le. 73.1% less than during the previous 1983-1987 period
(table 6.7). The strongest mortality decline was in infancy (100%) and in early
childhood, age 1 to 4 years (53.5%). Details of the measles deaths are given in
annex A-1.
The major achievement of a low case fatality ratio was due to the close
follow-up and careful treatment of each case from the first visit by the project
physician. Standard treatment was the following:
- systematic antiparasitic treatment, for intestinal worms (Mebendazole) and
malaria (Chloroquine);
- systematic treatment of fever (ASpirin);
systematic treatment of conjunctivitis, keratitis and stomatitis with
antiseptic (Aureomycin, Iduviran and Pyralvex);
- treatment of acute lower respiratory infection (ALRI) with antibiotics
(Cotrimoxazole, Ampicillin, ceporexin);
- treatment of diarrhea episodes with Unicef Oral Rehydration Salts (ORS);
- treatment of nutritional deficiencies: Protein-Energy-Malnutrition (PEM) with
a high energy mixture (oil-sugar-yoghurt) and anemia with iron pills;
- treatment of other diseases at home when possible; in particular otitis and
laryngitis;
- referral to a hospital for emergency treatment when needed, in particular:
+ croup
+ acute bronchopneumonia
+ any neurological complication
+ any hemorrhagic form
- referral to an ophthalmologist in cases of post measles keratitis.
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Figure 6.2
MEASLES INCIDENCE IN STUDY AREA, 1987-1990
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PART II : CLDUCAL CONFIRMATIOH
6.5 CLIHICAL SIGHS AND SCORES
Once a case was reported or at least suspected by the family or detected
directly during home visits, it was considered "compatible" and was clinically
examined once a week, more if treatment was needed, and at least 5 times if still
present in the study area. Clinical aspects of measles have been described for
centuries (Krugman et al. 1977). The field physician was asked to fill-out a forro
with all clinical signs of measles as well as other relevant signs. Most of the
signs were observed by the field physician. However, a mother's declaration was
also considered valid for cough and diarrhea, even if the physician did not have
the opportunity to observe these symptoms directly. Signs and symptoms
systematically recorded were:
1) Typical rash and desquamation: the exanthem begins as an erythematous
macopapular eruption. The rash appears on the average on day 2, first behind
the ears, then it spreads to the face on day 3, on the neck, thorax and arms on
day 4 and on the trunk and legs on day 5; the rash stays visible until day 7 to
8. When the rash begins to fade, the skin takes on a marble appearance
(staining). The desquamation then follows, in the same order as the rash.
2) Untypical rash: sometimes the rash is less typical, especially among
vaccinated children. It can be similar to a rash associated with common miliaria
(see chapter 4).
3) Koplik spots: they are pathognomonic of measles. They appear during the rash
and last for 2 to 3 days.
4) Con1unctivitis: appears during the prodromic phase. Eyes are red and tearful,
sometimes mucous is present; the child is often photophobie.
5) Stomatitis: follows the same pattern as conjunctivitis. It is often due to
Herpes virus.
6) Cough: occurs during the prodromic period, becomes milder later but usually
continues for all of the rash and desquamation periode
7) Fever: fever increases dramatically during the prodromic phase and can peak
above 40·C on day 3 or 4. It usually diminishes gradually later on, except in
the case of severe complications.
8) Pulmonary complications: all pulmonary complications were recorded, whatever
their origin: pneumonia, bronchitis, bronchopneumonia, lung abscess, pleurisy,
pneumothorax.
9) Diarrhea: all episodes of diarrhea were noted, usually from mother' s
declaration, whatever the number of stools per day, the aspect of the stools
and the duration.
10) Other symptoms: were noted as well on the forro, but not coded. Among them
were cases of keratitis, otitis, laryngitis and neurological complications and
one case of hemorrhagic measles.
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Figure 6 •.4
Clinical signs during measles
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Complications during measles
Niakhar 1988-1989
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6.6 OBSERVBD CLDIl:CAL SIGBS
Results of the clinical investigation are displayed in tables 6.S and 6.9
and in figures 6.4 and 6.5. The rash was present in virtually all cases from day
5 to 10 and staining or desquamation was visible for at least one more week until
day lS. In a small number of cases the rash either started late (day 4 or 5) or
ended early (day S or 9) which explains that the total percentage of children
with rash does not add up exactly to 100\. However, all children counted as
measles cases had a rash, either typical or untypical. All of them also had a
cough at one point in time, and usually the cough lasted as long as the
desquamation was visible.
Koplik signs were seen in 26.5 to 44.0 \ of cases when the child was seen
from day 1 to 6.
Conjunctivitis was present along with fever and stomatitis: these three
conditions were present in SO. 3 to 92.3\ of cases at day 5-6 and tended to
disappear around day 15, except in severe cases.
6.7 COMPLlCATIOBS: ALRI ABD DIARRBBA
Complications of measles, namely Acute Lower Respiratory tract Infection
(ALRI) and diarrhea were frequent. ALRI peaked at day 7-S in 33.1\ of cases.
Diarrhea had two local peaks: one around day 5-6 (19.7 \ of cases) and a second
peak around day 17-22 (11.1 \ of cases). Fever had a first local peak around day
3-4 (93.3\ of cases) and a second local peak around day 17-22 when diarrhea
complications seem to be relatively more prevalent.
These observations on dates of complications matched observations made
earlier about dates of measles deaths: most deaths occurred either during the
second week after onset of symptoms, and were usually associated with ALRI, or
during the third week, and were usually associated with diarrhea. Complications
virtually disappeared after day 35. This underlines the necessity to count as
measles deaths all deaths occurring during the 6 weeks after the first symptom
occurred: the 2, 3 or 4 weeks duration some researchers use does not seem to be
long enough to capture all deaths due to direct complications of measles.
6. S CLIBICAL SCORE ABD SEVERITr
A clinical score and a severity index were developed from those signs and
symptoms. The clinical score was a weighted average of the score for each
symptom. Weights were the following;
(6) typical rash/desquamation
(5) Koplik spot
(2) untypical rash
(2) conjunctivitis
(2) stomatitis
(1) cough
(1) fever (>=3S"C)
(0) ALRI
(0) Diarrhea
The maximum score was 17 (every symptom except the atypical rash). All
signs were directly examined by the project physician; however cough was not
always heard by the physician but mother' s declaration was considered acceptable.
For all symptoms a severity index was defined, with a value assigned to
each:
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Mean score during measles
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(1) mi1d, when the symptom was bare1y detectab1e,
(2) medium, when the symptom was as normally expected,
(3) severe, when the symptom was particularly severe.
The severity index was the sum of the severity for all 9 symptoms in the
above liste Its maximum value was 24 (al1 severe symptoms except the atypical
rash) •
Clinical score and severity differed for vaccinated and unvaccinated
children (table 6.10 and figures 6.6 and 6.7). Clinical score and severity peaked
around days 5-6 and then declined gradually to become virtually nil around day
42. For vaccine failures, the score and the severity were virtually the same
during the first week but were significantly lower afterwards. The score among
vaccinated children was about half that of unvaccinated children at day 29-35.
The severity was already much lower after the first week.
The frequency of complications was also much lower among vaccinated
children (table 6.11). On the average there were 46\ less diarrhea cases
(P<.0213) and 78\ less ALRI (P<.OOll) among vaccinated children. This suggests
that even when the vaccine does not have a protective effect against the
infection, it makes the infection milder and may well protect against mortality.
In the study area, never a case of measles death was recorded among a vaccinated
child.
6.9 CLDfICAL VALIDATION
The protocol made provision to validate clinical measles when the score
was at least equal to 8 (firm clinical evidence) and to consider a possible case
when clinical score was 7 or less • A score of 8 or more implies a rash in all
cases, a cough plus some additional symptom (table 6.12). A score of 6-7 almost
always implies a rash (98.8\).
Since children with measles were seen several times during the acute phase,
the physician had several opportunities to observe a high score. Measles cases
were characterized by their maximum score during the course of the disease (table
6.13). Among both the vaccinated and unvaccinated children, a large majority of
those who were examined during the day 1-42 period had a score greater than or
equal to 8 (89.6\ and 83.3 \ ). In comparison, no contact, that is children present
in the compound who did not develop measles, had a score greater than 7. One
fifth (20.0 \) of all measles case were not examined during the acute phase (day
1-42): most of these were cases which occurred outside the study area or isolated
cases which were reported too late.
In a few cases which were examined at least once between day land day 42,
a typical rash with cough could was not observed. Among the 24 vaccinated
children, all had a typical rash with cough but among the unvaccinated children,
5 out of 219 had only a typical rash, with no cough when examined (table 6.14).
To the clinically confirmed cases (at least a score higher than- or equal
to 8) one could add those who were in contact with a directly confirmed case in
the same compound (table 6.15). Among the 306 measles cases recorded during the
period from August 15, 1987 to December 31, 1989, 71.6 \ were directly confirmed
and an additional 10.8\ were indirectly confirmed. The proportion of confirmed
cases was 98.1\ for secondary cases, 89.8\ for index cases and only 24.1\ for
cases outside of the study area. This could be regarded as a high confirmation
rate, given the numerous difficulties of communication in this environment.
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PART III SBROLOGICAL CORlrIRMATIOR
6.10 SEROLOGICAL DATA
Sero1ogica1 confirmation of c1inica1 meas1es cases was sought for aIl
cases every time this was physically possible. Instructions were given to get
a micro blood sample before onset of the disease and four weeks after the onset.
This was possible for most secondary cases in the household; for index cases,
the first blood sample was taken at the time of the first visit. This could occur
within the first few days after the onset of the rash, but sometimes would occur
much later. When the first blood sample was taken late in the acute phase (at
week 2 or 3), an effort was made to take the second blood sarnple to document the
decrease of HI antibodies after the acute phase. For isolated cases, especially
cases outside of the study area, only one blood sarnple could usually be taken.
In this case, a high titer was not considered to be a confirmation of measles
infection but was considered a useful piece of information.
Blood samples were taken in the compound, by the field physician, during
thè visits for clinical exarnination. The handling of the blood sarnples was
identical to that of those taken after vaccination: samples were taken in cold
box to the field station where they were centrifuged at night and frozen. They
were taken to Dakar every Friday night and then to Fajarah regularly. The
tittering of HI antibodies was done exactly the sarne way as for post vaccination
samples.
6. 11 lUNETICS OF BI ARTIBODIES DURIRG THE COURSE OF IRFEC'l'IOR
Because blood sarnples were not all taken at the sarne time after onset of
infection, data permitted a crossectional analysis of the kinetics of HI
antibodies. The GMT of HI measles antibodies were lowest during the incubation
period and the first two days of clinical manifestation. It started rising at
day 3, approximately the day of onset of the rash and reached a maximum after
4 weeks of clinical manifestations. The GMT stayed at high levels for about two
weeks, after which it started to decay gradually (table 6.16, figure 6.8).
Distribution of HI antibodies was somewhat different for cases among
vaccinated (table 6.17). Among children who later developed measles, sampled at
most 42 days prior to infection and before day 3, there was a higher GMT among
vaccinated children; among cases sampled from day 28 to day 42 the GMT was higher
arnong unvaccinated children; among contacts who were susceptible but not infected
the GMT was higher among vaccinated children.
change in HI antibody titer during the course of infection was also
different between vaccinated and unvaccinated children (table 6.18). For children
sarnpled before day 3, the rise of HI antibodies was Il.1 times higher among
unvaccinated children (842/76); for children sampled between day 3 and day 14,
the rise of HI antibodies was 5.7 times higher among unvaccinated children
(223/39). In the first group all children had at least a 16-fold increase in
titer; in the second group this proportion was 83.1% in the unvaccinated group
and 72.2% in the vaccinated group.
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Figure 6 •. S
Kinetics of antibodies during clinical measles
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6. 12 SUBCLIRICAL MBASLBS AND BOOSTER BFFBe'r
There was no systematic attempt to study subclinical measles or booster
effects after exposure to measles in a compound. However, in several instances
blood samples with either a significant rise in antibody titers or with high
antibody titers were available for children who did not have any clinical
manifestation but were exposed in a compound. These 17 cases are displayed in
detail in annex A-l:
5 children had a significant rise in antibodies after exposure to measles:
- 3 children were vaccinated with the EZ-HT vaccine
- 1 child was vaccinated earlier with a standard vaccine
- 1 child was 3 months old and had no detectable antibodies at time of exposure.
He was vaccinated later at 5 months but failed to seroconvert.
12 children had very high titers (>=2 A 12) after exposure to measles:
- 5 children were vaccinated earlier with a standard vaccine
l child had measles earlier
6 children had an unknown vaccination and measles status.
There was no evidence that any of these children had transmitted the virus
to another child. In one of the compounds (01-002) there was a missing link
between two generations: we did not find evidence of an increase in antibodies
titer among the only susceptible child who could have been responsible for
transmission and who did not develop measles (the child was vaccinated).
6. 13 SEROLOGlCAL CONP'IRMATION
Serological confirmation was defined as follows:
- at least a 4-fold increase in HI antibodies during the acute phase
(that is during the first 42 days of clinical signs);
157 cases met this definition (51.3\)
- or at least a 2-fold decrease in HI antibodies after the acute phase
(that is after the first 42 days of clinical signs);
only 2 cases met this definition (0.6\)
As in the case of indirect clinical confirmation, indirect serological
confirmation was defined as a contact with a serologically confirmed case in the
sarne compound (table 6.19): 36 children met this definition (11.8%). Altogether,
63.8\ of cases were serologically confirmed.
The proportion of cases serologically confirmed depended upon the time at
which the first blood sample was taken and whether a blood sarnple had been taken.
There were only a few cases of systematic refusal of blood sarnpling: four entire
compounds, arnong them was the one with the largest number of cases. In addition,
in a number of cases the second blood sarnple could not be taken, due to refusal
by mother or temporary absence of the child.
As was the case for clinical confirmation, the proportion of cases that
were serologically confirmed strongly varied between cases outside of the study
area (5.6 \), index cases (66.3 \) and secondary cases (82.5 %). Altogether
52.0\ of cases were directly confirmed and an additional 11.8\ were indirectly
confirrned by contact within the sarne compound. These proportions were slightly
lower for vaccinated children, among whom only 46.7\ were directly confirmed and
13.3 \ indirectly confirmed.
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PART IV : CASE DBFIHITIOli
6.14 SElISITIVITY ABD SPBCIPICITY OP VlUUOUS CRITERIA
Table 6.20 displays the sensitivity and specificity of various criteria
used for characterizing measles cases. Sensitivity was computed as the proportion
of measles cases fitting the criteria. Specificity was computed as 1 minus the
the proportion fitting the criteria among contacts who did not develop measles.
Values of sensitivity were relative to the case detection strategy and to the
time at which the child was examined or had a blood sample taken. Therefore,
values of sensitivity and specificity were given for: 1) the population as a
whole 2) children who were examined or sampled at the optimal time; that is day
1-42 for rash and desquamation, day 1-8 for Koplik spots, day 3-10 for maximum
clinical score. Values of specificity were relative to the definition of measles.
In this study, emphasis was on clinical measles: therefore 100\ specificity for
major clinical signs was expected.
In optimal conditions, high values of sensitivity were obtained for typical
rash (99.2\), clinical score >= 8 (92.4\), 4 fold and 16 fold increase in HI
antibodies (100\). Low values of sensitivity were obtained for Koplik spots
(38.8\) and for titers at least equal to 16,000 miu (82.3\). High values of
specificity were obtained for all signs taken in optimal conditions.
In the population as a whole, values of sensitivity were lower because
Many cases were not examined or sampled at the optimal time. Values were low
for rash (78.8\), maximum score (71. 7\), 16 fold increase in HI antibodies
(51.8\), 4 fold increase in HI antibodies (60.9\), titers at least equal to
16,000 miu (57.6\) and very low for Koplik spots (25.4\).
6.15 CASE DBFIliITIOH
Due to the high values of sensibility and specificity found among children
who were examined and had blood taken at the appropriate time and to the lack
of evidence for subclinical measles among contacts, we considered two case
definitions:
Definition 1 : all cases, that is all cases reported by the family, that were
considered as being real measles after all possible investigations were made,
even if they were not clinically or serologically confirmed.
Definition 2 : confirmed cases, that is all cases meeting definition 1 that were
clinically and serologically confirmed, either directly or indirectly.
Definition 1 does not include all cases that were suspected by the
families, but all those that were later recognized as measles by the family and
accepted as such by the investigators. In fact, it happened that in the Middle
of an outbreak in a village, a mother would say that she feared that her child
was developing measles, because the child had, for instance, fever and cough.
These cases were investigated by the physician and found to be of another
etiology. Later, in May 1990, the physician went back to the family to ask the
mother if she felt that the child had in fact had measles at that time; in all
cases, the mother answered no. This matches previous observations in the study
area, where it was found that it was easier to determine measles retrospectively,
say after a few months, than it was for a physician who was examining a child
in a clinic at the time of an outbreak.
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Definition 2 is obviously quite restrictive in this context, since it
eliminates about one third of cases that were most likely real measles cases.
The proportion of confirmed cases among vaccinated children (53.3%) was slightly
lower than that of cases among unvaccinated children (67.4\). Therefore,
estimates of vaccine efficacy using definition 1 or definition 2 might be
slightly different. A simple computation showed that if the proportion of
confirmed cases was lower for vaccine failures (cv) than for unvaccinated cases
(cn), then the estimate of vaccine efficacy was overestimated with definition
2:
el = 1 - (iv)/(in)
e 2 = 1 - (cv*iv)/(cn*in)
(1-e2 )/(1-e1 ) = cv/cn
e 2 = (cv/cn)*e1 + (l-cv/cn)
if cv/cn < 1 then e 2 > el
where e is the vaccine efficacy, iv is the incidence among the vaccinated group
and in the incidence among the unvaccinated group. For instance, if cv/cn = .790
and el = .850, then e 2 = .882 which will overestimate the true vaccine failure
by 21\.
6 • 16 SUMKARY OP MAIB POINTS
- There were three outbreaks of measles between August 1987 and August 1990, with
a total of 548 cases; 60\ of cases were secondary in the compound. In addition
53 children developed measles outside of the study area.
- Incidence in the general population was lower than during previous years. Due
to the high level of care provided, measles mortality was 73\ lower than during
previous years.
- Among cases of vaccine failure, clinical signs were milder, severity was lower
and rates of complications were also lower.
- 80.1\ of all cases that occurred in 1987-1989 were confirmed by the observation
of clinical signs by the field physician. The proportion of children with a score
at least equal to 8 was 92.4\ when the child was examined during the acute phase
(3 to 10 days after onset).
- 60.0\ of all cases that occurred in 1987-1989 were serologically confirmed.
The proportion of cases with at least a 4 fold increase in antibodies was 100\
when the first sample was taken prior to 2 days after the onset of the rash and
when the second sample was taken at least 28 days after the onset of the rash.
46.1\ of all cases that occurred in 1987-1989 were directly confirmed
(clinically and serologically) and 15.0\ were indirectly confirmed. Proportion
of confirmed cases was lower among cases of vaccine failure.
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CHAPTER 7
VACCINE EFP'ICACY
Two studies of vaccine efficacy were conducted among project children: a
study of cohort efficacy among the 24 birth cohorts vaccinated, and a study of
case-contact efficacy among cases that occurred among the children present in
the study area during measles outbreaks. In addition, and for comparison, vaccine
efficacy of standard vaccines was also studied among older children who did not
participate in the study but who were vaccinated during earlier vaccination
campaigns. All measles cases that occurred between August 15, 1987 and August
14, 1990 were included for these studies of vaccine efficacy.
7.1 DKPIRITIORS
Measles cases
The case definition for measles cases was discussed at length in the
previous chapter. Two definitions were used in this chapter:
a) confirmed cases (N=211)
They include: all cases that were clinically confirmed and serologically
confirmed (directly or indirectly). Indirect confirmation here means in contact
with a confirmed case in the same compound.
b) all cases (N=589)
They include all confirmed cases plus:
- clinically confirmed cases which were not serologically confirmed (N=316);
most of these were cases from the spring of 1990 for which blood samples were
not available when this report was written;
- cases reported by family for which no confirmation could be made by the team
(N=78): most of them were cases outside of the study area or isolated cases that
were detected too late;
- there was no serologically confirmed case that was not clinically confirmed.
OUtbreak in a compound
An outbreak in a compound is a series of measles cases linked together,
ie for which there is evidence of transmission. Two outbreaks were considered
different when there was a discontinuity in the transmission within the compound
and when other cases developed later from another source. This occurred in a case
in September 1989, where a first case did not infect anybody because he was away
during the infective period, but the susceptible children were infected 17 days
later by another child from a neighboring compound.
Susceptibles
For the case-contact study, susceptibles were all children present at the
time of the measles outbreak in the compound, who never had measles, whatever
their vaccination status. The susceptible population was broken down according
to vaccination status and type of vaccine received.
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Contacts
Contacts were all susceptibles who did not develop measles during the
current outbreak plus all secondary cases in the compound. In certain compounds
there were two outbreaks at two different times during the study period. Some
of the children could be non infected contacts for one outbreak and cases for
the next outbreak. In a special case, a child was a secondary case in his own
compound, therefore a contact, and index case in another compound where he was
sent during the incubation period, therefore not counted as a contact in the
second compound.
Exposure to measles
Exposure to measles begins at age 140 days (20 weeks), since virtually no
case was ever recorded prior to this age in the study area. The exposure period
ends either at onset of measles rash, if the chi1d develops measles, or at the
end of the study, or at time of death or at time of outmigration, which ever
comes first. Exposure started on August 15, 1987 and lasted until August 14,
1990.
For the cohort studies, exact periods of exposure were computed in each
case for each child. Exposure in a vaccinated group, including the placebo group,
starts 14 days after the injection; before that date, the child is considered
to belong to the unvaccinated group. For instance a child can start his exposed
life in the unvaccinated group, from age 20 to age 21 weeks, then receive the
placebo at age 22 weeks and later the Standard measles vaccine at age 44 weeks
(see diagram below). He will have a first exposure period in the unvaccinated
group from age 20 to 23 weeks, then a second exposure period in the placebo group
from age 24 to 45 weeks, then a third exposure in the vaccinated group from age
46 weeks until the age at the end of the study.
Birth Placebo Vaccine End
Age in 1 1 1 1
weeks 0 22 44 88
1 1 1 1 1 i 1
Expo- 20 24 46
sure * * Period 1 * Period 2 * Period 3 *(not exposed) (unvaccinated) (placebo group) (vaccinated group)
For the case-contact study, the residence and susceptible situations of
the children were assessed separately for each outbreak. In the case of two
successive but different outbreaks in a compound, a child was considered a
contact not infected during the first outbreak and a case during the second
outbreak.
Incidence
Incidence was computed by dividing the number of measles cases by the
person-years at risk lived by the susceptible population during the period of
exposure. This could be done between two points in time or between two ages.
i = nb cases / PYS spent between time t l and time t 2(or between age al and age a 2 )in the susceptible population
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Case/contact ratio
In the case contact study, the case/contact ratio (secondary attack rate)
was defined as the ratio of cases over the contacts during the outbreak.
p = nb cases / nb contacts
Vaccine protection
Protection after vaccination was assumed to be effective 14 days after
the injection; therefore a case whose rash developed more than 14 days after
vaccination was considered a vaccine failure. In the sample, there was 1 case
of a child vaccinated the day before the onset of rash: he was counted as an
unvaccinated child. All the other cases among vaccinated children occurred at
least 87 days after the injection (1 case at 87 days and all the others at least
1 year after vaccination).
Cohort efficacy
Vaccine efficacy in cohorts was computed using the standard formula:
where i o = incidence in unvaccinated group
il = incidence in vaccinated group
Case-contact vaccine efficacy
Vaccine efficacy was estimated in case-contact situations using the
standard formula:
f = 1 - (Pl/PO)
where Po = case-contact ratio in unvaccinated group
Pl = case-contact ratio in vaccinated group
7.2 VACCINE BnICACY IB COHORTS
The cohort efficacy study was based on the 2470 children belonging to the
24 birth cohorts. 3 children were not considered because they received
accidentally a vaccine that was not scheduled. Children were considered exposed
to measles from the age of 20 weeks until either the end of the study, onset of
measles, death or outmigration. Among the 2470 children, 2224 were still resident
at age 20 weeks and 2044 were still resident at the end of the study. By August
15, 1990, the oldest cohort, born in February 1987, was exposed on the average
for 25.3 months to measles and the youngest cohort, born in January 1989 was
exposed only for 6.9 months.
Among the study children there were 68 cases of measles recorded prior to
August 15, 1990, of which 26 were confirmed cases (table 7.1). For all groups
combined, incidence was 14.0/1000 person-years, whatever the vaccination status
and 40.6/1000 person-years among the unvaccinated children.
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Four vaccine groups were considered for analyzing the exposure according
to vaccination status:
- EZ-HT, who received the Edmonston-Zagreb vaccine age at 5 months,
- SW-HT, who received the Schwarz high titer vaccine at age 5 months,
- Placebo, who received the placebo at age 5 months (only between 5 and 10
months)
- Standard, who received the standard measles vaccine at 10 months or more.
Not vaccinated, the unvaccinated group.
Results of the detailed computations of cohort efficacy are displayed in
tables 7. 2a to 7. 2c. Before the 5 months vaccination session there were 3 measles
cases: they all appear in the unvaccinated group. Between 5 and 10 months there
were 18 cases, 1 in the EZ-HT group, none in the SW-5 group, 5 in the placebo
group and 12 in the unvaccinated group. Between 10 months and the deadline, there
were 47 cases, 4 in the EZ-HT group, 5 in the SW-HT group, none in the Standard
group and 37 in the unvaccinated group. The remaining 3 cases were among non-
residents.
Contacts with measles within the compound were similar in all groups,
which gives a high value to the cohort studies (table 7.3). computed as the
number of project children exposed within a compound of the study area divided
by the number of person-years at risk, the exposure rate was for the first 16
cohorts: 45/1000 in the EZ-HT group, 32/1000 in the SW-HT group, 39/1000 in the
Standard group and 27/1000 in the unvaccinated group; for the last 8 cohorts,
the exposure rate was 41/1000 in the EZ-HT group, 54/1000 in the Standard group
and 51/1000 in the unvaccinated group.
Incidence was much lower in the vaccinated groups, as expected: between
5 and la months, measles incidence was 4.0/1000 in the EZ-HT group, a in the
SW-HT group, 19.4/1000 in the placebo group and 28.6/1000 in the unvaccinated
group. None of these differences was significant (table 7.2a).
After age la months, measles incidence was 4.2/1000 in the EZ-HT group,
8.0/1000 in the SW-HT group, 0.8/1000 in the Standard group and 56.8/1000 in
the unvaccinated group (table 7.2b). Each of the three vaccines was protective
against measles after la months, when compared to the unvaccinated group.
For all ages grouped together, final values of vaccine efficacy cou1d be
derived (table 7.2c). For a11 cohorts, vaccine efficacy was 98.0% for the
Standard vaccine, [95% confidence interval CI=85.8-99.7, p=1.0E-4], 89.9% for
the EZ-HT vaccine [CI=74.7-95.9, p=1.1E-6], and 83.6% for the SW-HT vaccine
[CI=58.9-93.4, p=1.2E-4]. There were 5.2 times more vaccine failures after the
EZ-HT vaccine and 8.3 times more vaccine failures after the SW-HT vaccine than
after the Standard vaccine (figure 7.1). These results could be correlated with
the low values of geometric mean titers of measles antibodies 5 months after the
vaccination (see chapter 5).
When restricted to confirmed cases, vaccine efficacy was: 100% for the
Standard vaccine, 84.4% for the EZ-HT vaccine [CI=47.6-95.3, p=0.0026], and
83.1% for the SW-HT vaccine [CI=28.0-96.0, p=0.0164].
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Figure 7.1
Cohort efficacy of the three vaccines
(with 95% confidence inteLVal)
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Figure 7.2
EZ-HT SW-I-IT Standard
Case-contact efficacy of the three vaccines
(with 95% confidence inteLVal)
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Staodard
7.3 CASE-<::OHTACT EFFICAcr
Results of the cohort study were confirmed by the case-contact study,
which controls for exposure. Therefore, all ages were combined (table 7.3). For
all cohorts, estimates of vaccine efficacy fell close to those of the cohort
study: 97.4% for the Standard vaccine [CI=81.4-99.6, p=0.0008], 91.7% for the
EZ-HT vaccine [CI=74.4-97.3, p=O.OOOl], 86.4% for the SW-HT vaccine [CI=47.7-
96.5, p=0.0072]. Relative risks of vaccine failure were also high for the two
high titer vaccines: 3.2 for the EZ-HT and 5.2 for the SW-HT (figure 7.2).
When restricted to confirmed cases, estimates of vaccine efficacy were
somewhat higher: 100% for the Standard vaccine, 94.2% for the EZ-HT vaccine
[CI=77.1-98.5, p=O.OOOl], 93.6% for the SW-HT vaccine [CI=56.0-99.1, p=0.0086].
7 • 4 MULTIVARIATB AHALYSIS
Since the number of cases was small, it was not possible to conduct an in-
depth multivariate analysis that included prevaccination antibody titers and
seroconversion. Only three variables were introduced in the multivariate
analysis: sex, age which is also a measure of the duration since vaccination
for those vaccinated and a proxy for maternal antibody titers for unvaccinated
children, and intensity of exposure based on a scale from 1 to 4 which measured
the social proximity between index and secondary cases. Results (table 7.4) show
that age and sex were not significant; intensity of exposure was a significant
factor (odds ratio RR=2.3, P=0.0272); vaccine efficacy was found to be highly
significant: P=5.6E-6 for the Standard vaccine, P=3.2E-7 for the EZ-HT vaccine,
2.0E-4 for the SW-HT vaccine. Higher values of the odds ratio were found in the
multivariate analysis because intensity of exposure was controlled for, but the
relative risks of vaccine failure in the two high titer vaccine groups were of
the sarne order of magnitude when compared to the univariate analysis: 2.7 for
the relative failure rate of the EZ-HT vaccine and 6.8 for the relative failure
rate of the SW-HT vaccine.
7. 5 EFFICAcr OF STANDARD VACCINES AKONG OTBBR CHILDRBN
The measles and vaccination status of other children living in the
community was also known for most children born since 1978 and for most children
of the phase II area. Incidence of measles for children born between January 1,
1978 and December 31, 1986 was also investigated during the period from August
15, 1987 to August 14, 1990. Although these children were not randomized, it was
still possible to control for exposure to measles in the study area and therefore
to compute valuable estimates of cohort and case-contact efficacy.
There were two vaccination campaigns that could have affected those
children: a campaign organized by the director of this study in the spring of
1981, 1982 and 1983 in the 8 villages of the phase II area (1089 children
vaccinated), for which the quality of the vaccine and the safety of the cold
chain were high; the national vaccination campaign which was monitored by the
team between October 1986 and April 1987 but for which there was no control on
the cold chain (1397 chi1dren vaccinated). Some of the children were also
vaccinated during the project (1987-1989). Other information on vaccination came
from vaccination cards which were systematically asked for every year during
the demographic census and every time a new immigrant arrived in the study area.
Children whose vaccination status and measles status were unknown as well as
children who had a record of two measles vaccinations were counted with the
"other and unknown". There were 28 cases of vaccine failure among other children,
451 cases among unvaccinated children and 41 cases among children of unknown
vaccine status (table 7.5).
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Results of the cohort efficacy study appear in table 7.6. The 81-83
campaign had a 96.4% efficacy [CI=74.2-99.5, p=0.0010); the 86-87 campaign had
a 86.4% efficacy [CI=77.2-91.9, p=1.0E-13).
Results of the case-contact efficacy study appear in table 7.7. The 81-
83 campaign had a 100% efficacy and the 86-87 campaign had a 92.5% efficacy
[CI=84.5-96.4, p c 3.2E-11). When restricted to confirmed cases, the efficacy of
the 86-87 campaign was 94.6% [CI=87.3-97.7, pa1.9E-10).
7.6 PROTBCTIVB VALUBS OP ARTIBOD:IBS
Since in many cases antibody levels were measured at time of exposure, it
was possible to evaluate the protective levels of measles antibodies. The
analysis was done separately for vaccinated and unvaccinated children (table
7.8). Among unvaccinated children, 42.9 % having a titer from 250-499, 40.0%
having a titer from 500-999, and 9.1% having a titer from 1000-1999 contracted
measles. A titer above 125 miu was fully protective among vaccinated children.
A titer below 125 miu was 26.1% protective among unvaccinated children and 66.7%
protective among vaccinated children. This indicates that our definition of
"sero-positivity" (at least 125 miu) might be the closest to vaccine protection
within two to three years after vaccination, despite the fact that it includes
a small proportion of children who are protected despite having no detectable
levels of antibodies.
7.7 DISCUSSION
The principal objective of the study was to assess whether high titer
measles vaccines were effective in protecting against clinical measles between
the ages of 5 and 10 months. Due to the low incidence of measles during the first
18 months, the study failed to provide a definitive answer to this question.
However, efficacy of the high titer vaccines was demonstrated both in cohort and
in case-contact studies after 10 months: this demonstrates a posteriori the
efficacy of the vaccines between the ages of 5 and 10 months.
The standard vaccine had a failure rate comparable to what was found in
the united States where the vaccine is administered in the second year of life
(chart 7.1). The fact that high relative vaccine failure rates were found among
the recipients of the high titer vaccines indicates that the strategy of
vaccinating early in life with high titer vaccines is not an optimal approach.
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Chart 7.1 Estimates of meas1es vaccine efficacy in the OSA.
Location Author Year Study Efficacy [95\ CI] (N) Age (most1y)
Texarcana Landrigan 1971 P-B 95.9 (606) 1-9
Connecticut DeWayne 1972 clc 95.9 (134) 3-14
N+S Dakota McCormick 1974 clc 97.3 [80.1-99.9] (9) 0-9
New Jersey Ziskin 1974 clc a 94.3 (172) 13-18
b 87.2 (75)
Chicago Bennish 1983 Hos 7 1 (85) all ( 0-10)
Waltham, MA Nkowane 1984 clc 94.4 [90.6-97.0] (27) school (14-18)
Montana Davis 1985 R-C 96.9 [89.5-98.2] (137) all 0-14)
Wisconsin Mast 1986 clc 93.2 [81-98] (10) school 1-24)
Colorado Hersh 1991 R-C a 94. [86-98] (84) college
b 80. 2
Method: c/c= case-contact, R-C= retrospective cohort, P-B= population based,
Hos=hospital based
1 92.5\ of cases were vaccinated; assuming 98\ coverage, this would lead to
an estimate of 74.5\.
2 if child vaccinated before 15 months.
7.8 SOMMARY OF MAIN FIRDIHGS
- Both EZ-HT and SW-HT were protecting against c1inical measles. This was
demonstrated in a cohort study as well as in a case-contact study. In the cohort
study, the EZ-HT vaccine had a 89.9% efficacy, the SW-HT vaccine a 83.6% efficacy
and the Standard vaccine a 98.0\ efficacy.
- The Standard vaccine had an efficacy comparable to values found in the USA.
- Within 2 to 3 years after vaccination, the failure rate of the EZ-HT vaccine
was 5 times higher than the fai1ure rate of the Standard vaccine; the failure
rate of the SW-HT vaccine was 8 times higher than the failure rate of the
Standard vaccine.
- These results were stable in a multivariate analysis which controlled for
intensity of exposure.
- The efficacy of the Standard vaccine among older children vaccinated in 1981-
1983 was also high (96.4%): this value was consistent with the efficacy of the
Standard vaccine given during the project, despite the fact that these children
were vaccinated 5-9 years before.
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DISCUSSION
8.1 BTBICAL ISSUES
An increase of mortality after high titer measles vaccine was obviously
not expected by the investigators. When preparing the research protocol for this
trial from March to November 1986, extensive consultations were held with experts
on measles vaccines worldwide, in West Africa, Europe and the United States. The
question of potential impact on mortality was raised at that time, but no
empirical evidence was found to support this hypothesis. In fact, the alternate
hypothesis was thought to be likely, and this was the aim of the project: that
is, that live vaccines given early in life would reduce mortality rates of
infants and children, by protecting them against measles. The EZ vaccine has been
used in Yugoslavia for about 22 years without any evidence of causing harm to
children. It is likely that the excess mortality effect the only relative to the
combination of high titer, early age at vaccination and poor health conditions
of the children.
Mortality data were carefully monitored month by month from 1987 to 1989,
using a computer program (SAFEMONE): mortality was similar in all groups during
the first two years of the trial. The differences in mortality by group were
presented at two of the Data Monitoring and Safety Committees, in OCtober 1988
and in June 1989. There was no significant difference in mortality between the
groups. The statistical evidence of excess mortality became clear in April 1990,
when the data from the 1989 rainy season became available and definite after the
1990 rainy season. The use of the EZ-HT vaccine was stopped in November of 1990.
The use of the SW-HT vaccine was stopped in OCtober 1988, when it became clear
that it produced a lower serologic response.
Children who participated in the trial and received the high titer measles
vaccines had at most the mortality rate of the cohorts preceding them. Children
who participated in the study but did not receive the high titer vaccines had
better chances of survival than previous cohorts. In addition, the population
benefitted from the project in terms of survival: there was a marked reduction
in age specific mortality rates at all ages. However, if the vaccine can account
for 5% of excess deaths among vaccinated children, then the potential harm is
greater than the potential benefit of an early vaccination at 5 months, which
would save only 0.4% lives.
The local population received information about the study, its aim and
methodology through three main channels. In February and March 1987, four months
before the trial started, village gatherings were organized: the field physician
explained the aims and the methodology of the project as well as the right of
the women to refuse to participate and the right to withdraw. Field workers who
had weekly contacts with the mothers were informed and were asked to provide
any further information to mothers and fathers at their request. The physicians
who were organizing the vaccination sessions were available to provide any
further information. Informed consent was simultaneously collective and
individual. Some families and even whole harnlets refused to participate in the
trial. Some changed their minds during the course of the study. Some mothers
individually refused to participate in the trial. Of course those who refused
to participate were offered the standard routine vaccines and received the sarne
care as the others.
Children who were at higher risk of dying after high titer measles
vaccines, seemed to have died from common childhood diseases. They should receive
more intensive care to compensate for their increased risk. A design for
appropriate care specially targeted to children who received a high titer measles
vaccine was presented to the health authorities.
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8.2 TUB CONTROL OF BARLY MEASLES MORTALIT!'
The issue of the control of early measles mortality remains open. A major
lesson of this study was that measles mortality could well be controlled in
local conditions when appropriate, timely care was provided to children. A
combination of early and appropriate medical care together with high vaccination
coverage, using standard vaccines at 9 months is one of the currently available
strategy to control measles in developing countries.
Alternatively, two or three doses strategies may be studied. Since a
proportion of children have already lost most of their maternal antibodies at
age 3 and a higher proportion at 6 and 9 months, it might be desirable to
investigate the impact of administering low titer measles vaccines systematically
two or three times before age 12 months. Furthermore, it is possible that early
vaccination prevents against the risk of death, if not against clinical
infection.
The development of new vaccines that would be efficient, safe and
immunogenic, even at very low titers and even when given early in life, could
be a third valuable strategy. The ideal situation would be to be able to combine
these new vaccines with other EPI vaccines.
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Table 0.1 Measles vaccines reported among the resident of the 8 villages
of phase II area, Ngayokheme, 1963-1989.
Year
Month 66 69 79 81 82 83 85 86 87 88 89 Total
Jan a 425 a a a a a a 41 14 15 495
Feb a a a a 122 a a a 218 6 9 355
Mar 156 a a 312 50 600 a a 90 14 14 1237
Apr 382 a a a a a a a a 11 15 408
May a a a a a a a a 1 17 21 39
Jun a a a a a a 0 a 0 15 24 39
Jul a a a a a a a a 1 13 23 37
Aug a a a a a a a a 27 22 23 71
Sep a a a a a a 2 a 12 11 23 48
OCt a a a a a a a a 11 9 8 28
Nov a a a 0 0 0 1 2 5 10 6 24
Dec a a 130 a a 63 4 15 13 8 16 249
Total 538 425 130 312 172 663 7 19 419 149 197 3031
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Table 0.2 Measles cases among the resident of the 8 villages of phase II
area, by month and year, Ngayokheme, 1963-1989.
Month
Year Jan Feb Mar Apr May Jun Ju1 Aug Sep OCt Nov Dec Total
1963 14 14 30 22 18 19 32 19 15 16 15 12 226
1964 6 5 17 35 la 4 7 20 11 6 3 8 132
1965 2 5 140 20 4 13 4 4 4 1 4 1 202
1966 1 73 86 18 4 2 1 2 1 1 1 2 192
1967 a 1 5 3 4 a a 1 a 2 a a 16
1968 1 2 2 2 a 1 1 a a a a a 9
1969 1 3 2 2 2 4 a 1 a 1 a a 16
1970 a a a a a 2 a a 1 a a a 3
1971 8 1 3 32 9 2 a 2 1 1 1 1 61
1972 2 1 a 11 36 3 1 9 1 a 3 2 69
1973 a 3 19 12 30 9 12 3 4 4 4 20 120
1974 42 2 2 1 4 3 3 1 6 5 2 2 73
1975 3 5 5 8 5 3 5 a 3 5 1 2 45
1976 2 1 7 2 6 5 4 a 5 3 8 a 43
1977 6 4 17 9 7 20 9 5 9 la 6 8 110
1978 14 21 18 28 39 7 6 16 8 9 9 18 193
1979 1 25 20 18 15 6 3 4 a 3 1 5 101
1980 1 1 9 9 15 a a 2 5 a 3 1 46
1981 8 la 3 1 9 a a 2 1 a 1 a 35
1982 1 5 9 2 2 a a a a 1 4 14 38
1983 69 55 45 45 13 a a 2 a a 1 a 230
1984 3 4 2 9 5 a 3 4 1 8 2 1 42
1985 6 5 2 8 12 4 3 2 6 9 4 28 89
1986 6 la 19 2 6 a a a a a a a 43
1987 a 1 14 13 3 a a 2 a a a a 33
1988 a a a a 1 a a a a a 1 a 2
1989 4 2 9 3 11 11 4 a a a a a 44
Total 201 259 485 315 270 118 98 101 82 85 74 125 2213
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Table 2.1 Basic demographic rates and events by calendar year,
Niakhar 1983-1989 (updated in April 1990).
Year 1983* 1984 1985 1986 1987 1988 1989 total
EVENTS
Resident 1/1 22830* 23137 23459 23569 24202 24865 25247 26356**
Births 713 1236 1096 1271 1247 1214 1252 8095
Deaths 276 555 706 432 567 410 314 3260
Nat. Increase 497 681 390 845 680 804 938 4835
Inmigration 609 718 646 1041 1087 995 874 6030
OUtJDigration 799 1137 926 1253 1104 1417 703 7339
Net migration -190 -359 -280 -212 -17 -422 171 -1309
Pop. growth 307 322 110 633 663 382 1109 3526
Move within 346 488 443 644 632 752 612 3917
Migrat. flow 2100 2891 2458 3582 3455 3916 2801 21203
Mean Populo 23171 23421 23459 23816 24560 25060 25722 24229
Duration 0.630 1.000 1.000 1.000 1.000 1.000 1.000 6.630
Person-years 14604 23420 23459 23816 24560 25060 25722 / 160643
RATES /1000
Birth 52.9 52.8 46.7 53.6 50.8 48.4 48.7 50.4
Death 18.9 23.7 30.1 18.1 23.1 16.4 12.2 20.3
Nat.increase 34.0 29.1 16.6 35.5 27.7 32.1 36.5 30.1
Inmigration 41. 7 33.2 27.5 43.7 44.3 39.7 34.0 37.5
OUtmigration 54.7 48.5 39.5 52.6 45.0 56.5 27.3 45.7
Net migration -13.0 -15.3 -11.9 -8.9 -0.7 -16.8 6.6 -8.1
Pop Growth 21.0 13.7 4.7 26.6 27.0 15.2 43.1 21.9
Moves within 23.7 20.8 18.9 27.0 25.7 30.0 23.8 24.4
Migrat. flow 143.8 123.4 104.8 150.4 140.7 156.3 108.9 132.0
* Year 1983 was incomplete. First Census was on average on 16 May 1983.
** Population on January 1, 1990.
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Table 2.2 Demographie events by month and year, Niakhar 1987-1989,
(updated in April 1990).
Year Jan Feb Mar Apr May Jun Jul Aug Sep oct Nov Dee Total
Births
1987 104 106 111 102 101 90 88 110 123 104 98 110 1247
1988 82 99 88 83 97 71 77 112 142 154 99 110 1214
1989 113 98 111 106 94 76 75 125 137 125 101 91 1252
Total 299 303 310 291 292 237 240 347 402 383 298 311 3713
Deaths
1987 44 30 27 26 62 56 52 52 49 63 69 37 567
1988 33 29 26 23 21 24 38 38 43 74 41 20 410
1989 26 29 21 28 25 14 20 31 47 36 21 16 314
Total 103 88 74 77 108 94 110 121 139 173 131 73 1291
Inmigration
1987 70 74 102 152 120 202 102 75 21 83 34 52 1087
1988 79 84 78 98 129 156 100 39 27 84 52 69 995
1989 84 57 106 61 121 120 80 41 34 106 34 30 874
Total 233 215 286 311 370 478 282 155 82 273 120 151 2956
OUtmigration
1987 50 68 82 164 170 204 65 66 54 88 40 53 1104
1988 68 96 119 174 218 220 142 85 71 99 47 78 1417
1989 80 75 99 115 121 116 23 11 14 22 19 8 703
Total 198 239 300 453 509 540 230 162 139 209 106 139 3224
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Table 2.4 Multiplicity, sex ratio and life status of deliveries,
Niakhar 1983-1989 (updated in April 1990).
l Sex ratio of live births according to multiplicity
Multiplicity F M total sex ratio confidence interval
Simple 3838 4030 7868 105.0 100.4 109.6
Twins 115 107 222 93.0 68.6 117.5
Triplets 3 2 5 66.7 0.0 183.5
Total 3956 4139 8095 104.6 100.1 109.2
II Sex ratio of still births according to duration of pregnancy
duration F M unknwon total sex ratio , unknown
< 7 mo 25 23 284 332 92.0 85.5
7-10 mo 141 159 17 317 112.8 5.4
Unknown 17 25 32 74 147.0 43.2
Total 183 207 333 723 113.1 46.1
III Life status of deliveries according to multiplicity
multi- born still number propo
plicity alive birth total deliv. still birth
/1000
Simple 7868 688 8556 8556 80.4
Twins* 222 34 256 128 132.8
Triplets 5 1 6 2 166.7
Total 8095 723 8818 8686 82.0
* 106 pairs 2 born alive, 12*2 still born, 10* one alive+one dead.
IV Multiplicity of deliveries according to life status
ratio of multiple
born still total number , per per
alive birth deliveries deliv. deliv. live birth
Simple 7868 688 8556 8556 98.5
Twins 222 34 256 128 1.5 67.9 36.5
Triplets 5 1 6 2 0.0 4343 1619
Total 8095 723 8818 8686 100.0
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Table 2.5 Life table of the population over the course of the project,
Niakhar 1987-1989 (updated in April 1990).
Observed Life table estimates
Age P.Years Deaths Rate Probab. Survivors Deaths P.years Cumul. Life ex.
x PYS D(x) nMx nQx l(x) nDx nLx T(x) e(x)
Male
0 1698.7 178 104.8 97.7 100000 9768 93219 5187305 51.9
1 5763.0 173 30.0 135.0 90232 12180 405760 5094085 56.5
5 5899.9 17 2.9 14.3 78052 1114 386703 4688325 60.1
10 4841.7 5 1.0 5.1 76938 396 383532 4301622 55.9
15 3265.5 3 0.9 4.6 76542 350 381852 3918089 51.2
20 2407.1 14 5.8 28.7 76192 2186 375932 3536237 46.4
25 2219.2 13 5.9 28.9 74006 2137 364794 3160305 42.7
30 2160.9 8 3.7 18.3 71869 1318 356050 2795510 38.9
35 1493.2 9 6.0 29.7 70551 2095 347622 2439460 34.6
40 1170.1 6 5.1 25.3 68456 1733 338086 2091838 30.6
45 1174.8 13 11.1 53.9 66723 3596 325020 1753752 26.3
50 1112.8 15 13.5 65.3 63127 4123 305946 1428731 22.6
55 965.7 22 22.8 108.0 59004 6374 279786 1122786 19.0
60 772.7 15 19.4 92.7 52630 4879 251342 842999 16.0
65 658.2 28 42.5 192.6 47751 9198 216219 591657 12.4
70 451. 7 28 62.0 268.5 38553 10351 166991 375437 9.7
75 324.9 24 73.9 311.6 28202 8787 118954 208446 7.4
80 181.1 23 127.0 480.6 19415 9331 73467 89491 4.6
85 112.5 30 266.6 1000.0 10084 10084 16023 16023 1.6
Pemals
0 1758.3 206 117.2 108.3 100000 10834 92479 5247643 52.5
1 5607.1 177 31.6 141.2 89166 12592 398894 -5155164 57.8
5 5790.6 25 4.3 21.3 76574 1630 . 377665 4756269 62.1
10 4449.4 8 1.8 8.9 74944 670 372761 4378604 58.4
15 2881.8 7 2.4 12.1 74274 896 369174 4005842 53.9
20 2778.4 6 2.2 10.7 73378 788 365077 3636667 49.6
25 2692.2 15 5.6 27.5 72590 1994 358064 3271590 45.1
30 2322.4 13 5.6 27.6 70596 1948 348110 2913525 41.3
35 1637.9 9 5.5 27.1 68648 1861 338680 2565415 37.4
40 1469.4 8 5.4 26.9 66787 1794 329593 2226734 33.3
45 1510.9 9 6.0 29.4 64993 1908 320404 1897141 29.2
50 1396.6 14 10.0 49.0 63085 3089 308165 1576736 25.0
55 1185.7 23 19.4 92.7 59996 5561 286689 1268570 21.1
60 1016.6 8 7.9 38.6 54435 2101 267090 981881 18.0
65 745.8 28 37.5 171.9 52334 8996 239629 714790 13.7
70 548.7 25 45.6 204.6 43338 8867 194611 475161 11.0
75 394.8 31 78.5 327.9 34471 11304 143982 280549 8.1
80 280.0 27 96.4 387.6 23167 8978 93120 136567 5.9
85 202.5 28 138.3 1000.0 14189 14189 43446 43447 3.1
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Table 2.6 Changes in age specifie death rates during the project,
Niakhar 1984-1989, (updated in April 1990).
Baseline Project % reduction
Age in death rate
at (mean) by age
death 84-86 1987 1988 1989 89/84-86
0 129.1 127.3 135.2 73.1 -43.4
1-4 58.1 43.8 28.3 20.8 -64.3
5-9 5.0 3.7 1.9 2.3 -53.5
15-24 2.7 2.7 3.7 1.5 -43.2
25-34 5.3 9.6 2.9 3.2 -40.0
35-44 6.8 6.4 5.8 4.5 -33.0
45-54 12.9 13.4 9.7 6.4 -50.5
55-64 24.8 23.9 12.9 15.1 -39.0
65-74 54.5 76.2 34.0 25.9 -52.4
75-84 96.8 98.0 82.8 86.5 -10.6
85+ 212.9 245.3 143.3 166.0 -22.0
all 23.9 23.1 16.4 12.2 -49.0
NB for details of interventions, see texte
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Table 2.7 Changes in cause-specifie probabilities of dying (/1000)
during the project, children age 0-14 years,
Niakhar 1987-1989, (updated in April 1990).
Baseline Project , reduction in
Cause proba. of dying
of (mean) by cause
death 84-86 1987 1988 1989 89/84-86
Neonatal
Tetanus 15.8* 32.1 25.5 14.4 -9.1*
Hypotrophy 15.5 8.0 22.3 8.8 -43.4
other,unknown 19.4 16.0 23.9 14.4 -25.9
Total 50.7 56.1 71.7 37.5 -26.0
Post-neonatal
Measles 3.0 0.0 0.0 0.0 -100.0
Pertussis 6.5 3.2 0.0 0.0 -100.0
Diarrhea 19.8 23.1 13.3 6.6 -66.5
ARI 15.1 8.8 9.5 3.3 -78.0
other , unknown 27.0 29.5 33.2 23.2 -13.8
Total 71.4 64.5 55.9 33.2 -53.5
Children age 1-4
Measles 25.4 3.5 0.0 3.6 -85.8
Pertussis 15.1 3.5 0.0 0.0 -100.0
Diarrhea 76.2 52.3 28.4 24.1 -68.4
ARI 19.8 8.1 16.6 3.6 -81.8
other,unknown 102.4 120.8 83.0 65.1 -36.4
Total 238.9 188.2 128.0 96.4 -59.6
Children age 5-14
Measles 3.0 0.0 0.0 2.6 -11.4
Pertussis 1.0 1.3 0.0 0.0 -100.0
Diarrhea 9.5 10.7 1.4 2.6 -72.0
ARI 1.0 1.3 1.4 1.3 +32.9
other,unknown 31.9 20.1 15.1 15.9 -50.2
Total 46.3 33.5 17.9 22.5 -51.4
* see text for comments
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Table 2.8 Residence status of the 24 monthly birth cohorts on 01/01/1990
(project children), Niakhar 1987-1989.
Birth Size Status on 01/01/90 % % Age
cohort at Dead OUtmig. on
birth Dead OUtmig. Resident 01/01/90
01 Feb 87 106 20 11 75 18.9 10.4 34
02 Mar 87 111 17 10 84 15.3 9.0 33
03 Apr 87 102 16 14 72 15.7 13.7 32
04 May 87 101 14 12 75 13.9 11.9 31
05 Jun 87 90 16 9 65 17.8 10.0 30
06 Jul 87 88 15 6 67 17.0 6.8 29
07 Aug 87 110 23 5 82 20.9 4.5 28
08 Sep 87 123 21 7 96 17.1 5.7 27
09 OCt 87 104 14 8 80 13.5 7.7 26
10 Nov 87 98 12 13 73 12.2 13.3 25
11 Dec 87 110 14 9 87 12.7 8.2 24
12 Jan 88 82 13 8 61 15.9 9.8 23
13 Feb 88 99 15 7 77 15.2 7.1 22
14 Mar 88 88 11 9 68 12.5 10.2 21
15 Apr 88 83 17 3 63 20.5 3.6 20
16 May 88 97 13 9 75 13.4 9.3 19
17 Jun 88 71 8 6 57 11.3 8.5 18
18 Jul 88 77 9 9 59 11. 7 11. 7 17
19 Aug 88 112 15 6 91 13.4 5.4 16
20 Sep 88 142 17 9 115 12.4 6.3 15
21 OCt 88 154 21 8 125 13.6 5.2 14
22 Nov 88 99 13 0 86 13.1 0.0 13
23 Dec 88 110 12 4 94 10.9 3.6 12
24 Jan 89 113 4 3 106 3.5 2.7 11
Total 2470 350 185 1933 14.2 7.5
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Table 2.9 Burvival of birth cohorte before and during project,
Niakhar 1983-1989, from age 0 to 36 monthe.
Baeeline Project %
Age Cohorte Feb 83-Jan 84 Cohorte Feb 87-Jan 89 reduction
in (N 2073) (N = 2470) in death
monthe rate
x Deathe nQx B(x) Deathe nQx B(x)
0 109 52.6 100000 157 63.6 100000 20.9
1 76 39.5 94742 47 20.8 93644 -47.2
6 75 41.1 90999 68 31.6 91692 -23.2
12 97 57.5 87257 37 22.6 88797 -60.6
18 73 46.3 82239 18 16.2 86787 -65.1
24 58 39.3 78431 15 23.4 85384 -40.4
30 25 18.1 75348 2 12.0 83382 -33.6
36 73983 82379
NB Cohorte are truncated for project children.
Age 0 ie < 28 daye (neonatal period)
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Table 3.1 Attendance to vaccination sessions 01 through 29,
Niakhar 1987-1989.
Vaccination Among project children convoked Other % %
session refusal not conv
Present Absent Refusal Emig Death P.C. else 3/ 6+7/
No Week (1) (2) (3) (4) (5 ) (6) (7) 1+3 1+6+7
01 10/08/87 178 4 3 2 10 0 7 1.7 3.8
02 17/08/87 165 13 7 8 13 1 14 4.1 8.3
03 07/09/87 138 17 11 6 13 6 31 7.4 21.1
04 26/10/87 183 25 43 10 25 1 24 19.0 12.0
05 23/11/87 210 24 30 7 33 8 26 12.5 13.9
06 07/12/87 197 22 50 10 33 8 13 20.2 9.6
07 18/01/88 174 51 51 9 32 4 8 22.7 6.5
08 15/02/88 169 33 81 9 28 8 3 32.4 6.1
09 14/03/88 183 32 54 9 20 16 16 22.8 14.9
10 11/04/88 142 42 48 13 23 20 6 25.3 15.5
11 23/05/88 182 24 55 8 24 22 7 23.2 13.7
12 13/06/88 168 26 46 12 27 20 10 21.5 15.2
13 18/07/88 195 10 55 6 31 14 9 22.0 10.6
14 15/08/88 171 17 57 14 19 11 2 25.0 7.1
15 05/09/88 146 18 42 17 22 17 6 22.3 13.6
16 17/10/88 170 16 54 12 27 17 6 24.1 11.9
17 21/11/88 171 19 43 8 22 15 6 20.1 10.9
18 12/12/88 196 28 53 6 32 19 97 21.3 37.2
19 23/01/89 219 46 44 9 32 20 9 16.7 11.7
20 13/02/89 194 34 48 5 37 23 6 19.8 13.0
21 20/03/89 216 38 56 14 33 17 13 20.6 12.2
22 17/04/89 225 29 47 6 21 17 6 17.3 9.3
23 15/05/89 275 56 64 21 50 16 7 18.9 7.7
24 19/06/89 288 33 74 8 27 24 13 20.4 11.4
25 24/07/89 279 25 78 18 28 22 2 21.8 7.9
26 07/08/89 280 36 73 12 29 9 6 20.7 5.1
27 25/09/89 165 16 45 1 20 19 6 21.4 13.2
28 23/10/89 177 19 43 6 28 21 6 19.5 13.2
29 13/11/89 218 18 55 3 13 7 4 20.1 4.8
Total 5674 771 1410 269 752 402 369 19.9 12.0
% 63.9 8.7 15.9 3.0 8.5 6.2 5.7
NB vaccination sessions were conducted from Tuesday to Thrusday.
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Table 3.2 Attendance to vaccination sessions at age 5 months,
according to birth cohort, Niakhar 1987-1989.
Cohort Konth Date of Attendance at 5 months session ,
of 5 months attend.
birth session Present Absent Refus. Emig Death Total
(1) (2) (3) (4) (5 ) (6) 1/1+2+3
01 02/87 17/08/87 78 12 2 6 8 106 97.5
02 03/87 10/08/87 99 6 1 0 5 111 99.0
03 04/87 07/09/87 71 11 11 3 6 102 86.6
04 05/87 26/10/87 65 10 16 3 7 101 80.2
05 06/87 23/11/87 58 9 12 3 8 90 82.9
06 07/87 07/12/87 53 8 16 1 10 88 76.8
07 08/87 18/01/88 66 15 9 3 17 110 88.0
08 09/87 15/02/88 66 12 32 1 12 123 67.3
09 10/87 14/03/88 65 12 16 4 7 104 80.2
10 11/87 11/04/88 50 14 20 6 8 98 71.4
11 12/87 23/05/88 69 12 18 4 7 110 79.3
12 01/88 13/06/88 46 12 14 4 6 82 76.7
13 02/88 18/07/88 69 6 15 2 7 99 82.1
14 03/88 15/08/88 59 5 15 5 4 88 79.7
15 04/88 05/09/88 48 7 13 2 13 83 78.7
16 05/88 17/10/88 60 6 15 5 11 97 80.0
17 06/88 21/11/88 48 4 11 4 4 71 81.4
18 07/88 12/12/88 52 5 11 2 7 77 82.5
19 08/88 23/01/89 77 17 8 1 9 112 90.6
20 09/88 13/02/89 92 16 20 2 12 142 82.1
21 10/88 20/03/89 96 12 26 5 15 154 78.7
22 11/88 17/04/89 57 10 20 0 12 99 74.0
23 12/88 15/05/89 82 8 10 2 8 110 89.1
24 01/89 19/06/89 80 6 21 3 3 113 79.2
AH cohorts 01-24 1606 235 352 71 206 2470 82.0
, 65.0 9.5 14.2 2.9 8.3 100.0
(2) Absent = not present in the village on vaccination day,
(3) Refusal = did not come to vaccination, although present in the village
on vaccination day, whatever the reason.
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Table 3.3 status of birth cohorts at the 5 months vaccination session,
according to vaccination group, Niakhar 1987-1989.
Cohorts 01-16 Cohorts 17-24
Vaccination group N \ N \
(1) EZ-HT 336 21.1 292 33.3
(2) SW-HT 323 20.3 0 0.0
(3) Placebo 357 22.4 281 32.0
(4) Participant to trial 1016 63.8 573 65.3
(5) Not participant 391 24.6 217 24.7
(6) Dead or outmigrated at 5 mo 185 11.6 88 10.0
(7) Total 1592 100.0 878 100.0
(4/4+5) \ participant if resident 72.3 72.5
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Table 3.4 Status at the 5 months and the la months vaccination sessions,
according to groups of cohorts, Niakhar 1987-1989.
Presence Presence at 5 months
at
la months Present Absence OUtmigrant other Total
+refusal +death
1 Cohorts 01-16
Present 689 137 2 3 831
Absent+refusal 275 216 a 4 495
OUtmig+dead 45 23 186 a 254
other 7 5 a a 12
Total 1016 381 185 7 1592
II COhorts 17-24
Present 447 83 2 8 540
Absent+refusal 93 107 a a 200
OUtmig+dead 16 la 86 1 113
other 17 6 a 2 25
Total 573 206 88 11 878
Nb : other included children who were sick, who came at the vaccination session
but were not vaccinated because of contra-indication, as well as children who
did not receive the expected vaccine.
132
Table 3.5 Measles vaccine coverage in December 1989, project children
still resident, Niakhar 1987-1989.
Measles vaccine given Cohort Cohort Total %
01-16 17-24
EZ-HT at 5 months 275 277 552 29.1
SW-HT at 5 months 274 0 274 14.5
Placebo at 5 + Standard at 10 mo 272 218 490 25.9
other resident vaccinated 146 84 230 12.4
with standard vaccine
Resident not vaccinated 200 148 348 18.4
Total
% vaccinated against measles
1167
82.9
133
727
79.6
1894
81.6
100.0
Table 3.6 Age at vaccination in weeks for the three scheduled sessions,
preject children, Niakhar 1987-1989.
3 menths session 5 months session 10 months session
Age
in Cohorts Cohorts Cohorts
weeks 01-02 03 04-24 01 02-24 01-24
9 3
10 57
11 212
12 270
13 334
14 284
15 181
16 13 73
17 24 4
18 18 8
19 19 104
20 5 260
21 331
22 347
23 290
24 10 132
25 22 44
26 17
27 15
28 14
29
30
31
32
33
34 28
35 35
36 26
37 28
38 20
39
40 26
41 112
42 236
43 320
44 310
45 247
46 109
47 10
Total 137 79 1418 78 1516 1370
Mean 8.26 4.09 3.00 6.00 5.00 10.01(months)
St.dev 0.31 0.27 0.36 0.30 0.35 0.35
(months)
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Table 3.7 Distribution of difference in weeks between the vaccination
sessions at 5 and la months, according to vaccination group,
Niakhar 1987-1989.
Vaccine received at 5 monthsDifference
in number
of weeks EZ-HT SW-HT Placebo Total
l Cohort 01
16 16 14 19 49
II Cohorts 02-16
20 26 22 30 78
21 50 59 64 173
22 46 45 59 150
23 57 70 71 198
24 13 11 17 41
III Cohorts 17-24
20 41 a 37 78
21 84 a 81 165
22 15 a 19 34
23 81 a 89 170
Total 221 a 226 447
Mean 21.53 21.57 21.59
St.dev 1.58 1.81 1.60
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Table 4.1: Age specifie probabilities of dying from birth until time of
5 menths vaccination, according te vaccination group assigned
at birth, preject children, Niakhar 1987-1989,
(/1000 children at risk).
q O/N
o - 27 daysVaccination
group assigned ----------------
at birth
Cohorts 01-16
28 days - 5 months
q O/N
o - 5 months
q O/N
EZ-HT
SW-HT
Standard
Total
Cohorts 17-24
EZ-HT
Standard
Total
Cohorts 01-24
EZ-HT
SW-HT
Standard
Total
62.7
58.8
63.1
61.6
67.9
71.1
69.5
65.1
58.8
66.7
64.4
(33/526)
(31/527)
(34/539)
(98/1592)
(30/442)
(31/436)
(61/878)
(63/968)
(31/527)
(65/975)
(159/2470)
28.4
22.2
15.8
22.1
9.7
12.3
11.0
19.9
22.2
14.3
18.2
(14/493)
(11/496)
( 8/505)
(33/1494)
(4/412)
(5/405)
(9/817)
(18/905)
(11/496)
(13/910)
(42/2311)
89.4
79.7
77.9
82.3
76.9
82.6
79.7
83.7
79.7
80.0
81.4
(47/526)
(42/527)
(42/539)
(131/1592)
(34/442)
(36/436)
(70/878)
(81/968)
(42/527)
(78/975)
(201/2470)
NB 5 months = date of the scheduled 5 months vaccination session.
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NB 5 months date of the scheduled 5 months vaccination session.
10 months date of the scheduled 10 months vaccination session.
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Table 4.3a: Survival after the 10 months vaccination, by vaccination group,
2 sexes combined, project children, Niakhar, 1987-1990,
cohorts 01-16, updated in OCtober, 1990.
Age Survival per 1000 at 10 months Standard deviations
in
month EZ-HT SW-HT Standard other EZ-HT SW-HT Standard other
at 5 at 5 at 10 at 5 at 5 at 10
10 1000.0 1000.0 1000.0 1000.0 0.0 0.0 0.0 0.0
11 993.8 990.2 992.3 1000.0 4.4 5.7 4.4 0.0
12 990.7 986.9 984.7 990.4 5.4 6.5 6.2 5.5
13 990.7 983.6 979.5 977 .6 5.4 7.3 7.2 8.4
14 984.4 980.3 979.5 977 .6 6.9 8.0 7.2 8.4
15 981.3 980.3 979.5 971.1 7.6 8.0 7.2 9.5
16 974.9 973.6 974.3 964.6 8.8 9.2 8.0 10.5
17 955.8 970.3 971. 7 964.6 11.6 9.8 8.4 10.5
18 949.4 970.3 971. 7 964.6 12.3 9.8 8.4 10.5
19 943.0 960.2 971. 7 957.9 13.1 11.3 8.4 11.4
20 933.4 956.8 971. 7 957.9 14.0 11. 7 8.4 11.4
21 930.2 953.5 966.4 954.6 14.4 12.1 9.2 11.9
22 930.2 943.3 966.4 954.6 14.4 13.4 9.2 11.9
23 927.0 943.3 966.4 954.6 14.7 13.4 9.2 11.9
24 917.3 939.9 966.4 951.2 15.5 13.7 9.2 12.3
25 917.3 939.9 958.5 951.2 15.5 13.7 10.2 12.3
26 914.1 936.5 955.8 944.3 15.8 14.1 10.5 13.1
27 914.1 929.7 955.8 934.1 15.8 14.8 10.5 14.3
28 901.1 929.7 955.8 923.7 16.9 14.8 10.5 15.3
29 897.8 929.7 955.8 923.7 17.1 14.8 10.5 15.3
30 888.0 926.3 947.8 920.3 17.8 15.1 11.4 15.6
31 881.0 919.0 944.9 920.3 18.4 15.9 11. 7 15.6
32 881.0 915.1 944.9 920.3 18.4 16.3 11. 7 15.6
33 881.0 915.1 944.9 920.3 18.4 16.3 11.7 15.6
34 881.0 915.1 944.9 920.3 18.4 16.3 11. 7 15.6
35 881.0 910.3 944.9 910.4 18.4 16.9 11.7 16.9
36 870.8 904.9 941.0 910.4 19.5 17.6 12.3 16.9
37 870.8 904.9 941.0 910.4 19.5 17.6 12.3 16.9
38 858.9 904.9 941.0 910.4 21.0 17.6 12.3 16.9
39 852.3 897.9 941.0 910.4 21.9 18.8 12.3 16.9
40 852.3 897.9 941.0 910.4 21.9 18.8 12.3 16.9
41 852.3 897.9 941.0 910.4 21.9 18.8 12.3 16.9
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Table 4.3b: Surviva1 after the 10 months vaccination, by vaccination group,
2 sexes combined, project chi1dren, Niakhar, 1987-1990,
cohorts 01-24, updated in October, 1990.
Age Surviva1 per 1000 at 10 months Standard deviations
in
month EZ-HT SW-HT Standard other EZ-HT SW-HT Standard other
at 5 at 5 at 10 at 5 at 5 at 10
10 1000.0 1000.0 1000.0 1000.0 0.0 0.0 0.0 0.0
11 993.4 990.2 994.2 995.9 3.3 5.7 2.9 2.9
12 991. 7 986.9 985.6 987.7 3.7 6.5 4.5 5.0
13 990.1 983.6 981.3 979.4 4.0 7.3 5.2 6.4
14 985.1 980.3 979.8 979.4 4.9 8.0 5.3 6.4
15 981.8 980.3 975.4 973.1 5.4 8.0 5.9 7.3
16 978.4 973.6 972.5 964.8 5.9 9.2 6.2 8.4
17 968.3 970.3 971.1 964.8 7.1 9.8 6.4 8.4
18 965.0 970.3 971.1 962.6 7.5 9.8 6.4 8.6
19 961.6 960.2 971.1 958.4 7.8 11.3 6.4 9.1
20 954.9 956.8 968.1 958.4 8.5 11. 7 6.7 9.1
21 953.2 953.5 962.2 956.3 8.6 12.1 7.3 9.3
22 949.8 943.3 959.3 956.3 8.9 13.4 7.5 9.3
23 946.1 943.3 959.3 954.0 9.3 13.4 7.5 9.6
24 938.2 939.9 956.0 949.2 10.0 13.7 7.9 10.1
25 938.2 939.9 950.8 946.7 10.0 13.7 8.4 10.4
26 933.5 936.5 948.9 941.2 10.5 14.1 8.6 11.0
27 933.5 929.7 948.9 932.2 10.5 14.8 8.6 12.1
28 921.9 929.7 948.9 922.7 11.8 14.8 8.6 13.2
29 918.8 929.7 948.9 922.7 12.2 14.8 8.6 13.2
30 908.8 926.3 940.9 919.3 13.4 15.1 9.7 13.6
31 901.6 919.0 938.1 919.3 14.2 15.9 10.0 13.6
32 901.6 915.1 938.1 919.3 14.2 16.3 10.0 13.6
33 901.6 915.1 938.1 919.3 14.2 16.3 10.0 13.6
34 901.6 915.1 938.1 919.3 14.2 16.3 10.0 13.6
35 901.6 910.3 938.1 909.4 14.2 16.9 10.0 15.1
36 891.2 904.9 934.2 909.4 15.8 17.6 10.7 15.1
37 891.2 904.9 934.2 909.4 15.8 17.6 10.7 15.1
38 879.0 904.9 934.2 909.4 17.8 17.6 10.7 15.1
39 872.2 897.9 934.2 909.4 18.9 18.8 10.7 15.1
40 872.2 897.9 934.2 909.4 18.9 18.8 10.7 15.1
41 872.2 897.9 934.2 909.4 18.9 18.8 10.7 15.1
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Table 4.4a: Survival after the 5 months vaccination, by vaccination group,
2 sexes combined, project children, Niakhar, 1987-1990,
Cohorts 01-16, updated in October, 1990.
Age Survival per 1000 at 5 months standard deviations
in
month EZ-HT SW-HT Standard ether EZ-HT SW-HT Standard ether
5 1000.0 1000.0 1000.0 1000.0 0.0 0.0 0.0 0.0
6 1000.0 996.9 994.4 997.4 0.0 3.1 4.0 2.6
7 991.0 987.6 986.0 997.4 5.1 6.2 6.2 2.6
8 985.1 975.1 977.5 994.8 6.6 8.7 7.8 3.7
9 979.0 962.6 977.5 986.8 7.8 10.6 7.8 5.9
10 976.0 950.1 969.1 981.5 8.4 12.2 9.2 6.9
11 969.9 943.9 963.4 978.8 9.4 12.9 10.0 7.4
12 966.9 940.7 957.7 968.0 9.8 13.2 10.7 9.1
13 966.9 937.6 957.7 951.8 9.8 13.5 10.7 11.1
14 960.8 934.5 957.7 951.8 10.7 13.8 10.7 11.1
15 957.7 934.5 954.8 949.0 11.1 13.8 11.0 11.4
16 951.5 928.1 946.1 946.2 11.8 14.4 12.0 11. 7
17 932.8 924.9 943.2 946.2 13.8 14.7 12.3 11. 7
18 926.6 924.9 943.2 946.2 14.4 14.7 12.3 11. 7
19 920.4 915.3 943.2 940.6 15.0 15.6 12.3 12.3
20 911.0 912.1 943.2 940.6 15.8 15.9 12.3 12.3
21 907.9 908.9 937.3 937.8 16.0 16.1 12.9 12.6
22 907.9 899.2 937.3 937.8 16.0 16.9 12.9 12.6
23 904.7 899.2 937.3 937.8 16.3 16.9 12.9 12.6
24 895.3 896.0 937.3 935.0 17.0 17.1 12.9 12.8
25 895.3 896.0 928.5 935.0 17.0 17.1 13.8 12.8
26 892.2 892.7 925.5 929.2 17.2 17.4 14.1 13.4
27 892.2 886.3 925.5 920.7 17.2 17.9 14.1 14.2
28 879.5 886.3 922.5 914.9 18.1 17.9 14.3 14.6
29 876.3 886.3 922.5 914.9 18.3 17.9 14.3 14.6
30 866.7 883.0 913.5 912.0 18.9 18.1 15.1 14.9
31 859.8 876.0 910.4 912.0 19.4 18.6 15.4 14.9
32 859.8 872.4 910.4 912.0 19.4 18.9 15.4 14.9
33 859.8 872.4 910.4 912.0 19.4 18.9 15.4 14.9
34 859.8 872.4 910.4 912.0 19.4 18.9 15.4 14.9
35 859.8 867.7 910.4 903.8 19.4 19.4 15.4 15.8
36 849.9 862.6 906.0 903.8 20.4 19.9 15.9 15.8
37 849.9 862.6 906.0 903.8 20.4 19.9 15.9 15.8
38 838.3 862.6 906.0 903.8 21.7 19.9 15.9 15.8
39 831.8 856.0 906.0 903.8 22.5 20.8 15.9 15.8
40 831.8 856.0 906.0 903.8 22.5 20.8 15.9 15.8
41 831.8 856.0 906.0 903.8 22.5 20.8 15.9 15.8
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Table 4.4b: Survival after the 5 months vaccination, by vaccination group,
2 sexes combined, project children, Niakhar, 1987-1990,
cohorts 01-24, updated in OCtober, 1990.
Age Surviva1 per 1000 at 5 months Standard deviations
in
month EZ-HT SW-HT Standard ether EZ-HT SW-HT Standard Other
5 1000.0 1000.0 1000.0 1000.0 0.0 0.0 0.0 0.0
6 998.4 996.9 996.9 995.0 1.6 3.1 2.2 2.9
7 993.6 987.6 992.2 995.0 3.2 6.2 3.5 2.9
8 990.4 975.1 985.9 989.9 3.9 8.7 4.7 4.1
9 987.2 962.6 982.7 984.8 4.5 10.6 5.2 5.0
10 982.3 950.1 974.8 979.7 5.3 12.2 6.2 5.8
11 977 .5 943.9 968.4 974.5 6.0 12.9 6.9 6.5
12 975.8 940.7 960.5 965.9 6.2 13.2 7.7 7.5
13 974.2 937.6 958.9 955.5 6.4 13.5 7.9 8.5
14 969.3 934.5 957.3 955.5 6.9 13.8 8.0 8.5
15 966.0 934.5 950.9 952.0 7.3 13.8 8.6 8.8
16 962.7 928.1 944.4 948.5 7.6 14.4 9.1 9.2
17 952.8 924.9 942.8 948.5 8.6 14.7 9.3 9.2
18 949.5 924.9 941.2 948.5 8.8 14.7 9.4 9.2
19 946.2 915.3 941.2 945.0 9.1 15.6 9.4 9.5
20 939.6 912.1 937.9 945.0 9.6 15.9 9.6 9.5
21 937.9 908.9 931.4 943.2 9.8 16.1 10.1 9.6
22 934.6 899.2 928.2 943.2 10.0 16.9 10.3 9.6
23 930.9 899.2 928.2 941.3 10.3 16.9 10.3 9.8
24 923.1 896.0 926.3 935.4 10.9 17.1 10.5 10.3
25 923.1 896.0 920.5 933.3 10.9 17.1 10.9 10.5
26 918.5 892.7 918.4 928.8 11.3 17.4 11.1 10.9
27 918.5 886.3 918.4 921.3 11.3 17.9 11.1 11.6
28 907.1 886.3 915.8 916.1 12.5 17.9 11.4 12.1
29 904.1 886.3 915.8 916.1 12.9 17.9 11.4 12.1
30 894.2 883.0 906.9 913.2 13.9 18.1 12.4 12.5
31 887.1 876.0 903.8 913.2 14.7 18.6 12.7 12.5
32 887.1 872.4 903.8 913.2 14.7 18.9 12.7 12.5
33 887.1 872.4 903.8 913.2 14.7 18.9 12.7 12.5
34 887.1 872.4 903.8 913.2 14.7 18.9 12.7 12.5
35 887.1 867.7 903.8 905.0 14.7 19.4 12.7 13.6
36 876.9 862.6 899.5 905.0 16.2 19.9 13.4 13.6
37 876.9 862.6 899.5 905.0 16.2 19.9 13.4 13.6
38 864.9 862.6 899.5 905.0 18.1 19.9 13.4 13.6
39 858.2 856.0 899.5 905.0 19.1 20.8 13.4 13.6
40 858.2 856.0 899.5 905.0 19.1 20.8 13.4 13.6
41 858.2 856.0 899.5 905.0 19.1 20.8 13.4 13.6
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Table 4.5 Comparison of the vaccination groups according to family
characteristics, cohorts 01-16, Niakhar 1987-1990.
Variable EZ-HT SW-HT
Not
standard participant
Mean age of mother 27.7 28.1 28.0 28.6
% mother literate 3.7 3.8 3.2 3.6
Size of compound 22.8 22.8 23.0 23.4
Distance to dispensary 3.8 3.9 3.9 4.1
(km)
Mortality of older 0.313 0.309 0.313 0.297
siblings of sarne mother
% outmigrant 6.5 4.7 6.1 11.1
Death rate in compound 17.6 17.9 17.3 20.0
of residence (/1000)
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Table 4.6 Comparison of the groups according to characteristics
of children at 5 menths, cohorts 01-16, Niakhar 1987-1990.
Variable EZ-HT SW-HT Standard
Mean age at vaccination 21.6 21.6 21.5
(weeks)
Mean weight (kg) 6.45 6.46 6.40
Mean height (cm) 63.0 63.3 63.2
Mean arm circumference 132 132 132
(mm)
Mortality 0-4 months 89 80 78
(/1000)
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Table 4.7 Clustere of deaths by month, village and vaccine group,
Cohorte 01-16, Niakhar 1987-1990, updated in OCtober, 1990.
Date Vaccine group Village Vaccine group
in number
month EZ sw st NP Total EZ SW St NP Total
08/87 1 a a a 1 1 a a a a a
09/87 a 1 1 a 2 2 a 3 a 3 6
10/87 1 a 2 2 5 3 1 2 1 a 4
11/87 2 2 3 a 7 4 1 a a 2 3
12/87 a a a a a 5 1 1 a a 2
01/88 a a a a a 6 1 4 3 4 12
02/88 a 2 a a 2 7 a 1 1 1 3
03/88 a 1 a 1 2 8 2 a 1 2 5
04/88 a a a a a
05/88 a 1 1 1 3 la a 1 a a 1
06/88 3 a 2 a 5 11 2 a a 5 7
07/88 3 3 1 a 7 12 2 1 1 a 4
08/88 4 a 2 2 8 13 2 1 a a 3
09/88 1 3 2 a 6 14 a 1 1 a 2
10/88 7 8 2 9 26 15 a a a a a
11/88 a 3 2 3 8 16 a 1 2 2 5
12/88 a a a a a 17 1 3 2 2 8
01/89 a a a 1 1 18 2 1 a 2 5
02/89 a 1 a 2 3 19 4 3 5 4 16
03/89 a 1 a 1 2 20 a a 1 1 2
04/89 1 a a a 1 21 5 5 2 a 12
05/89 1 a a a 1 22 6 2 2 1 11
06/89 a a 2 1 3 23 3 2 3 a 8
07/89 2 2 1 a 5 24 3 4 1 1 9
08/89 3 2 5 2 12 25 2 3 2 1 8
09/89 8 4 2 1 15 26 a a a a a
10/89 4 1 a 2 7 27 6 1 1 1 9
11/89 1 a 1 1 3 28 a a a a a
12/89 1 a a 1 2 29 2 1 2 2 7
01/90 a 1 a a 1 30 a 1 a a 1
02/90 a a a a a 31 4 1 1 a 6
03/90 a a a a a
04/90 a 1 1 1 3
05/90 a a a a a
06/90 a a a a a
07/90 a a a a a
08/90 2 1 1 2 6
09/90 4 2 a a 6
10/90 1 3 1 1 6
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Table 4.8 Distribution of probable causes of death (from verbal autopsies),
after the 5 months vaccination, by various characteristics,
Niakhar, 1987-1990, updated in OCtober, 1990.
Probable
cause of
death
EZ-HT
a+b
SW-HT
a
Not
Standard participant
a+b a+b
< Principal Cause >
Acute diarrhea 4+1 2 3+1 1+2
Chronic Diarrhea 19+6 13 13+4 19+5
Dysentery 1 5 0+2 0
Meningitis 1 1 1 2
Septicemia 0 0 0 1+1
Chicken pox 3 0 0 0
Measles 0 0 0 1
Hepatitis 1+1 0 0 0
Malaria 8+2 6 7+3 2
Kwashiorkor 8+1 2 2+2 1+1
ether malnutrition 2 2 3+1 3+1
Acute Respiratory Inf 0+1 8 0+4 2+2
Accident 0 0 0 1
ether and Unknown 3+1 4 3+7 2+2
Total 50+13 43 32+24 35+14
< Immediate Cause >
Acute diarrhea 2+1 4 2+1 3+1
Chronic diarrhea 9+1 7 0+2 2+3
Dysentery 1 0 0 0
Septicemia 0 0 1 0
Malaria 0+1 0 1 0
Acute Respiratory Inf 1 1 1+1 1
ether and Unknown 4 0 4 4+2
< Associated cause >
Chronic diarrhea 0 2 0+1 1
Whooping cough 1 0 0 0
Chichen pox 1 1 0+1 0+1
Kwashiorkor 0 1 0 0
ether malnutrition 1 2 1 1
ether and Unknown 4 0 3 6+2
NB a cohorts 01-16
b cohorts 17-24
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Table 4.9 Distribution of deaths after the 5 months vaccination by
vaccination group, according to various characteristics,
cohorts 01-16, Niakhar 1987-1990, updated in OCtober 1990.
EZ-HT SW-HT Standard Not Total CHI2 (df) P
participant
Period of death
Jul 87-OCt 87 2 1 3 2 8
Nov 87-Jun 88 5 6 6 2 19
Jul 88-OCt 88 15 14 7 11 47
Nov 88-Jun 89 2 5 5 8 20
Jul 89-OCt 89 17 9 7 5 38
Nov 89-Jun 90 2 2 2 4 10
Jul 90-OCt 90 7 6 2 3 18 19.0 (18) 0.3908
Age at death (in months)
V5-16 mo 22 24 20 20 86
17-28 mo 18 12 7 12 49
29-40 mo 10 7 5 3 25 4.7 (6) 0.5807
% >= 17 mo 56.0 44.2 37.5 42.9 46.9
Season of death
Dry (Nov-Jun) 9 13 13 14 49
Rainy (Jul-0ct) 41 30 19 21 111 6.7 (3) 0.0818
% rainy season 82.0 69.8 59.4 60.0 69.4
Sex
Male 21 18 20 16 75
Female 29 25 12 19 85 4.0 (3) 0.2543
% female 58.0 58.1 37.5 54.3 53.1
Season of vaccination
Dry (Nov-Jun) 19 26 13 23 81
Rainy (Jul-OCt) 31 17 19 12 79 9.3 (3) 0.0253 *
% rainy season 62.0 39.5 59.4 34.3 49.4
Mean age at vaccination
Age in weeks 22.4 22.3 22.0 22.2 22.2
Total 50 43 32 35 160
* P<.05
NB : There was no death after 40 months by OCtober, 1990.
One death by accident among non-participants not included.
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Table 4.10 Results of the multivariate survival analysis after the 5 months
vaccination, Cox model, cohorts 01-16, Niakhar 1987-1990,
updated in OCtober, 1990.
Covariate Estimate st. Dev. T P
(2 T)
Vaccine (ref=placebo)
EZ-HT 0.531 0.227 2.341 .0196
*SW-HT 0.414 0.234 1. 769 .0774 *
Sex (ref=male) 0.014 0.179 0.077 .9386
Season of vaccination 0.034 0.180 0.186 .8526
Age at vaccination -0.051 0.043 -1.201 .2300
Score test X2 (5) = 6.686, P= 0.245 (NS)
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Table 4.11 Results of the multivariate Logit analyses of age specifie
death rates after the 5 months vaccination, by age and season,
cohorts 01-16, Niakhar 1987-1990, updated in OCtober, 1990.
Covariate Estimate Standard
Error
T-test P
(2 T)
l General Model: X2(7)=94.1, P=E-13
Vaccine (ref=placebo)
EZ-HT
SW-HT
Season (ref=dry)
Age (in months)
Age at vaccination
Season of vaccination
Sex (ref=male)
Constant
II Models by vaccine
Coefficient of age
EZ-HT
SW-HT
Placebo
0.5340
0.4179
1.5858
-0.0313
-0.0387
-0.1311
0.0128
-3.9502
-0.0111
-0.0456
-0.0459
0.2295
0.2365
0.2015
0.0088
0.0478
0.1837
0.1818
1.0685
0.0132
0.0160
0.0183
2.3264
1.7671
7.8636
-3.5452
-0.8084
-0.7137
0.0704
-3.6967
-0.8451
-2.8448
-2.5015
0.0204 *
0.0778
2E-13 *
0.0004 *
0.4192
0.4756
0.9438
0.0002 *
0.3984
0.0046 *
0.0126 *
COefficient of titer at 5 months
EZ-HT
SW-HT
Placebo
-0.0108
0.0118
0.0955
0.1094
0.1054
0.1230
-0.0988
0.1125
0.7761
.9214
.9106
.4382
Coefficient of seroconversion
EZ-HT
SW-HT
-0.6146
0.0081
0.6924
0.6651
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-0.8876
0.1218
.3760
.9032
Table 4.12a: Results of simulations of mortality experience,
(1000 samp1es in each vaccination group)
cohorts 01-16, Niakhar 1987-1990, updated in October, 1990.
Hypotheses :
- mean monthly probability of dying = .00172
- same mortality for males and females
- linear decline of mortality with age
relative risk of death in rainy season 3.1
Expected EZ-HT SW-HT standard
Not
participant
Number of deaths
mean 30.839 29.625 33.052 34.871
st. deviation 5.782 5.638 5.920 6.130
Proportion of deaths in rainy season
mean 0.6322 0.6367 0.6371 0.6376
st. deviation 0.0908 0.0886 0.0814 0.0830
Proportion of female deaths
mean 0.5362 0.5339 0.4809 0.5121
st. deviation 0.0843 0.0852 0.0819 0.0806
Proportion of deaths after age 17 months
mean 0.5351 0.5345 0.5346 0.5286
st. deviation 0.0857 0.0878 0.0828 0.0818
Relative risk (observed/expected)
mean 1.680 1.506 1.000 1.005
st. deviation 0.0325 0.0296 0.0182 0.0178
Log Relative risk = log (observed/expected)
mean 0.501 0.391 -0.017 0.010
st. deviation 0.188 0.191 0.179 0.174
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Table 4.12b Empirical probabilities in 1000 simulations for each group.
Event
EZ-HT group
- at least 50 deaths
- at least 82.0% of deaths in rainy season
- at least 58.0% of female deaths
- at least 56.0% of deaths after 17 months
SW-HT group
- at least 43 deaths
- at least 69.7% of deaths in rainy season
- at least 58.1% of female deaths
- at least 44.2% of deaths after 17 months
standard group
- at most 37.5% of female deaths
* P < 0.05 (1 tail)
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Empirical
probability
in 1000
samples
.004 *
.012 *
.296
.400
.025 *
.249
.302
.859
.110
Computed
probability
from mean+
st. deviat.
.0005 *
.0193 *
.3019
.3855
.0088 *
.2481
.2901
.9376
.0982
Table 4.13a : Comparison of testing procedures, cohorts 01-16,
Niakhar 1987-1990.
A) Mortality after 5 months
Vaccin RR 95% CI Test P(2 T)
1) Life table : Kaplan-Meier, (T test, STD= KM)
EZ-HT
SW-HT
1.80
1.53
1.18 2.74
0.99 - 2.37
T = 2.706
T = 1.911
0.0070 *
0.0564
2) Death rates : D/PYS (T test, STO= rn/PYS
EZ-HT
SW-HT
1.71
1.52
1.10
0.96
2.66
2.40
T = 2.368
T 1. 784
0.0182 *
0.0750
3) Direct D/N (Binomial)
EZ-BT
SW-HT
1.66
1.49
1.10
0.96
2.53
2.29
T
T
2.258
1.689
0.0242 *
0.0918
4) Age Standardized death rates : (Mantel-Haenzel, in EPIINFO)
EZ-HT
SW-HT
1. 70
1.50
1.09 - 2.59
0.96 - 2.33
x2= 5.15
X2= 2.73
0.0232 *
0.0938
5) Linear Logistic Model
(Odds Ratio)
EZ-HT (1.71) 1.53
SW-HT (1.52) 1.49
6) Proportional Bazards
1.08
0.96
2.64
2.43
T = 2.326
T = 1. 767
0.0204 *
0.0778
EZ-HT
SW-HT
1. 70
1.51
1.09 2.65
0.96 - 2.39
T 2.326
T = 1. 767
0.0204 *
0.0778
7) Log Rank Test
EZ-HT
SW-HT
x2= 5.628
X2= 3.184
0.0180 *
0.0740
8) Simulations (testing log(RR) directly)
EZ-HT
SW-HT
* P< 0.05
1.65
1.48
1.14 2.39
1.02 - 2.15
T = 2.665
T = 2.047
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.0080 *
.0414 *
Table 4.13b : Comparison of testing procedures, cohorts 01-16,
Niakhar 1987-1990.
B) Mortality after 10 months
Vaccin RR 95\ CI Test P(2 T)
1) Life table : Kaplan-Meier, (T test, STD= KM)
EZ-HT 2.50 1.52 4.13 T 3.537 .0004
SW-HT 1. 73 1.00 - 2.98 T = 1.925 .0560
2) Death rates . D/PYS (T test, STD= rn/PYS.
EZ-HT 2.37 1.41 3.97 T = 3.233 .0012
SW-HT 1.63 0.93 - 2.85 T = 1.677 .0940
3) Direct D/N (Binomial)
EZ-HT 2.32 1.42 3.81 T 3.174 .0016
SW-HT 1.64 0.96 2.80 T = 1.693 .0910
4) Age Standardized death rates (Mantel-Haenzel, in EPIINFO)
EZ-HT 2.37 1.43 - 3.93 X2=11.070 .0009
SW-HT 1.66 0.96 - 2.87 X2= 2.810 .0936
5) Linear Logistic Model
(Odds Ratio)
EZ-HT (2.52) 2.06 1.39 - 3.97 T = 3.459 .0006
SW-HT (1. 75) 1.62 0.99 3.08 T 1.930 .0540
6) Proportional Hazards
EZ-HT 2.39 1.42 - 4.01 T = 3.299 .0010
SW-HT 1.65 0.94 2.88 T 1.754 .0798
7) Log Rank Test
EZ-HT X2=1l.702 .0006
SW-HT X2= 3.154 .0757
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Table 4.14: Survival of preceding birth cohorte between 5 and 41 monthe
by eex, Niakhar, 1983-1989, Cohort 1 born from 2/83 to 1/85,
and cohort 2 born from 2/85 to 1/87
Age Survival per 1000 at 5 monthe Standard deviatione
in
monthe Cohort 1 Cohort 2 Cohort 1 Cohort 2
M F M F M F M F
5 1000.0 1000.0 1000.0 1000.0 0.0 0.0 0.0 0.0
6 993.8 989.8 989.3 996.3 2.5 3.4 3.1 1.9
7 992.8 984.2 983.1 989.7 2.7 4.2 3.8 3.1
8 987.6 979.7 975.0 985.0 3.6 4.7 4.7 3.7
9 980.3 974.0 968.7 978.4 4.5 5.4 5.2 4.5
10 969.9 968.2 966.0 973.6 5.5 5.9 5.4 4.9
11 963.6 953.2 958.8 966.9 6.0 7.1 6.0 5.5
12 955.2 945.1 954.2 959.2 6.7 7.7 6.3 6.1
13 941.4 938.1 949.7 956.3 7.6 8.2 6.6 6.3
14 934.0 928.6 946.1 950.6 8.0 8.7 6.8 6.7
15 927.7 914.4 941.5 944.8 8.4 9.5 7.0 7.1
16 916.0 906.1 937.8 939.9 9.0 9.9 7.3 7.3
17 906.4 902.6 933.2 936.0 9.4 10.1 7.5 7.6
18 900.0 893.0 924.8 932.1 9.7 10.5 7.9 7.8
19 895.7 889.4 922.0 927.2 9.9 10.7 8.1 8.0
20 890.3 883.4 916.4 922.2 10.2 11.0 8.4 8.3
21 877.3 881.0 911.6 918.3 10.7 11.1 8.6 8.5
22 868.7 872.5 902.2 913.3 11.0 11.4 9.0 8.7
23 863.2 866.4 892.7 908.3 11.2 11.7 9.4 9.0
24 860.0 849.4 885.0 904.3 11.3 12.3 9.7 9.2
25 856.7 842.0 878.3 902.3 11.4 12.5 9.9 9.2
26 849.1 835.9 875.5 898.2 11. 7 12.7 10.0 9.4
27 844.7 831.0 869.7 890.0 11.8 12.9 10.2 9.8
28 836.0 823.6 867.8 890.0 12.1 13.1 10.3 9.8
29 831.6 821.1 861.9 886.9 12.2 13.2 10.5 9.9
30 824.9 817.4 860.0 883.7 12.4 13.3 10.6 10.0
31 819.4 816.1 858.0 881.7 12.6 13.4 10.6 10.1
32 818.3 812.4 852.2 878.5 12.6 13.5 10.8 10.2
33 816.0 811.1 852.2 874.3 12.7 13.5 10.8 10.4
34 813.8 809.9 851.2 873.3 12.8 13.6 10.9 10.4
35 813.8 806.1 850.2 871.2 12.8 13.7 10.9 10.5
36 810.4 802.2 846.3 870.1 12.8 13.8 11.0 10.6
37 808.2 798.4 844.2 865.6 12.9 13.9 11.1 10.7
38 807.1 794.5 844.2 864.5 12.9 14.0 11.1 10.8
39 804.8 790.6 844.2 862.0 13.0 14.1 11.1 10.9
40 801.4 789.3 841.8 862.0 13.1 14.2 11.2 10.9
41 801.4 788.0 841.8 859.1 13.1 14.2 11.2 11.1
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Table 4.15: Follow-up of morbidity after vaccination sessions,
details of person-months and absences,
project children, cohorts 01-24, Niakhar 1987-1989.
Category and age Vaccine group
l From 3 months to 5 months
Group : (A) (B) (C)
No children 403 413 416
No absences 46 57 64
Mean duration absence 13.1 9.4 11.2
Person-years lived 63.57 65.60 67.03
Person-years lost 1.65 1.46 1.97
Persori-years at risk 61.92 64.13 65.06
II From 5 months to 10 months
Group : EZ-HT SW-HT Placebo
No children 336 322 358
No absences 189 158 179
Mean duration absence 15.2 16.1 13.2
Person-years lived 134.9 129.1 144.4
Person-years lost 7.88 6.97 6.48
Person-years at risk 127.0 122.1 137.9
III From 10 months to 12 months
Group : EZ-HT SW-HT Standard
No children 322 306 425
No absences 99 87 99
Mean duration absence 12.3 16.9 12.7
Person-years lived 50.8 48.4 66.6
Person-years lost 3.35 4.03 3.45
Person-years at risk 47.5 44.4 63.2
NB A, B, C groups assigned at birth.
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Table 4.16 Number of morbid episods registered by the field workers
according to disease and field worker, project children,
cohorts 01-24, Niakhar 1987-1989.
Field No No of episodes recorded
worker of
1 children Fever Diarrhea ARI Rash other Total
1 227 507 392 122 82 389 1492
2 210 621 286 106 33 405 1451
3 285 656 289 69 42 342 1398
4 215 525 280 105 50 324 1284
5 258 593 300 76 43 256 1268
6 193 524 180 199 50 285 1238
7 251 480 293 57 77 292 1199
8 154 369 229 128 82 264 1072
9 260 437 171 67 52 311 1038
10 178 313 144 76 33 199 765
11 235 208 98 39 48 79 472
12 * 314 290 95 50 318 1067
Total 2470 5547 2952 1139 642 3464 13744
NB field worker 1 12 includes ail supervisors or enumerators
who replaced field workers who were either sick or in vacation
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Table 4.17 Incidence of morbid episods after vaccination sessions,
(/ 100 person-months), according to age and vaccine group
cohorts 01-16, Niakhar 1987-1989,
(N=number of episods terminated).
Disease Incidence (N) Incidence (N) Incidence (N)
l From 3 months to 5 months
Group: A B C
Fever 49.0 364 48.2 371 47.3 369
Diarrhea 15.7 117 12.6 97 15.2 119
ARI 8.9 66 7.5 58 7.4 58
Rash 6.6 49 4.2 32 3.3 26
other 20.7 154 21. 7 167 18.7 146
AU 100.9 750 94.2 725 92.0 718
II From 5 months to 10 months
Group EZ-HT SW-HT Placebo -
Fever 41.2 628 41.8 612 38.9 643
Diarrhea 20.5 313 23.7 347 20.5 340
ARI 9.1 139 8.1 118 8.9 148
Rash 5.2 80 5.0 74 5.4 90
other 25.5 388 25.5 374 26.2 434
AU 101.6 1548 104.1 1525 100.0 1655
III From 10 months to 12 months
Group EZ-HT SW-HT - Standard -
Fever 37.2 212 37.2 198 42.6 323
Diarrhea 22.6 129 20.1 107 23.5 178
ARI 5.4 31 6.0 32 4.1 31
Rash 2.3 13 3.2 17 3.8 29
other 24.4 139 19.1 102 16.2 123
AU 92.0 524 85.6 456 90.2 684
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Table 4.18 Incidence of persistent diarrhea between age 5
and 12 months, by vaccine group,
cohorts 01-16, Niakhar 1987-1989.
EZ-HT SW-HT Placebo
No of children 336 321 358
No of episodes 98 86 119
Incidence / 100 29.2 26.8 33.2
Mean duration (days) 24.2 22.3 24.9
S.dev duration (days) 12.2 9.7 12.7
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Table 4.19 Sex specifie morbidity between vaccinations at 5 and 10
months, according to vaccination group, cohorts 01-16,
Niakhar 1987-1989.
Oisease
EZ-HT
Incidence (N)
SW-HT
·Incidence (N)
Placebo
Incidence (N)
l Males
Fever 42.9 293 43.3 298 43.6 368
Oiarrhea 23.4 160 27.0 186 23.1 195
ARI 8.4 57 8.0 55 9.8 83
Rash 5.0 34 5.2 36 5.1 43
Other 25.6 175 25.8 178 26.0 220
All 105.4 719 109.3 753 107.6 909
II Females
Fever 39.8 335 40.4 314 34.0 275
Oiarrhea 18.2 153 20.7 161 17.9 145
ARI 9.7 82 8.1 63 8.0 65
Rash 5.5 46 4.9 38 5.8 47
Other 25.3 213 25.2 196 26.4 214
All 98.5 829 99.4 772 92.1 746
III Sex ratio of incidences
Fever 107.9 106.9 128.3
Oiarrhea 129.0 130.2 128.9
ARI 85.7 98.4 122.4
Rash 91.1 106.8 87.7
Other 101.3 102.3 98.5
All 107.0 109.9 116.8
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Table 4.20: Mother'B hiBtory of convulBionB, according to dateB of
vaccination (or Bcheduled vaccination) and vaccine received
CohortB 01-16, Niakhar 1987-1989.
Vaccine received (N) < 28 daYB
after
>= 28 daYB
after
l Between 3 and 5 monthB
BCG + DPTP (1055) 0 2
Not vaccinated ( 365) 0 1
II Between 5 and 10 monthB
DPTP + EZ-HT (336) 1 (D-18) 7
DPTP + SW-HT (322) 0 2
DPTP + Placebo (357) 0 6
Not vaccinated (387) 0 2
III After 10 monthB
DPTP + YF (428) 1 (D-2) 2
DPTP + YF + Standard (392) 1 (D-20) 2
Not vaccinated ( 511) 1 (D-5) 0
D-n = n daYB after vaccination or date of Bcheduled vaccination.
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Table 4.21 Anthropometry of children at time of vaccination,
project children, cohorts 01-24, and comparison
with those who died after high titer vaccines.
Niakhar 1987-1989.
Anthropometrie
measurement
3 months
mean (std)
5 months
mean (std)
10 months
mean (std)
All children (N=1886) (N=1872) (N=1419)
Age in weeks 13.1 (1. 57) 21.7 (1. 56) 43.5 (1. 50)
Weight (kg) 5.64 ( .828) 6.56 ( .957) 7.56 (1. 091)
Height (mm) 595 (25.3) 635 (26.0) 693 (28.9)
Arm circumference (mm) 128 (12.0) 133 (12.6) 134 (13.2)
Z-score weight/age 0.340 (1. 023) -0.162 (1. 042) -1. 542 (1.093)
Z-score height/age 0.130 (0.977) -0.217 (0.965) -1.032 (1. 056)
Z-score weight/height 0.310 (0.833) -0.017 (0.902) -0.853 (0.910)
Chi1dren who died
after EZ-HT vaccine (N= 54) (N= 62) (N= 32)
Weight (kg) 5.88 (0.911) 6.45 (0.857) 7.62 (1.277)
Height (mm) 603 (33.5) 631 (25.1) 691 (33.3)
Arm circumference (mm) 129 ( 9.5) 133 (11. 2) 133 (14.1)
Z-score weight/age 0.197 (1.189 ) -0.254 (1.050) -1.440 (1. 324)
Z-score height/age -0.082 (1. 021) -0.340 (0.921) -1.062 (1.231)
Z-score weight/height 0.342 (0.906) -0.002 (0.933) -0.693 (0.932)
Children who died
after SW-HT vaccine (N= 34) (N= 42) (N= 22)
weight (kg) 5.51 (1.094 ) 6.29 (1.191) 7.09 (1.237)
Height (mm) 591 (34.9) 630 (32.3) 677 (39.1 )
Arro circumference (mm) 126 (16.1) 131 (15.9) 130 (13.6)
Z-score weight/age -0.034 (1. 280) -0.447 (1. 312) -1.904 (1.234)
Z-score height/age -0.256 (1.070) -0.389 (1.167) -1.449 (1.450)
Z-score weight/height 0.204 (1.083) -0.232 (1.014) -0.880 (0.871)
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Table 4.22 Adverse reactions during post-vaccination medical examination,
project children vaccinated at 5 months, according to vaccination
group, session 10-24, Niakhar 1988-1989.
A) Presence and point prevalence of condition
Vaccine No , present , diarrhea , fever , rash
children (No visits) (No days) (No days) (No days)
EZ-HT 87 86.6 (377 ) 9.4 41) 8.7 38) 26.2 ( 114)
SW-HT 35 85.7 (150) 7.3 11) 10.6 16) 6.0 9)
Placebo 102 88.0 (449) 12.8 61) 10.5 50) 27.5 (131)
Total 224 87.1 (976) 10.0 (113) 9.2 (104) 27.6 (254)
NB 15 children were randomly chosen after each vaccination session;
each child was visited up to 5 times, randomly, within 3 weeks
after the 5 months vaccination.
Diarrhea : from mother's declaration
Fever : temperature >= 37.5 ·C
Rash: any kind
B) Prevalence of disease during the 5 visits (at 1east one episode)
Vaccine No , diarrhea , fever , rash , measles like
children (any kind) rash
EZ-HT 87 29.8 (26) 39.0 (34 ) 45.9 (40) 11.4 (10)
SW-HT 35 20.0 (7) 31.4 ( 11) 17.1 (6) 17.1 (6)
Placebo 102 35.2 (36) 37.2 (38) 41.1 (42) 5.8 (6)
Total 224 30.8 (69) 37.0 (83) 39.2 (88) 9.8 (22)
NB: Measles like rash: rash looking like a rash after natural measles,
although mild: occuring 6-14 days after vaccination, starting from the
face, spreading on the body symetrically and followed by sorne kind of
desquamation.
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Table 5.1 Proportion of mothers who refused the blood sample at
vaccination session, according to age of the child and
birth cohort, Niakhar 1987-1989 •
5 months la months
,
Cohort Refusal / Refusal / refusal
t children t children
al - 04 5 / 311 2 / 200 1.4 ,
05
- 08 14 / 243 13 / 227 5.7 ,
09 - 12 7 / 230 28 / 209 8.0 ,
13
- 16 12 / 235 17 / 195 6.7 ,
17
- 20 27 / 261 20 / 245 9.3 ,
21
- 24 18 / 313 23 / 295 6.7 ,
Total 83 / 1593 103 / 1371 6.3 ,
, refusal 5.2 7.5
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Table 5.2 Detail of batches for the titering of measles antibodies,
Niakhar 1987-1990.
batch date 1 of standard samples taken at 5 months
1 analyzed samples HW N mean st. deviation
1 21/09/87 80 3.0 74 1.176 1.070 *2 22/09/87 86 3.3 2 1.000 1.000 *3 15/10/87 69 5.0 69 1. 739 1.800
4 17/11/87 61 5.0 61 1.590 1.210
5 10/02/88 100 5.0 14 2.929 0.800
*6 11/02/88 100 5.0 20 1.700 0.900
7 16/02/88 67 5.0
8 23/02/88 100 5.0 56 2.125 1.350
9 24/02/88 100 5.0 68 0.971 0.940
10 29/02/88 70 0.0 29 1.586 1.190
11 31/03/88 108 5.0 20 1.650 1.390
12 04/04/88 96 5.0 55 0.691 1.170
'*13 07/04/88 96 5.0 44 1.682 1. 740
14 12/04/88 5 5.0 4 1.000 0.710
15 04/05/88 99 5.0 48 2.125 1.070
*16 04/07/88 100 5.0 35 1.543 1.200
17 05/07/88 113 5.0 58 1.621 1.110
18 07/07/88 34 5.0 18 1.500 1.890
19 28/10/88 28 5.0 9 0.000 0.000
20 17/01/89 79 5.0 35 2.286 1.300
21 18/01/89 70 5.3 32 3.500 1.820
'*22 19/01/89 76 5.0 45 2.244 2.320
23 23/01/89 73 5.0 29 1.483 1.500
24 24/01/89 77 5.3 33 1.242 1.500
25 25/01/89 93 5.0 47 1.255 1.330
26 26/01/89 87 5.0
27 06/03/89 85 5.0 2 0.000 0.000
28 07/03/89 86 5.0
29 23/05/89 85 5.0 1 3.000 0.000
30 25/05/89 84 5.0
31 29/05/89 88 5.0
32 31/05/89 61 5.0 57 2.107 1.520
33 28/09/89 77 7.0
*34 23/10/89 87 5.0
35 25/10/89 54 5.0
36 26/10/89 100 5.0
37 02/04/90 98 5.0
38 03/04/90 100 5.0
39 04/04/90 100 5.0
40 05/04/90 51 5.3
41 10/04/90 98 5.0 42 2.952 1.630
'*42 16/04/90 18 4.7
Not yet titered 1185
All samples 4524
* outstanding high or low titer
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Table 5.3 Statistics of the reciprocal of dilution for blood samples
analyzed twice, Niakhar 1987-1989.
origin (N) Statistic Value 1 Value 2 r P
R-07 (58) batch (08+10) (11)
mean 1.914 2.655
standard deviation 1.546 1.935
percent negative 31.0 20.7
correlation .809 E-04
R-01 (59) batch (01+06) (32)
mean 1.254 2.051
standard deviation 1.051 1.534
percent negative 30.5 30.5
correlation
-.071 (NS)
sero- (28) batch (varia) (19)
converters mean 1.286 1.107
standard deviation 1.887 1.858
percent negative 53.6 32.2
correlation .837 E-04
others (20) batch (varia) (41)
mean 2.450 5.300
standard deviation 2.906 3.195
percent negative 50.0 15.0
correlation .707 E-04
Difference
between mean 0.896
sample 1 standard deviation 1. 759
and sample 2 percent identical 34.0
(N=106)*
* All but R-01
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Table 5.4 Cross tabulation of the reciprocal of dilution
in 106 samples analyzed twice, Niakhar 1987-1989.
Second First sample
sample Total
0 1 2 3 4 5 6 7 8 9
0 26 6 1 33
1 2 2
2 5 3 6 5 1 20
3 4 1 4 3 2 1 15
4 2 1 4 6 1 1 15
5 1 3 1 5
6 2 1 2 1 6
7 2 2 2 6
9 2 2
10 1 1
13 1 1
Total 41 11 16 20 11 1 2 1 2 1 106
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Table 5.5: Natural decay of antibodies according to age, cohorts 01 to 16,
children not vaccinated, who never had measles, without any
known exposure to measles, Niakhar 1987-1989.
Mean
Age age GMT (N) , (N) GMT (N) , (N)
(weeks) (month) (miu) <125 >=125 >=1000
10-13 2.9 490 (33) 6.1 (2) 559 (31) 30.3 (10)
14-17 3.5 366 (82) 13.4 (11) 481 (71) 22.0 (18)
18-25 5.0 207 (871) 31.1 (271) 355 (600) 11.4 (99)
26-33 6.5 112 (19) 57.9 (11) 250 (8) 5.3 (1)
34-41 8.8 133 (82) 69.5 (57) 737 (25) 14.6 (12)
42-49 10.0 121 (334) 67.1 (224) 442 (113) 10.2 (34)
50+ 16.0 102 (27) 77.8 (21) 561 (6) 7.4 (2 )
NB batches 01 and 02 eliminated.
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Table 5.6: Response to high titer measles vaccines according to various
definitions, cohorts 03-16, children who never had measles,
without any known exposure to measles, who came at both the
5 months and the 10 months session, Niakhar 1987-1989.
Criteria
EZ-HT
(N= 163)
SW-HT
(N= 168)
Placebo
(N= 204)
mean conf. int. mean conf. int. mean conf. int.
At 5 months (before vaccination)
% <125 miu 32.5 [28.7-36.9] 35.1 [31.1-39.7] 30.4 [27.1-34.1]
GMT (aH) 197 167- 232] 198 168- 235] 206 179- 237]
GMT if>= 125 343 301- 390] 371 325- 424] 347 312- 385]
At 10 months (5 months after vaccination)
% <125 miu 3.7 [ 3.2- 4.3] 22.0 [19.3-25.2] 67.6 [62.6-73.1]
GMT (aH) 1638 [1287-2085] 678 [ 509- 905] 111 96- 127]
GMT if>=125 1856 [1482-2324] 1331 [1043-1697] 365 316- 421]
Seropositive 96.3 [93.5-99.2] 78.0 [72.6-83.7] 32.4 [28.9-36.2]
Seroresponse 89.0 [84.5-93.6] 68.5 [62.9-74.5] 24.0 [21.3-27.1]
Seroconversion 71.2 [65.5-77.3] 50.6 [45.5-56.3] 13.2 [11.6-15.0]
Definitions seropositive at 10 mo: >=125 miu
seroresponse at 10 mo: at least same titer if >=125
or from <125 to >=125
seroconversion 5-10 m: at least four fold increase in GMT
or from <125 to >=250
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Table 5.7 Distribution of measles antibody titers at 5 and 10 months,
cohorts 03-16, children who never had measles,
without any known exposure to measles, who came at both the
5 months and the 10 months session.
At 10 months (after vaccination at 5 months)
At
Titer 5 months EZ-HT SW-HT Placebo
in (before
miu vaccination) N
"
N
"
N
"
< 125 174 6 3.7 37 22.0 138 67.6
125 57 0 0.0 7 4.2 15 7.4
250 167 15 9.2 19 11.3 26 12.7
500 79 26 16.0 30 17.9 12 5.9
1000 31 35 21.5 22 13.1 8 3.9
2000 15 33 20.2 18 10.7 1 0.5
4000 10 19 11. 7 13 7.7 1 0.5
8000 2 16 9.8 6 3.6 2 1.0
16000 0 4 2.5 7 4.2 1 0.5
32000 0 1 0.6 5 3.0 0 0.0
64000 0 2 1.2 1 0.6 0 0.0
128000 0 5 3.1 2 1.2 0 0.0
256000 0 0 0.0 1 0.6 0 0.0
512000 0 1 0.6 0 0.0 0 0.0
Total 535 163 100 168 100 204 100
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Table 5.8: Analysis of response to measles vaccines, according to
the level of antibody at time of vaccination (5 months),
cohorts 03-16, children who never had meas1es,
without any known exposure to measles, who came at both the
5 months and the 10 months session, Niakhar 1987-1989.
Meas1es EZ-HT SW-HT Placebo
antibody
titer at (N= 169) (N= 168) (N=204)
5 months
in miu mean conf. int. mean conf. int. mean conf. int.
GMT at 10 months, for those with at least 125 miu
< 250 3044 [2037- 4549] 1621 [1062-2475] 136 105- 176]
250-999 1175 [ 909- 1520] 393 [ 272- 569] 94 81- 108]
1000+ 579 [ 292- 1145] 177 [ 95- 328] 108 63- 184]
, sero-positive
< 250 98.6 [95.9- 99.9] 92.1 [86.5-98.1] 40.5 [34.3-47.7]
250-999 97.3 [93.6- 99.9] 72.2 [63.9-81. 6] 26.7 [22.6-31.6]
1000+ 84.2 [70.4- 99.9] 45.0 [32.5-62.3] 26.3 [17.9-38.7]
, sero-response
< 250 98.6 [95.9- 99.9] 92.1 [86.5-98.1] 40.5 [34.3-47.7]
250-999 94.5 [89.6- 99.7] 59.7 [51. 6-69.2] 13.9 [11. 6-16.6]
1000+ 31.6 [ 21.8- 45.8] 10.0 [ 6.6-15.2] 5.3 [ 3.4- 8.2]
, sero-conversion
< 250 98.6 [95.9- 99.9] 85.5 [78.5-93.2] 28.6 [23.8-34.2]
250-999 61.6 [53.5- 71.1] 26.4 [21. 6-32 .2] 2.0 [ 1. 6- 2.4]
1000+ 5.3 [ 3.4- 8.2] 5.0 [ 3.3- 7.7] 5.3 [ 3.4- 8.2]
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Table 5.9 Multinomial Logit ana1ysis of the factors of sero-conversion,
sero-positivity and sero-response, children of cohorts 03-16,
who never had measles, without any known exposure to measles,
who came at both the 5 months and the 10 months session,
Niakhar 1987-1990.
Variable or
interactions
Coef-
ficient
standard
Deviation
T P
(2 tail)
Dependent variable Sero-conversion
Constant -2.494 2.439 -1.022 0.307
Vaccine (EZ/SW) 1.574 0.341 4.608 5.8E-06 *
Titer at 5 months -1.527 0.173 -8.805 1.0E-13 *
Age at vacc (weeks) 0.204 0.104 1.965 0.050 *Cohort 0.097 0.044 1.204 0.229
Season (dry/rainy) -0.296 0.341 -0.866 0.387
CHI (5 ) : 198.40 P = 1.0E-13
Dependent variable sero-positivity
Constant -4.139 2.738 -1.511 0.132
Vaccine (EZ/SW) 2.289 0.505 4.526 6.4E-06 *Titer at 5 months -0.640 0.119 -5.363 1.5E-07 *Age at vacc (weeks) 0.274 0.125 2.183 0.030
*Cohort 0.080 0.048 1.679 0.094
Season (dry/rainy) 0.064 0.388 0.166 0.868
CHI (5 ) = 71.99 P 1.0E-13
Dependent variable sero-response
Constant
-1.612 2.772 -0.581 0.561
Vaccine (EZ/SW) 2.117 0.433 4.885 1.6E-06 *
Titer at 5 months
-1.307 0.170 -7.664 3.6E-13 *
Age at vacc (weeks) 0.165 0.120 1.365 0.172
Cohort 0.096 0.048 1.975 0.049 *Season (dry/rainy) 0.335 0.379 0.883 0.377
CHI (5 ) : 152.50 P = 1.0E-13
For definitions see table 5.6
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Table 5.10 : Multinomial Logit analysis of sero-positivity at 10 months
(probability of having a seropositive at 10 month),
Niakhar 1987-1989.
Variable Estimate standard T p
error (2 tail)
Vaccine = EZ-HT
Constant 3.5672 6.6058 0.540 0.590
Titer at 5 months -0.8754 0.2755 -3.177 0.001 *
Age at vaccination (weeks) 0.0682 0.2823 0.241 0.809
Cohort 0.0573 0.1140 0.502 0.616
Season (dry/rainy) 0.0779 0.9379 0.083 0.934
Chi (4) = 13.99 P = 0.0073
Vaccine = SW-HT
Constant -5.1306 3.0288 -1.694 0.092
Titer at 5 months -0.5823 0.1338 -4.349 2.4E-05 *
Age at vaccination (weeks) 0.3169 0.1409 2.248 0.026 *
Cohort 0.0804 0.0529 1.520 0.130
Season (dry/rainy) 0.0343 0.4266 0.080 0.936
Chi (4 ) = 32.37 P 1.6E-06
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Table 5.11 Multinomial regression analysis of the log(GMT) at 10 months,
for seropositive cases at 10 months, Niakhar 1987-1990
Variable Coefficient standard Standard T P
error coefficient (2 tail)
Vaccine = EZ-HT
Constant 2.383 2.405 0.000 0.991 0.323
Log (GMT) at 5 mo -0.493 0.111 -0.330 -4.439 0.000 *
Age at vacc (week) 0.056 0.102 0.041 0.550 0.583
Cohort 0.108 0.040 0.209 2.674 0.008 *Season (dry) 0.673 0.332 0.158 2.025 0.045 *
R = 0.159 F(4,152) = 7.163 P = 2.6E-05
Vaccine = SW-HT
Constant 2.845 2.894 0.000 0.983 0.327
Log (GMT) at 5 mo -0.562 0.139 -0.340 -4.053 0.000 *
Age at vacc (week) 0.091 0.124 0.063 0.736 0.463
Cohort 0.057 0.052 0.101 1.110 0.269
Season (dry) -0.138 0.423 -0.030 -0.327 0.744
R = 0.130 F(4,126) = 4.711 P = 0.001
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Table 5.12: Change in antibody titere after vaccination, according to age,
cohorte 01 to 16, children who never had meaelee and
without any known expoeure to meaelee, for whom an extra
bood eample wae taken after 10 monthe, Niakhar 1987-1989,
(revaccinated children are excluded).
EZ-HT SW-HT Standard
Age at 5 monthe at 5 monthe at 10 monthe
at (N= 41) (N= 32) (N= 31)
eample
mean conf. int. mean conf. int. mean conf. int.
5 monthe 139 [96 - 202] 209 [144- 303]
10 monthe 90 [62-131 ]
11-24 mo 1402 [762-2580] 859 [375-1967] 4090 [1598-10470]
(mean age at
third eample) (16.5) (16.2) (17.4)
% < 125 miu 19.5 34.4 22.6
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Table 5.13 Mortality after 10 months according to immunigenicity criteria,
cohorts 03-16, chi1dren who never had measles, without any
known exposure to measles, who came at both the 5 months and
the 10 months session (/1000 chi1dren), Niakhar 1987-1990.
Criteria
EZ-HT
(N= 163)
SW-HT
(N= 168) RR
P
(2 taU)
Seroconversion
Yes 112 (13) 82 (7) 0.77 0.5483
No 128 ( 6) 120 (10)
Seroresponse
Yes 117 (17) 104 (12) 1.13 0.9862
No 111 ( 2) 94 ( 5)
Seropositivity
Yes 121 (19) 104 (12) 0.93 0.9749
No 0 ( 0) 94 ( 5)
A11 categories 117 (19) 101 (17)
RR (/ placebo) 1.59 1.38
p (/ placebo) 0.158 0.344
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Table 5.14 Expected percentage of children who would respond to
high titer vaccines, according to various criteria of
antibody response, Niakhar 1987-1990.
Age at , expected , expected , expected
vaccination sero-conversion sero-response sero-positivity
(in weeks)
EZ-HT SW-HT EZ-HT SW-HT EZ-HT SW-HT
10-13 46.8 23.5 75.7 46.6 93.4 65.2
14-17 54.2 29.6 81.2 53.1 94.6 68.9
18-25 66.7 42.4 88.6 64.1 96.2 75.3
26-33 80.1 59.5 93.6 75.8 97.4 82.3
34-41 79.1 64.4 88.1 74.9 96.3 82.1
42-49 80.7 63.9 90.8 76.4 96.8 82.8
50+ 86.2 70.8 93.0 81.2 97.3 85.7
NB computed from tables 5.5 and 5.6; see text for details.
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Table 6.1 Incidence of measles by month and year (date at onset
of measles rash), and according to residence status,
Niakhar 1987-1989.
1987 1988 1989
Month Total
RA + RP + VP RA +RP +VP RA +RP +VP
January a + 15 + a a + a + a 4 + 17 + a 36
February 3 + 14 + a a + a + a 4 + 6 + a 27
March a + 32 + a a + a + a 8 + 21 + a 61
April a + 29 + a a + a + a 6 + 16 + 2 53
May 2 + 9 + a 3 + 6 + a 3 + 15 + a 38
June a + a + a 2 + a + a 4 + 16 + 1 23
July a + a + a a + 8 + a a + 5 + a 13
August 2 + a + a 2 + 5 + a 3 + 3 + 1 16
September a + a + a 1 + a + a a + 30 + 1 32
OCtober a + a + a 2 + a + a a + 23 + a 25
November 1 + a + a 2 + 7 + 1 a + 14 + a 27
December 2 + a + a 4 + 12 + 1 2 + 57 + 3 81
---- -- ----- -- -----
Total la + 99 + 0 16 + 37 + 2 34 +225 + 8 431
Resident (RA+RP) 109 53 259 421
Present (RP+VP) 99 40 231 370
Nb RP
RA
VP
resident, present (within study area)
resident, absent (outside study area)
visitor, present (within study area)
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Table 6.2 Three outbreaks of measles after the start of the study,
according to residence status (date of first case in
compound), Niakhar 19B7-1990.
Cases within the study area No cases Total
outside No of
Period t Villages t compound t cases t cases study cases
attacked infected resident visitor area studied
(VL) (CC) (RP) (VP) (RA) RP+VP+RA
1) Before trial started
01 Jan B7 - 14 Aug B7 15 2B 103 0 B 111
2) After trial started
15 Aug B7 - 30 Apr BB 0 0 0 0 3 3
3) First outbreak
01 May BB - 30 Sep BB 2 5 19 0 B 27
4) Second outbreak
01 oct BB - 14 Aug B9 20 4B 117 5 39 161
5) Third outbreak
15 Aug B9 - 14 Aug 90 11 119 396 11 6 413
Total 26 200 635 16 64 715
NB : There are 30 villages in the study area
During vaccine trial
First outbreak
Second outbreak
Third outbreak
first case - last case in study area:
02 May BB - 03 Aug BB
06 Nov BB - lB Jul B9
17 Aug B9 - 14 Jul 90
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Table 6.3 Pattern of contamination of index cases in compounds,
Niakhar, 1987-1989.
Source of contamination
of index case in compound
.No of compounds
Village lite (games, ceremonies etc. ) 44 48.9 ,
Travel outside study area 18 20.0 ,
School 11 12.2 ,
Visitor from outside study area 8 8.9 ,
Dispensary 5 5.6 ,
Unknown 4 4.4 ,
Total 90 100.0 ,
Nb Unknown: most likely infected in village, but clear evidence of the index
case was not found (several were possible).
Travel outside of study area includes 3 cases of children infected
in a dispensary or medical center while outside of study area.
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Table 6.4 Definition of generations within a compound: intervals
between cases of the same and of successive generations,
Niakhar, 1987-1989.
In same generation Wrt previous generation
Nb of days
since :
First
case
Previous
case
First
case
Source
case
Last
case
0 22 14
1-2 37 19
3-4 16 5
5-6 9 2
7-8 1 12 13 15
9-10 28 30 36
11-12 41 39 41
13-14 40 39 35
15-16 23 24 21
17-18 9 9 4
19-20 0
21-22 1
Total 85 38 154 154 154
Mean 1.88 1.13 12.36 12.24 11.72
st. dev 1. 74 1.20 2.72 2.68 2.56
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Table 6.5 Distribution of cases and compounds according to the generation,
measles cases in the study area, Niakhar, 1987-1989.
Among unvaccinated children
No No Mean No No No Secondary
Generation generations measles cases par measles suscep- attack
k cases generation cases tibles rate /100
(1) (2 ) (3) (3/2) (5) (6) (5/6)
1 89 98 1.10
2 52 108 2.08 98 248 39.6
3 20 38 1.90 31 103 30.1
4 3 4 1.33 4 35 11.4
5+ 2 2 1.00 2 11 18.2
a11 166 250 1.50 135 248 54.8
Note mean length between 2 generations : 12.2 days
Gl->G2 = 11.9 days; G2->G3 = 12.1 days; G3+->G4+
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14.6 days
Table 6.6 Incidence of measles according to age, sex and survival,
resident population, 1987-1989.
Keasles cases Person Keasles
Age group -years Incidence deaths cm
male female aH lived /1000 PYS /1000
0-3 months 0 0 0 924.2 0.0 0 0.0
4-5 months 2 3 5 448.3 11.2 0 0.0
6-7 months 5 2 7 453.0 15.5 0 0.0
8-9 months 5 5 10 442.5 22.6 0 0.0
10-11 months 2 2 4 446.3 11.2 0 0.0
1-2 years 25 29 54 4842.8 11.4 3 54.5
3-4 years 5 16 21 4253.2 4.9 0 0.0
5-9 years 62 70 132 9361.3 14.1 2 15.2
10-14 years 38 30 68 7499.0 8.8 0 0.0
15-29 years 7 8 15 12939.0 1.2 0 0.0
Total 151 165 316 41609.6 7.6 5 15.8
NB measles death = death within 42 days after onset of measles rash.
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Table 6.7 Measles case fatality ratios, with and without medical intervention
Niakhar 1983-1989, (CFR /1000 measles cases).
Age at
measles
onset
March 83 - July 87
without medical interv.
CFR (D/cases)
August 87- Dec 89
With medical interv.
CFR (D/cases)
%
decrease
in CFR
< 1 year 102.0 (20/196) 0.0 (0/26)
1-4 years 86.0 (76/884) 40.0 (3/75)
5-9 years 10.4 5/480) 15.2 (2/132)
10+ years 0.0 0/157) 0.0 (0/83)
Total 58.8 (101/1717) 15.8 (5/316)
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100.0 %
53.5 %
73.1 %
Table 6.8 Clinieal features of measles, aeeording to duration sinee onset,
(% ehildren with elinieal sign among ehildren who had measles),
Niakhar 1987-1989.
Dura- Rash/desquam Koplik Conjune Stoma Cough Pulmo. Diar Fever
tion typieal untyp sign tivitis titis sign -rhea >38°C (N)
0 0.0 0.8 0.0 3.3 1.6 13.8 0.0 0.8 20.9 123
1-2 25.5 2.1 31.9 66.0 25.5 63.8 2.1 10.6 85.4 47
3-4 74.7 0.0 44.0 93.4 64.8 95.6 8.8 16.5 93.3 91
5-6 92.3 1.7 26.5 92.3 80.3 100.0 14.5 19.7 82.2 117
7-8 99.2 0.0 9.9 86.8 74.4 100.0 33.1 17.4 47.4 121
9-10 98.1 0.9 0.9 62.0 47.2 95.4 23.1 6.5 38.5 108
11-12 97.5 1.7 0.8 44.5 25.2 95.0 10.9 8.4 20.7 119
13-14 97.1 1.0 0.0 23.5 9.8 93.1 7.8 4.9 21.0 102
15-16 98.0 0.0 0.0 16.7 6.9 91.2 5.9 2.9 11.1 102
17-18 97.7 1.1 0.0 13.8 6.9 77.0 4.6 9.2 16.7 87
19-20 92.1 0.0 0.0 2.2 2.2 75.3 2.2 4.5 13.3 89
21-22 90.9 0.0 0.0 7.1 1.0 73.7 2.0 11.1 16.7 99
23-24 88.6 0.0 0.0 5.7 2.3 65.9 2.3 5.7 16.7 88
25-26 81.9 1.1 0.0 5.3 3.2 63.8 4.3 6.4 11.2 94
27-28 58.2 1.0 0.0 4.1 1.0 53.1 3.1 5.1 13.7 98
29-30 53.2 1.3 0.0 5.1 5.1 62.0 1.3 2.5 15.6 79
31-32 28.1 0.0 0.0 9.4 0.0 51.6 1.6 4.7 6.7 64
33-34 40.0 0.0 0.0 8.0 4.0 36.0 2.0 4.0 12.8 50
35-36 26.9 3.8 0.0 7.7 3.8 23.1 0.0 0.0 0.0 26
37-42 20.0 0.0 0.0 6.7 6.7 26.7 0.0 0.0 8.3 15
43 + 20.8 0.0 0.0 0.0 0.0 8.3 0.0 0.0 16.7 24
Total 74.2 0.7 5.7 114.5 21.7 72.6 7.9 7.8 29.6 1743
Nb duration 0 = before onset of first symptom.
1 first day of first symptom.
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Table 6.9 Mean score and mean severity according to duration since onset
and to vaccination status, Niakhar 1987-1989.
Unvaccinated chi1dren Vaccine failure Ratio vac/unvac
Duration
(N) Score severity (N) Score severity Score severity
0 101 0.2 0.4 10 1.2 1.6
1-2 39 5.3 4.3 4 8.8 5.3 1.64 1.23
3-4 73 11.5 9.0 11 10.2 8.7 0.89 0.97
5-6 99 12.0 10.2 13 11.3 8.5 0.94 0.83
7-8 98 10.8 8.6 11 10.3 7.5 0.95 0.87
9-10 90 9.4 6.7 13 8.8 5.2 0.94 0.78
11-12 104 8.3 5.5 8 8.5 5.0 1.02 0.91
13-14 82 7.6 4.6 15 6.8 3.1 0.90 0.67
15-16 91 7.4 4.2 4 5.8 2.5 0.78 0.60
17-18 76 7.2 3.9 9 6.4 3.0 0.90 0.76
19-20 72 6.4 3.0 10 5.6 2.8 0.87 0.92
21-22 86 6.5 3.1 9 5.4 2.2 0.84 0.71
23-24 76 6.3 2.6 8 3.8 2.3 0.60 0.86
25-26 82 5.8 2.5 8 4.6 1.9 0.79 0.74
27-28 81 4.3 1.9 10 3.8 1.8 0.88 0.94
29-30 72 4.3 2.0 2 0.0 0.0 0.00 0.00
31-32 51 2.3 1.2 10 2.1 1.2 0.91 0.97
33-34 47 3.1 1.4 2 0.0 0.5 0.00 0.37
35-36 23 2.3 0.8 1 0.0 0.0 0.00 0.00
37-38 12 2.2 0.9 1 0.0 0.0 0.00 0.00
39-40 5 1.2 0.4 0 0.0 0.0 0.00 0.00
41-42 2 3.0 0.5 0 0.0 0.0 0.00 0.00
Total 1361 7.2 4.6 149 6.7 4.1 0.93 0.89
Nb duration 0 = before onset of first symptom.
1 = first day of first symptom.
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Table 6.10 Comparison of score and severity among vaccinated and
unvaccinated children, Niakhar 1987-1989.
Duration Unvaccinated children Vaccine failure Comparison vac/unvac
since
onset (N) mean st.dev. (N) mean st.dev. ratio T-test P (2T)
Score
1-7 250 10.7 4.37 37 10.5 3.32 0.98 -0.35 .7266
8-14 335 8.8 2.12 38 8.0 2.22 0.91 -2.14 .0130 *15-21 273 6.9 1.50 29 5.8 2.70 0.83 -2.31 .0216 *22-28 291 5.7 2.67 29 4.3 3.02 0.76 -2.36 .0190
*29-35 185 3.2 3.17 14 1.4 2.19 0.44 -2.96 .0034 *36-42 27 2.4 2.86 1 0.0 0.00 0.00 -4.44 .0001
*
Severity
1-7 250 8.7 3.75 36 8.0 3.23 0.92 -1.17 .2430
8-14 335 6.1 2.88 37 4.4 2.20 0.72 -4.45 1. 2E-5 *
15-21 273 3.7 1.82 29 2.8 1.43 0.75 -3.14 .0018 *
22-28 291 2.5 1.92 28 1.9 1.66 0.77 -1. 74 .0828
29-35 185 1.5 1.51 14 0.9 0.88 0.57 -2.57 .0110 *
36-42 27 0.8 0.90 1 0.0 0.00 0.00 -4.68 .0007 *
* P< 0.05
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Table 6.11 Frequence of diarrhea and ALRI among vaccinated and unvaccinated
children, Niakhar 1987-1989.
Duration Unvaccinated children Vaccine failure Comparison vac/unvac
since
onset (N) % mean (N) % mean ratio T-test P
diarrhea sever. diarrhea sever (2T)
Diarrhea
1-7 250 17.6 1.91 42 13.5 1.80 0.77 -0.70 .4844
8-14 335 9.9 1. 70 58 0.0 0.00 0.00 -6.05 3.4E-09 *15-21 273 7.3 1. 70 12 0.0 0.00 0.00 -4.65 9.3E-06 *22-28 291 6.5 1.95 11 10.3 2.00 1.58 0.41 .1152
29-35 185 3.2 1.67 3 0.0 0.00 0.00 -2.49 .0136 *36-42 27 0.0 0.00 0 0.0 0.00
Total 1361 9.0 1.81 126 5.4 1.88 0.54 -1.67 .0952
ALRI
1-7 250 16.8 1.81 42 0.0 0.00 0.00 -7.10 9.6E-12
8-14 335 17.3 1.84 58 7.9 1.67 0.46 -2.30 .0220 *15-21 273 4.4 1.67 12 0.0 0.00 0.00 -3.54 .0004 *
22-28 291 3.8 2.00 11 0.0 0.00 0.00 -3.38 .0008 *29-35 185 1.6 2.00 3 0.0 0.00 0.00 -1. 75 .0818
36-42 27 0.0 0.00 0 0.0 0.00
Total 1361 9.3 1.83 126 2.0 1.67 0.22 -4.90 1.1E-6 *
* P< 0.05
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Table 6.12 Analysis of score among cases according to major symptoms
associated and to date of examination (all cases examined),
Niakhar 1987-1989.
Clinical Measles cases examined Measles cases examined
score day 1-42 day 3-10
N major symptoms N major symptoms and analysis
0 164 none (after end) 1 after rash (day 9)
1 96 cough (94) 2 before rash (day 3)
2 16 various 2 before rash (n=9)
3 23 combinat ion 5 after rash (n=l)
4 10 without rash 2 rash not seen that day
5 7 3 but seen before or after (n=2)
6 186 rash only (180) 6 rash only (3) rash not seen (3)
7 705 rash+cough (700) 56 idem
8 40 rash+cough+ 9
9 201 stomatitis or 77 idem
10 25 conjunctivitis 20
11 175 or combinat ion 141
12 94 90
13 0 (impossible) 0 (impossible)
14 6 rash+koplik+ 4
15 20 other signs 19 idem
16 18 18
17 49 all possible 44
Total 1835 499
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Table 6.13 Maximum score obtained according to when examinations occurred
and to vaccination status, Niakhar 1987-1989.
Maximum
score
Unvaccinated children
day 1-42 day 3-10
Vaccinated children
day 1-42 day 3-10
susceptible
contacts
not infected
0-1 4 * 1 * 0 0 232
2-5 1 * 2 * 0 2 * 20
6-7 18 8 4 3 1
8-12 145 129 16 14 0
13-17 54 48 5 5 0
No exam 54 88 5 6 76
Total 276 276 30 30 329
, 8+ 89.6 94.1 84.0 79.2 0.0
, no exam 19.6 31.9 16.7 20.0 23.1
* See text for comments
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Table 6.14 Clusters of clinical symptoms among cases and contacts and
according to vaccination status (maximum signs in at least
one of the examinations), Niakhar 1987-1989.
Cluster of clinical
signs
cases among
unvaccinated
children
cases among
vaccinated
children
susceptible
contacts
not infected
Typical rash with cough 212 25 0
Typical rash without cough 5 0 0
Untypical rash 0 0 6
No rash, score>=6 0 0 0
None of above 7 * 0 323
No examination day 1-42 52 5 0
Total 276 30 329
* Children examined late without any symptom.
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Table 6.15 z Clinical confirmation of measles cases during repeated home visits,
Niakhar 1987-1989.
Nature of case Not
confirmed
Directly
confirmed
Indirectly
confirmed
Total ,
confirmed
AlI measles cases
OUtside study area 46 5 3 54 14.8
Index case 10 79 9 98 90.0
Secondary case 5 136 13 154 96.8
Total 61 220 25 306 80.1
, 19.9 71.9 8.2 100.0
Cases among
vaccinated children 8 21 1 30 73.3
Directly confirmed : score >= 8 during at least one examination
Indirectly confirmed : in contact with a confirmed case in same compound.
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Table 6.16 Geometrie mean levels of measles antibodies
during the course of clinical measles,
Niakhar 1987-1989.
Day 95 %
after onset N GMT confidence
of illness in miu interval
min max
< 02 152 79 68 90
03-04 26 393 161 963
05-06 27 903 330 2467
07-08 22 4986 1627 15279
09-10 15 11058 3175 38508
11-14 16 11314 3576 35793
15-21 6 90510 37120 220689
22-28 35 61521 31988 118319
29-35 148 89140 67035 118534
36-42 23 89140 43262 183670
43-49 9 29630 8463 103736
NB day 1 = day of onset of illness
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Table 6.17 distribution of antibody titers according to exposure status,
vaccine status and infection, Niakhar 1987-1989.
Antibody Measles cases Measles cases Contacts
Class levels sampled prior sampled after not infected
in miu to onset infection +/- 42 days
(0-42 to 02) (028 to 042) around exposure
Not Vacci- Not Vacci- Not Vacci-
vacc. nated vacc. nated vacc. nated
a < 125 107 8 1 * 1 * 38 14
1 125 3 a a a 3 a
2 250 2 a a a 5 2
3 500 3 1 a 1 6 6
4 1000 1 a a 1 12 22
5 2000 a a 5 a 13 22
6 4000 a a la 1 13 21
7 8000 a a 15 a 7 23
8 16000 a 1 12 a 4 17
9 32000 a a 8 2 8 13
la 64000 a a 15 4 2 8
11 128000 a a 35 6 3 3
12 256000 a a 1 1 a a
13 >=512000 a a 61 2 3 6
Total 116 la 163 19 117 157
GMT (miu) 75 250 50224 14341 948 3165
* 80th cases <125 were clinically confirmed;
one was serologically confirmed by another sample.
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Table 6.18: Rise in measles HI antibodies titers during the course of infection,
(second sample taken from day 15 to 42), children for whom
two samples were availab1e, Niakhar 1987-1989.
First sample
taken before day 3
Increase in
HI titers
from first to
second sample no vacc vacc
First sample
taken from day 3 to day 14
no vacc vacc
no increase a a 13 3
2 fold a a 4 2
4 fold a a 6 a
8 fold a a 3 a
16 fold a a 7 1
32 fold 4 a 7 a
64 fold 8 a 13 a
128 fold 8 a 9 a
256 fold 6 a 7 1
512 fold 5 a 8 1
1024 fold 9 5 la 5
2048 fold 20 2 23 4
4096 fold 1 a 1 a
8192 fold 38 1 43 1
Total 99 8 154 18
Geometrie mean 842 76 223 39
, 16+ fold 100 100 83.1 72.2
Day 1 onset of illness
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Table 6.19 serological confirmation and validation of measles cases,
Niakhar 1987-1989.
Nature of case Not
confirmed
Directly
confirmed
Indirectly
confirmed
Total %
confirmed
Directly confirmed
All measles cases . serological confirmation.
OUtside study area 51 2 1 54 5.6
Index case 33 48 17 98 66.3
Secondary case 27 109 18 154 82.5
Total 111 159 36 306 63.7
% 36.3 52.0 11.8 100.0
Cases among
vaccinated children 12 14 4 30 60.0
All measles cases : serological and clinical confirmation
OUtside study area 52 1 1 54 3.7
Index case 35 45 18 98 64.3
secondary case 32 95 27 154 79.2
Total 119 141 46 306 61.1
% 38.9 46.1 15.0 100.0
Cases among
vaccinated children 13 12 5 30 56.7
NB:
4+ fold increase in antibody titers during acute phase,
or -2 fold decrease after acute phase (2cases)
Indirectly confirmed : in contact with a confirmed case in same compound.
(for definitions of clinical signs, see table 6.15)
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Table 6.20 Sensitivity and specificity of various criteria for diagnosis,
Niakhar 1987-1990.
Criteria (N) Sensitivity Specificity
1) Typical rash (all cases) (307) 78.8 100.0
Typical rash (examined day 1-42) (242) 99.2 100.0
2) Koplik spots (all cases) (307) 25.4 100.0
Koplik spots (examined day 1-8) (196) 38.8 100.0
3) Score >= 8 (all cases) (307) 71.7 100.0
Score >=8 (examined day 3-10) (212) 92.4 100.0
4) 16 fold increase in AB (all cases) (307) 51.8 99.4
16 fold increase in AB (112) 100.0 99.1
(first<02, second >=028)
5) 4 fold increase in AB (all cases) (307) 60.9 99.5
4 fold increase in AB (112) 100.0 95.7
(first<02, second >=028)
6) Titer >= 16000 miu (all cases) (307) 57.6 67.5
Titer >= 16000 miu (after 028) (175) 82.3 96.6
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Table 7.1 Heas1es cases among project children according to vaccination
status and various characteristics, Niakhar 1987-1990.
vaccine failures Not
vaccinated Total
EZ-HT SW-HT Standard
(5 mo) (5 mo) (la me)
Total 5 5 1 57 68
Confirmation
Direct 1 2 a 16 19
Indirect 2 a a 5 7
Not confirmed 2 3 1 36 42
Residence statua
Resident 5 5 1 54 65
Not resident a a a 3 3
Exposure status in compound
Single, index 2 2 a 11 15
secondary 3 2 1 30 36
Outside study area a 1 a 16 17
Age
< la months 1 a a 18 19
>= la months 4 5 1 39 49
Sex
Hale 4 3 a 29 36
Female 1 2 1 28 32
Cohort
01-16 2 5 1 34 42
17-24 3 a 23 26
Seroconversion after
vaccination
Yes a a a
No a 4 4
Unknown 5 1 1 57 64
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Vaccine group
Table 7.2a: Cohort efficacy of three measles vaccines among project children,
between age 5 and 10 months, Niakhar 1987-1990,
(confirmed cases in parentheses).
Not
----------------------------- participant Total
l Cohorts 01-16
EZ-HT
(5 mol
SW-HT
(5 mol
Placebo
(5 mol
No children
Measles cases
Person-years
Incidence /1000
Cohort efficacy \
II Cohorts 17-24
No children
Measles cases
Person-years
Incidence /1000
Cohort efficacy \
Confidence interval
T
P
III Cohorts 01-24
No children
Measles cases
Person-years
Incidence /1000
Cohort efficacy \
Confidence interval
T
P
336
o
134.3
0.00
100.0
291
1
118.7
8.42
67.9
0-95.5
0.984
0.3256
627
1
253.1
3.95
79.6
0-97.1
1.451
0.1470
323
o
128.3
0.00
100.0
(0)
321
(0) 0
128.3
0.00
100.0
197
357
2
143.4
13.95
281
3
114.3
26.24
639
5
257.7
19.38
0.0
397
(0) 2
271.9
7.36
224
(0) 10
148.2
67.46
621
(0) 12
420.0
28.57
1413
(1) 4
677.9
5.90
796
(7) 14
381.3
36.72
2208
(8) 18
1059.2
16.99
(1)
(7 )
(8)
Vaccine group
Table 7.2b: Cohort efficacy of three meas1es vaccines among project chi1dren,
after 10 months, Niakhar 1987-1990,
(confirmed cases in parentheses).
Not
-------------- vaccinated Total
EZ-HT
(5mo)
SW-HT Standard
(5 mo) (10 mo)
l Cohorts 01-16
No chi1dren 322 304 469 233 1328
Meas1es cases 2 (2) 5 (2) 1 28 (11) 36 (15)
Person-years 644.2 621. 7 896.1 486.0 2648.0
Incidence /1000 3.10 8.04 1.12 57.62 13.59
Cohort efficacy % 94.6 86.0 98.1 0.0
Confidence interva1 77.4-98.7 63.8-94.6 85.8-99.7
T 3.991 4.056 3.876
P 7.4E-5 5.8E-5 1.lE-4
II COhorts 17-24
No chi1dren 281 317 145 743
Measles cases 2 (1) 0 9 (2) 11 (3)
Person-years 316.9 354.3 165.4 836.6
Incidence /1000 6.31 0.00 54.42 13.15
Cohort efficacy % 88.4 100.0 0.0
Confidence interval 46.2-97.5
T 2.756
P 0.0062
III COhorts 01-24
No chi1dren 603 304 786 378 2071
Measles cases 4 (3) 5 (2) 1 (0) 37 (13) 47 (18)
Person-years 961.1 621.7 1250.5 651.3 3484.6
Incidence /1000 4.16 8.04 0.80 56.81 13.49
Cohort efficacy % 92.7 85.8 98.6 0.0
Confidence interval 79.4-97.4 64.0-94.4 89.7-99.8
T 4.966 4.103 4.207
P 8.0E-7 4.6E-5 2.8E-5
IV Cohorts 01-24, confirmed cases only
Efficacy / 100 84.4 83.9 100.0 0.0
COnfidence interval 45.1-95.5 28.6-96.4
T 2.897 2.403
P 0.0038 0.0166
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Table 7.2c: Cohort efficacy of three measles vaccines among project children,
all ages, Niakhar 1987-1990,
(confirmed cases in parentheses).
Vaccine group
l Cohorts 01-16
EZ-HT
(5 mol
SW-HT
(5 mol
Standard
(10 mol
Not
vaccinated Total
No children
Measles cases
Person-years
Incidence /1000
Cohort efficacy ,
Confidence interval
T
P
II Cohortes 17-24
336
2
778.6
2.57
92.8
69.8-98.3
3.603
0.0004
323
(2) 5 (2)
750.0
6.67
81.2
51. 8-92.7
3.478
0.0006
357
1 (0)
896.1
1.12
96.9
77.0-99.6
3.407
0.0006
397
32
901.2
35.50
(ref)
1413
(12) 40
3325.9
12.03
(16)
No children
Measles cases
Person-years
Incidence /1000
Cohort efficacy ,
Confidence interval
T
P
III Cohortes 01-24
291
3 (1)
435.6
6.89
86.6
55.2-96.0
3.266
0.0012
281
o
354.3
0.00
100.0
224
22
427.9
51.41
0.0
(ref)
796
(9) 25 (10)
1217.8
20.53
No children
Measles cases
Person-years
Incidence /1000
Cohort efficacy ,
Confidence interval
T
P
Relative risk of
vaccine failure
627 323 638 621 2209
5 (3) 5 (2) 1 (0) 54 (21) 65 (26)
1214.2 750.0 1250.5 1329.4 4543.7
4.12 6.67 0.80 40.63 14.31
89.9 83.6 98.0 0.0
74.7-95.9 59.0-93.4 85.8-99.7
4.896 3.865 3.892
1.lE-6 1.2E-4 1.0E-4
5.15 8.34 (ref)
IV Cohortes 01-24, confirmed cases only
Cohort efficacy ,
Confidence interval
T
P
84.4
47.6-95.3
3.006
0.0026
83.1
28.0-96.0
2.404
0.0164
199
100.0 0.0
Table 7.3 Case-contact efficacy of three measles vaccines among project
children, Niakhar 1987-1990,
(confirmed cases in parentheses).
Vaccine received
l COhorts 01-16
EZ-HT
(5 mo)
SW-HT
(5 mo)
Standard
(10 mo)
Not
vaccinated
35
778.6
45.0
1 (1)
28.6
95.4
67.7-99.4
2.987
0.0042
1.00
No children exposed
Person-years at risk
Exposure rate / 1000
No secondary cases
Secondary attack rate/1000
Case-contact efficacy %
Confidence interval
T
P
RR of vaccine failure
II Cohorts 17-24
24
750.0
32.0
2 (1)
83.3
86.7
47.9-96.6
2.677
0.0102
2.92
35
896.1
39.1
1 (0)
28.6
95.4
67.7-99.4
2.987
0.0042
1.00
24
901.2
26.6
15
625.0
(ref)
(6 )
No children exposed
Person-years at risk
Exposure rate /1000
No secondary cases
Sec. attack rate /1000
Case contact efficacy %
Confidence interval
T
P
III Cohorts 01-24
18
435.6
41.3
2 (1)
111.1
83.7
37.9-95.7
2.410
0.0228
19
354.3
53.6
o
0.0
100.0
22
427.9
51.4
15 (7)
681.8
(ref)
(2)
No children exposed
Person-years at risk
Exposure rate /1000
No secondary cases
Sec. attack rate /1000
Case contact efficacy %
Confidence interval
T
P
RR of vaccine failure
53
1214.2
43.7
3
56.6
91.3
73.4-97.2
4.037
0.0001
3.06
24
750.0
32.0
2 (1)
83.3
87.2
51. 0-96. 7
2.817
0.0072
4.50
54
1250.5
43.2
1 (0)
18.5
97.2
80.0-99.6
3.504
0.0008
1.00
46
1329.2
34.6
30
652.2
(13)
IV Cohorts 01-24, confirmed cases only
Case contact efficacy %
Confidence interval
T
P
94.2
77.1-98.5
3.902
0.0001
93.6
56.0-99.1
2.706
0.0086
200
100.0
Table 7.4 Linear logistic analysis of the risk factors of vaccine failure,
among project children, (case-contact efficacy),
Niakhar 1987-1990.
Variable Odds
ratio
Estimate Standard T P
Error statistic (2 tail)
Constant -2.268 1.2133 -1.8700 0.0632
Vaccine
EZ-HT 0.0129 -4.354 0.8179 -5.3231 3.2E-7
*SW-HT 0.0317 -3.452 0.9306 -3.7095 2.0E-4
*Standard 0.0047 -5.367 1.1434 -4.6939 5.6E-6
*(ref=not vaccinated)
Age in months 1.050 0.049 0.0341 1.4372 0.1526
Sex (ref=male) 0.493 -0.708 0.5771 -1.2273 0.2214
Intensity of exposure 2.284 0.826 0.3708 2.2285 0.0272
*
NB: based on 34 secondary cases and 172 children exposed.
Log Likelihood: -46.455, X2 (6) = 78.113, P= E-13.
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Table 7.5 Measles cases among other children, according to vaccination
status, and various characteristics, Niakhar 1987-1990.
Vaccine failures other &
after standard vaccine Not unknown
vaccinated status
81-83 86-87 Else
Total 2 15 10 465 44
Confirmation
Direct 1 4 3 115 12
Indirect 0 3 0 42 4
Not confirmed 1 8 7 308 28
Residence status
Resident 2 15 10 452 41
Not resident 0 0 0 13 3
Exposure status in compound
Single, index 2 5 3 166 14
Secondary 0 7 5 268 27
Outside study area 0 3 2 31 3
Age
< 1 year 0 0 0 22 0
1-4 years 0 8 1 77 10
5-9 2 7 9 366 34
Sex
Male 1 5 4 238 17
Female 1 10 6 227 27
Duration since vaccination
< 5 years 0 15 6 0
5+ years 2 0 4 1
Not vaccinated 0 465 43
Age at vaccination
< 9 months 1 4 1 0
9+ months 1 11 9 1
Cohorts 1978-1986 1 15 10 332 38
81-83
86-87
ORSTOM vaccination in 8 villages
National EPI campaign
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Table 7.6 Cohort efficacy of standard measles vaccines, among children
born from 1978 to 1986, according to vaccination campaign,
Niakhar 1987-1990.
Vaccine failures other &
after standard vaccine Not unknown
vaccinated status
81-93 86-87 else
l A11 cases
No children 301 1190 635 3745 3435
Measles cases 1 15 8 307 60
Person-years at risk 821.9 3289.6 1557.2 9132.7 7914.7
Incidence /1000 1.22 4.56 5.14 33.62 7.58
Cohort efficacy % 96.4 86.4 84.7 (ref)
Confidence interval 74.2-99.5 77.2-91. 9 69.2-92.4
T 3.313 7.555 5.245
P 0.0010 1.0E-13 1. 7E-7
II Confirmed cases
Cohort efficacy % 92.9 87.6 88.8 (ref)
Confidence interval 49.4-99.0 73.6-94.2 64.9-96.4
T 3.308 7.144 4.906
P 0.0010 1.0E-13 9.8E-7
81-83
86-87
ORSTOM vaccination campaigns in 8 villages
National EPI campaign
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Table 7.7 Case-contact efficacy of standard measles vaccines among other
children, according to vaccination campaign, Niakhar 1987-1990.
Vaccine failures
after standard vaccine
l All cases
81-83 86-87 Else
Not
Vaccinated
other &
unknown
vaccination
status
No children exposed
No secondary cases
Sec. attack rate /1000
Case contact efficacy %
Confidence interval
T
p
II Confirmed cases
Case contact efficacy %
Confidence interval
T
p
10
o
0.0
100.0
100.0
156
7 (5)
44.9
92.5
84.5-96.4
6.766
3.2E-ll
94.6
87.3-97.7
6.485
1.9E-10
52
5 (2)
96.2
83.9
62.9-93.0
4.051
5.9E-5
93.6
74.9-98.4
3.867
l.2E-4
441 101
264 (101) 22 (9)
598.6 21.8
81-83
86-87
ORSTOM vaccination campaigns in 8 villages
National EPI campaign
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Table 7.8 Protective values of various levels of antibodies at time of
exposure in a compound, according to vaccination status,
(cases within study area, of known vaccine status),
Niakhar 1987-1989.
Antibody Secondary cases Contact Protective
C1ass 1eve1s samp1ed prior not infected value of
at time of to onset in compound antibody 1eve1
exposure
in miu Not Vacci- Not Vacci- Not Vacci-
vaccin. nated vaccin. nated vaccin. nated
0 < 125 88 7 31 14 26.1 66.7
1 125 3 0 1 2 25.0 100.0
2 250 3 0 4 2 57.1 100.0
3 500 2 0 3 5 60.0 100.0
4 1000 1 0 10 24 90.9 100.0
5 2000 0 0 14 18 100.0 100.0
6 4000 0 0 12 18 100.0 100.0
7 8000 0 0 7 20 100.0 100.0
8 16000 0 0 4 16 100.0 100.0
9 32000 0 0 8 11 100.0 100.0
10 64000 0 0 2 7 100.0 100.0
11 128000 0 0 3 2 100.0 100.0
12 256000 0 0 0 0 100.0 100.0
13 >=512000 0 0 3 6 100.0 100.0
Total 97 7 102 145
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ANNEX 1
LISTS OF CASES
A-1.1 LIST OF MEASLES DEATHS FROM AUGUST 1987 TO DECEMBER 1989.
During the study period, August 1987 to December 1989, the five measles
deaths were the following:
Death 1 : 06-199-58162 M 07/06/87 died on 20/02/89 (20 months) on day 11.
The child contracted measles in Dakar where he was with his mother.
He died on day 11 of acute diarrhea in Dakar. He was seen by a nurse there but
did not receive appropriate care. We learned about his death on June 28, 1989,
about four months later. The child was eligible for vaccination during the
project but his mother refused to bring him at 5 and 10 months when called.
Death 2 : 11-002-51266 F 30/01/84 died on 21/04/89 (5 years) at day 22.
She developed measles on 25 March 89; she was the index case in the
compound, infected in the village. She was seen by the physician on April 18 only
for the first time (day 19): she had high fever (39.5 "C), pneumonia and
laryngitis and a peor nutritional status; she was first treated at home with
antibiotics (Ceporexin) and aspirin and fever was down to 36.8"C the following
day. However her health worsened three days later and she was referred to the
Fatick hospital where she died during the night.
Death 3 : 11-002-20563 F 24/01/83 died on 25/04/89 (6 years) at day 10.
Same compound as death 2. She was a secondary case, infected by a boy
sleeping in the same hut. She was also seen on April 18 for the first time, at
day 3 of her measles. She was a deaf and dumb child with a poor nutritional
status (14 kg). On day 10 she developed acute diarrhea, laryngitis and pneumonia
and had epistaxis and cardiac arrythmia. She was treated with corticoid and
antibiotics (ampicillin) and was transferred to Dakar Fann hospital, where she
died during the night.
As for the previous case, this child was too young to have been
vaccinated in March 1983, the last major vaccination campaign in the study area
prior to 1986, and too old to be in the target group for the 1986 National
Vaccination campaign. Both could have been vaccinated during the project if they
had come spontaneously.
Death 4 : 16-031-60856 F 01/11/87 died on 03/09/89 (22 months) at day 14.
The child was infected in Dakar, she was sleeping in the same bed as
another girl, and developed measles on August 21. She came back to the study area
on the same day and was seen for the first time on August 30 by the physician.
She was severely malnourished and with severe anemia, she had an acute pneumonia
and cardiac arrythmia. She was treated with corticoid and antibiotics (Bactrim)
and supplemented in iron, in addition to standard treatment (Aspirin, Pyralvex,
Aureomycine, Mebendazole). The following day she was better and corticoid was
stopped. Her health worsened at night and she was transferred the following
morning to the Fatick hospital where she died at night.
She was an in-migrant in the study area, therefore she was not
eligible to be called by the team. She could have been vaccinated, had she come
spontaneously.
Death 5 : 17-051-58656 F 30/10/87 died on 03/10/89 (23 months) at day 13.
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Secondary case in compound, she was seen before the rash for the first
time on September 5; she developed measles on September 22, infected by a boy
living in the sarne hut; she was seen on September 29 with pneumonia; she was
treated with antibiotics (Ampicillin); the physician was notified that her health
had worsened on OCtober 3; unfortunately his car was not working that day and
we he carne to transfer her at night, the child was already dead.
The child was eligible for vaccination during the project but her
mother refused to bring her at the 3, 5 and 10 months sessions when called.
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A-l.2 LIST OF NON-CASES WITH AT LEAST 4 FOLO INCREASE IN ANTIBODY TITER
OR WITH VERY HIGH TlTERS DURING EXPOSURE TO MEASLES.
Case 1 : booster to a vaccinated chi1d
VC=01-007 Id=61439 M born 01/10/88 exposed 15/06/89 -> 08/07/89
vaccinated at 5 months with EZ-HT vaccine on 21/03/89
b100d samp1es R-21-045' 21/03/89 titer= 2 A 4
M-00-581 20/06/89 titer= 2 A 4 (non converter)
R-26-903 08/08/89 titer= 2 A 13 (booster)
Case 2 : booster to a vaccinated chi1d
VC=06-001 Id=54190 F
vaccinated at 8 mo with
b100d samp1es M-00-227
M-00-264
R-26-903
born 05/11/85 exposed 07/11/88 -> 04/01/89
standard vaccine on 28/07/86
10/01/89 titer= 2 A 8
03/02/89 titer= 2 A 12 (booster)
08/08/89 titer= 2 A 13 (booster confirmed)
Case 3 : high titer to a vaccinated chi1d
VC=20-003 Id=50319 M born 19/09/83 exposed 07/11/88
vaccinated at 3 years with standard vaccine on 20/12/86
b100d samp1es M-00-198 30/11/88 titer= 2 A 13 (high titer)
Case 4 : high titer to a vaccinated chi1d
Vc=20-003 Id=50319 M born 19/09/83 exposed 07/11/88
vaccinated at 3 years with standard vaccine on 20/12/86
b100d samp1es M-00-198 30/11/88 titer= 2 A 13 (high titer)
Case 5 : high titer to a chi1d who had meas1es ear1ier
Vc=20-014 Id=50321 F born 23/04/79 exposed 17/12/88 -> 28/12/88
had meas1es on 31/03/83
b100d samp1es M-00-216 20/12/88 titer= 2 A 12 (high titer)
Case 6 : 4 fo1d increase to a 3 months old chi1d
VC=20-014 Id=61200 F born 03/09/88 exposed 17/12/88 -> 28/12/88
vaccinated after exposure with EZ-HT vaccine on 16/02/89
b100d samp1es M-00-220 20/12/88 titer= 2 A O (no detectab1e)
R-20-030 16/02/89 titer= 2 A 4 (4 fo1d increase)
R-25-859 27/07/89 titer= 2 A 4 (not converter)
Case 7: booster to a vaccinated chi1d
VC=22-012 Id=57941 F
vaccinated at 6 months
b100d samp1es R-02-370
R-04-857
R-06-400
M-00-962
born 25/02/87 exposed 19/12/89
with the EZ-HT vaccine on 20/08/87
20/08/87 titer= 2 A l
29/10/87 titer= 2 A 3 (seroconverter)
10/12/87 titer= 2 A 5
27/12/89 titer= 2 A 13 (booster)
Case 8: high titer to a vaccinated chi1d
VC=22-012 Id=30734 M born 09/05/78 exposed 19/12/89
vaccinated at 3 years with the standard vaccine on 15/04/81
b100d samp1es M-00-959 27/12/89 titer= 2 A 13
Case 9: high titer to a vaccinated chi1d
VC=22-038 Id=31034 F born 10/01/78 exposed 25/11/89 -> 09/12/89
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vaccinated at 2 years with the standard vaccine on 15/05/80
blood samples K-00-819 30/11/89 titer~ 2 A 13
Case 10: high titer to child of unknown vaccination status
VC~22-040 Id=31066 K born 16/11/77 exposed 21/12/89 -> 30/12/89
unknown status
blood samples K-00-968 28/12/89 titer= 2 A 13
Case 11: high titer to a child of unknown status
VC=22-042 Id=31080 K born30/06/76 exposed 19/12/89 -> 18/12/89
unknown statua
blood samples K-00-857 15/12/89 titer= 2 A 13
Case 12: high titer to child of unkown previous measles status
VC=22-066 Id=52508 F born 03/04/84 exposed 14/11/89 -> 27/11/89
unknown prior measles status
blood samples K-00-782 21/11/89 titer= 2 A 13
Case 13: high titer to child of unknown vaccination statua
VC=22-098 Id=31844 K born 05/04/77 exposed 20/12/89 -> 30/12/89
unknown vaccination statua
blood samples K-00-953 20/12/89 titer= 2 A 13
Case 14: booster to vaccinated child
VC=22-107 Id=60441 F born 31/01/88 exposed 16/01/90
vaccinated with the EZ-HT vaccine at 5 months on 16/06/88
blood samples R-12-089 16/06/88 titer= 2 A 2
R-17-089 24/11/88 titer= 2 A 5 (seroconverter)
K-00-980 03/01/90 titer= 2 A O (decay)
K-01-378 24/01/90 titer= 2 A l0 (booster)
Case 15: high titer to vaccinated child
VC=23-035 Id=56824 K born 30/04/86 exposed 28/11/89 -> 07/12/89
vaccinated with standard vaccine on 08/01/87
blood samples K-00-828 01/12/89 titer= 2 A 13
Case 16: high titer to child of unknown statua
VC=23-035 Id=30988 K born 14/12/75 exposed 28/11/89 -> 07/12/89
unknown statua
blood samples K-00-884 20/12/89 titer= 2 A 13
Case 17: high titer to a child of unknown vaccinated statua
VC=23-070 Id=32494 F born 06/04/72 exposed 02/08/88 -> 16/08/88
unknown vaccination status
blood samples K-00-152 05/08/88 titer= 2 A 13
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A-1.3 VACCINE FAILURES AMONG PROJECT CHILDREN (1)
Case 1 : SW-HT
VC=29-020 Id=58087 M born 24/02/87 (cohort 01)
20/08/87;
titer(3)= 500 miu
titer(2)= 250 miu
titer(l)= 125 miu
or seroresponder;
Vaccinated at 25 weeks with SW-HTvaccine on
blood sample taken at vaccination R-02-390
2 blood samples taken on 29/10/87 R-04-946
. and on 10/12/87 R-06-456
does not fit the definitions of seroconverter
Developed measles on 22/10/88 (14 months after vaccination);
case outside of study area; no blood sample was taken;
seen at Diohine dispensary and in Pikine dispensary;
seem to have had a normal course of disease;
physician has seen desquamation + cough on 10/12/88 (J50);
not confirmed.
Case 2 : EZ-HT
Vc=31-020 Id=61507 M born 30/09/88 (cohort 20)
Vaccinated at 19 weeks with EZ-HT vaccine on 15/02/89;
blood sample taken at vaccination R-20-969 titer(4)=1000 miu;
no other blood sample at 10 months;
Developed measles on 13/05/89, 2 months after vaccination;
had a normal course of disease; maximum score= 9 (J5);
single case in compound; probably infected at the village well.
2 blood samples taken on 17/05/89 M-00-511 titer(3)=500 miu
and 09/06/89 M-00-562 titer(3)=500 miu
No evidence of increase in antibodies;
not confirmed.
Case 3 : EZ-HT
Vc=16-031 Id=60044 M born 29/12/87 (cohort 11)
Vaccinated at 21 weeks with EZ-HT vaccine on 25/05/88
blood sample taken at vaccination R-11-948 titer(2)= 250 miu
no other b100d sample at 10 months;
Developed measles on 31/08/89, 15 months after vaccination
had a normal course of disease although attenuated; maximum score=12 (J4);
Third case in compound, although co-index, probably infected by a visitor;
3 blood samples taken on 30/08/89 M-00-703 titer(3)= 500 miu
and 11/10/89 M-00-722 titer(13)=512000 miu
and 15/11/89 R-29-172 titer(13)=512000 miu
Directly confirmed.
Case 4 : SW-HT
VC=23-017 Id=60519 F born 09/04/88 (cohort 15)
Vaccinated at 21 weeks with SW-HT vaccine on 08/09/88;
blood sample taken at vaccination R-15-412 titer(2) c 250 miu
1 blood samples taken on 16/02/89 R-20-018 titer(l) = 125 miu
does not fit the definitions of seroconverter or seroresponder.
Developed measles on 26/11/89, 14 months after vaccination;
single case in the compound;
had a normal course of disease; maximum score= 17 (J6);
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2 blood samples taken on
Directly confirmed.
Case 5 : SW-HT
01/12/89 M-00-833
27/12/89 M-00-896
titer(3) = 500 miu
titer(ll)= 128,000 miu
Vc=21-035 Id=60528 F born 22/04/88 (cohort 15)
Vaccinated at 19 weeks with SW vaccine on 08/09/88;
blood sample taken at vaccination R-15-396 titer(O)< 125 miu
other blood sample at 10 months R-20-010 titer(l)= 125 miu
does not fit the definition of seroconverter;
Developed measles on 09/12/89, 15 months after vaccination;
had a normal course of disease; maximum score= 17 (J6);
secondary in compound (third case, generation B);
2 blood samples taken on 30/11/89 M-00-799 titer(O)< 125 miu
and 12/01/90 M-00-926 titer(ll)= 128,000 miu
Directly confirmed.
Case 6 : EZ-HT
Vc=21-035 Id=57885 M born 06/03/87 (cohort 02)
Vaccinated at 22 weeks with EZ vaccine on 13/08/87;
blood sample taken at vaccination R-01-205 titer(3)= 500 miu
other blood sample at 10 months R-05-180 titer(3)= 500 miu
other blood sample at 12 months R-07-559 titer(4)=1000 miu
does not fit the definition of seroconverter;
Developed measles on 21/12/89, 28 months after vaccination
had a normal course of disease although attenuated, maximum score=7 (J7);
secondary case in compound (seventh case, generation C);
2 blood samples taken on 30/11/89 M-00-800 titer(O)< 125 miu
and 17/01/90 M-00-942 titer(10)= 64,000 miu
Indirectly confirmed.
Case 7 : EZ-HT
Vc=16-023 Id=61356 F born 25/09/88 (cohort 20)
Vaccinated at 20 weeks with EZ-HT
blood sample taken at vaccination
and at 10 months
seroconverter statue unknown;
vaccine on
R-20-949
R-25-825
15/02/89;
titer(?)=
titer(?)=
Developed measles on 07/01/90 (6 months after vaccination);
secondary case in compound (sixth case, generation C);
had a normal course of disease, maximum score=7 (Jl0);
1 blood sample taken on 02/02/90 M-01-310 titer(13)=512,000 miu
Indirectly confirmed.
Case 8 : SW-HT
Vc=22-142 Id=60669 M born 19/05/88 (cohort 16)
Vaccinated at 22 weeks with SW-HT vaccine on 20/10/88;
blood sample taken at vaccination R-16-556 titer(O)< 125 miu;
and at 10 months R-21-146 titer(l)= 125 miu
does not fit the definition of seroconverter;
Developed measles on 16/01/90, 14 months after vaccination;
had a normal course of disease; maximum score= 9 (J5);
secondary case in compound (third case, generation B);
2 blood samples taken on 12/01/90 M-00-920 titer(O)< 125 miu
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and 13/02/90 H-01-340 titer(?)
evidence of increase in antibodies unknown;
Not confirmed.
Case 9 : SW-HT
Vc=17-080 Id=60269 H born 21/02/88 (cohort 13)
Vaccinated at 21 weeks with SW-HT vaccine on 20/07/88
blood sample taken at vaccination R-13-170 titer(4)= 1000 miu
and at 10 months R-18-722 titer(O)< 125 miu
does not fit the definitions of seroconverter or seroresponder.
Developed measles on 05/03/90, 19 months after vaccination
had a normal course of disease, maximum score=17 (J6);
Index case in compound, probably infected by
1 blood sample taken on 10/03/90 H-01-756 titer(?)
Not confirmed.
Case 10 : EZ-HT
VC=17-037 Id=61905 H born 26/12/88 (cohort 23)
Vaccinated at 20 weeks with EZ-HT vaccine on 17/05/89;
blood sample taken at vaccination R-23-415 titer(?)=
seroconverter status unknown;
Deve10ped measles on 26/03/90 (10 months after vaccination);
secondary case in compound (fourth case, generation B);
had a normal course of disease, maximum score=6 (J32);
1 blood sample taken on 21/03/90 H-01-699 titer(?)=
Not confirmed.
Case Il : Standard
VC=23-012 Id=57983 F born 04/04/87 (cohort 3)
Vaccinated at 45 weeks with the standard vaccine on 18/02/88;
blood sample taken at vaccination R-08-679 titer(O)< 125 miu
and at 25 months on 18/05/89 R-23-566 titer(?)
seroconverter status unknown;
Developed measles on 28/06/90 (14 months after vaccination);
secondary case in compound (fifth case, generation B);
had a normal course of disease, maximum score=ll (J8);
2 b100d samples taken on 21/06/90 H-02-551 titer(?)=
and on 26/07/90 H-02-125 titer(?)=
Not confirmed.
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A-1.3 LIST OF VACCINE FAILURES AMONG OTHER CHILDREN
Persona1 identification vaccination Meas1es Confirmation of case
Vi1-Conc Ident S Date of n Date
birth
Age Date
(mo)
Age Score B100d Confir
(ye) max samp1es mation
ORSTOM campaigns, 1981-1983
3 1 11614 F 21/04/80 1 27/02/82 22 07/05/89 9 7 3-> ? no
2 16/12/86 79 (revaccinated)
4 36 9692 F 08/10/77 1 02/03/83 64 12/02/90 12 11 ? no
8 7 12270 M 22/08/82 1 09/03/83 6 04/03/89 6 16 0-> 9 dir
National EPI campaign, 1986-1987
5 25 12347 F 11/11/82 1 31/12/86 49 11/06/89 6 10 ?-> 8 no
7 53 52121 M 29/01/84 1 17/02/87 36 06/03/90 6 7 ? no
8 7 54290 F 03/03/85 1 20/02/87 23 09/03/89 4 11 0->10 ind
8 7 56294 F 03/09/86 1 25/03/87 6 27/03/89 2 12 0-> ind
10 17 50308 F 01/06/83 1 16/02/87 44 18/10/89 6 16 ? ind
11 33 54382 F 29/05/85 1 13/03/87 21 10/05/89 3 ? ? no
17 31 56485 M 22/03/86 1 10/01/87 9 28/03/90 4 ? ? no
17 73 50811 M 29/12/83 1 10/01/87 36 16/03/90 6 17 ? no
19 154 56626 M 10/07/86 1 07/01/87 5 03/08/88 2 11 ?->13 no
20 3 56646 F 04/09/86 1 30/01/87 4 03/12/88 2 12 0->11 dir
20 14 50901 F 09/12/83 1 20/12/86 36 28/12/88 5 11 0->10 dir
21 127 56719 F 06/04/86 1 19/02/87 10 04/12/87 1 99 ? no
22 52 31225 F 31/05/83 1 26/12/86 42 02/09/89 6 12 0->11 dir
22 52 31229 M 30/03/83 1 26/12/86 44 04/09/89 6 12 0->11 dir
22 81 56762 F 16/08/86 1 08/01/87 4 22/02/90 3 11 ? no
ether Vaccinations
3 2 50281 F 04/06/83 1 03/09/85 27 18/05/89 5 11 6-> no
2 16/12/86 42 (revaccinated)
4 50 53912 F 25/09/82 1 21/03/86 41 28/05/89 6 9 0->10 dir
6 1 54190 F 05/11/85 1 28/07/86 8 04/01/89 3 11 8 12 dir
16 3 22801 F 17/07/78 1 01/04/83 56 19/02/89 10 12 0 ? no
16 24 23067 M 23/11/78 1 15/12/79 12 27/03/90 11 7 ? no
16 58 23438 M 06/07/78 1 08/04/83 57 26/02/89 10 7 ?-> 9 no
17 45 24987 F 26/12/78 1 15/03/83 50 29/03/90 11 17 ? no
21 102 52351 M 21/04/84 1 15/12/85 19 15/01/89 5 99 ? no
21 105 29927 F 15/07/82 1 15/12/85 41 15/01/89 7 99 ? no
22 3 30621 M 30/09/83 1 15/01/86 27 30/12/89 6 99 0->10 no
23 9 32548 F 15/11/80 1 11/11/83 35 19/07/88 7 11 0->13 dir
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ANNEX 2
VACCINES U'l'ILIZED : 1987-1989
1. Keas1es vaccines
Producer/ No Date Date No No Date No doses
Brand batch received expiry vials doses end not used
A) Project vaccines
Edmonston-Zagreb 81/3 15/03/87 30/06/89 750 Bl 23/06/89 0
(EZ-RT) 137 06/01/89 01/10/90 1400 Bl 30/10/90
Mérieux (SW-HT) 0980 15/03/87 30/11/88 750 Bl 30/10/88 487
Mérieux (Standard) 15/03/87 01/03/89 750 Bl 17/02/89
01/03/89 01/03/90 500 Bl
Mérieux (Placebo) 15/03/87 01/03/89 750 Bl 17/02/89
01/03/89 01/03/90 50 Bl0
B) other vaccines
RlMEVAX Ml02GllA 07/09/87 01/03/89 250 Bs 17/02/89 290
16/11/87 01/03/89 500 Bs 17/02/89
MORBILUAX 32A07 31/11/88 31/05/89 500 Bl0 19/05/89 360
32A02 26/04/89 13/06/90 500 Bl0
1. BCG vaccines
Producer/
Brand
No Date Date No No Date No doses
batch received expiry vials doses end not used
Pasteur FR 03A86
04A86
16sA86
162B86
10/08/87
07/09/87
16/11/87
27/10/88
10/11/88
26/04/89
01/06/89
01/06/89
01/06/89
01/04/90
216
500
200
800
1200
1000
500
Bl0 08/09/87
B20 15/03/88
B20 22/07/88
B20 14/02/89
B20 20/06/89
Bl0
400
3. DPTP vaccines
producer/
Brand
No
batch
Date
received
Date
expiry
No No Date No doses
vials doses end not used
Mérieux
B0022
B0022
BOI05
B1232
10/08/87 .
07/09/87
16/11/87
27/04/88
02/02/89
01/01/89
01/06/89
01/02/89
01/11/89
1500
400
1600
1200
2600
B20
B20
B20
B20
B20
18/01/88
18/10/88
18/10/88
27/01/89 120
4. Yellow-fever vaccines
producer/
Brand
No
batch
Date Date No No Date No doses
received expiry vials doses end not used
Pasteur-Dakar 1051 10/08/87 500 B20 24/11/87
1038 16/11/87 31/03/88 600 B20 15/03/88
1042 16/11/87 31/03/88 B20 15/02/88
1073 16/11/87 31/10/88 B20 22/07/88
1089 27/04/88 25/01/88 600 B20 13/12/88
1103 10/11/88 24/08/88 100 BI0
5. Tetanus-toxoid
Producer/ No
Brand batch
Behring 2701375
Berna 35892
Torlak Institute 147
162
Date
received
10/08/87
10/11/88
27/04/88
26/04/89
Date
expiry
03/09/89
07/11/89
01/07/89
01/10/90
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No
vials
1000
1000
1800
1800
No Date No doses
doses end not used
B20 17/07/88
B20 03/05/89
B20 11/01/89
B20
.ANNEX 3
MEDICAL DRUGS UTILIZED : 1987-1989
Name / DCI Date Number Cost Priee Origin Not
up-date received (CFA) /unit used
Ampicilline 07/89 18,968 234,171 12.34 MSF/LAS/SIP 1,000
Acide Acetyl-Salicylique
(500 mg) 07/89 23,000 31,842 1.38 MSF/SIP 8,000
(75 mg) 07/89 45,000 18,128 0.40 19,000
ButyI-scopolamine 08/88 200 6,340 31. 70 MSF 156
Chloroquine 07/89 63,000 163,723 2.59 MSF/SIP 4,000
Chloramphenicol 07/89 2,760 25,235 9.14 0
Co-trimoxazole 07/89 14,400 183,143 12.71 MSF/LAS 3,800
Dexamethasone 07/89 1,450 13,370 9.22 MSF/LAS 30
Diazepam 07/89 690 17,135 24.83 MSF/SIP 300
Fanasil 07/89 5,000 SIP 5,000
Acide Folique 07/89 10,400 11,640 1.12 MSF/LAS 100
Fumarate Fer 07/89 70,000 72,000 1.02 MSF/SIP 38,500
Griséofuline 07/89 3,000 11,385 3.79 MSF 2,000
Iduviran 07/89 44 20,057 455.84 LAS 0
Indométacine 08/88 1,020 855 0.85 MSF 750
Mebendazole 07/89 12,456 76,950 6.17 MSF/LAS 4,072
Metronidazole 07/89 19,000 82,000 4.31 MSF/LAS 3,340
Nystatine, 10000 07/89 5,000 28,625 5.72 MSF 1,700
Nystatine, 50000 07/89 1,200 13,790 11.49 MSF 900
Nystatine, pomade 07/89 150 25,028 166.85 MSF 97
Paluject 02/87 200 3,222 16.11 SIP 0
Peni-G 07/89 50 4,726 94.52 PNA 0
Phenobarbital 07/89 4,000 4,985 1.44 MSF 1,000
Praziquantel 07/89 240 49,530 206.37 MSF 120
Pyralvex 07/89 113 68,232 603.82 LAS 21
Retinol 07/89 200 5,850 2.92 LAS 0
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Name / DCI Date Number Cost Priee Origin Not
received (CFA) /unit used
Tetracycline 3% 07/89 990 146,433 147.91 MSF/SIP 261
Tetracycline 1% 07/89 2,090 166,120 79.48 MSF/SIP 150
Tetracycline 07/89 11,184 86,589 7.75 MSF/SIP 5,088
KMN04 07/89 7,632 PNA
Cotton 07/89 13,500 PNA
Compresses 07/89 18,805 PNA
Alcool 07/89 27,854 PNA/LAB
Sparadrah 07/89 30,140 PNA
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ANNEX 4
TECHNlCAL NOTE
computations of age :
Age in difference of months
Age in months = int«date
Age in weeks = int«date
Age in years = int«date
= (12*year+month) - (12*year+month of birth)
date of birth)/30.4375)
date of birth)/7)
date of birth)/365.25)
computations of periods at risk:
= sum(date of end - date of beginning)
= PDS/30.4375
= PDS/365.25
= Events / PYS
= n*RAT/(l+(n-a)*RAT)
= duration of period,
= mean duration lived by those who failed
PDS
PMS
PYS
RAT
(from rate)PRO
where n
a
Person-days at risk :
Person-months at risk:
Person-years at risk:
Rates
Probability
Computations of GMT in international units:
GMT = 62.5*2x
where x is the mean reciprocal of dilutions.
Coefficient of variations of rates and ratios:
Rate computed from PYS (m) CV2 = lIE
Probability (p) CV2 = (l-p)/E
Variance of logarithms of rates and ratios:
Log(rate)
Log (proba)
VAR = lIE
VAR = (l-p)/E
(where E is the number of events).
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ANNEX 5
LIST OF PERSONNEL
1) INVESTIGATORS
Michel Garenne, PhD. Project Director. Head UR population et santé. Senior
Researcher at ORSTOM, Dakar. Now Associate Professor of Demography, Harvard
School of Public Health. Boston.
Odile Leroy, MO, MA. Assistant Director. Member UR Population et Santé. ORSTOM.
Now Medical Officer, in charge of measles vaccines, Pasteur Mérieux, Paris.
Jean Pierre Beau, MO. Member UR population et santé. ORSTOM. Senior Researcher
at ORSTOM, Dakar. In charge of verbal autopsies and treatment of
malnourished children.
Ibra Sène, MO. Head Circonscription Médicale de Fatick, Senegal. In charge of
supervising the field work and treatment of sick children.
Hilton Whittle, MO. Senior researcher, Medical Research Council, Fajarah near
Banjul, The Gambia. In charge of the laboratory work.
Abdourahmane Sow, MO. Head Infectious Diseases Department, Fann Hospital, Dakar.
Now at WHO/GPA. In charge of case assessment and treatment of severely sick
children.
2) MEMBERS OF THE DATA MONITORING AND SAFETY COMMITTEE
AND OF THE SCIENTIFIC COMMITTEE (SC).
Ministry of Public Health, Senegal
Colonel Sy, Dr. Directeur de l'Hygiène et de la Protection Sanitaire. Dakar.
Commandant Fode Diouf. Chef du Service des Grandes Endémies. Dakar
Task Force for Child Survival
John V. Bennett, MO. Task Force for child Survival.
Hector Traverso, MO. Task Force for child Survival.
M. Giordano. Task Force for Child Survival (adm).
Tom Ortiz. Task Force for Child Survival (adm).
Roger Bernier, MO. Centers for Disease Control (SC).
Laury Markowitz, MO. Centers for Disease Control (SC).
ORSTOM representatives at DMSC
Mr Bernard Dalmayrac, Head Centre ORSTOM de Dakar.
Mr Galat, Senior researcher at ORSTOM, Dakar.
3) OTHERS AND CONSULTANTS
Olivier Fontaine, MO. Participated to the writing of the protocol.
Susan Zimicki, MPH. participated to the writing of the protocol.
Ibrahima Sarr, PhD. Head Census Bureau, Dakar.
Awa Marie Coll, MO. Replaced Dr Sow when he left in sept 1989.
Michel Cadoz, MO. Visited and invited at SC.
Peter Aaby. Visited and invited at DMSC.
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3) DAKAR STAFF
Michel Ndiaye
Takhy Diop
Emile Ndiaye
Antoine Ndour
Ousmane Ndiaye
Emilie Ndiaye
4) FIELD STAFF
FIELD PHYSICIANS AND MIDWIFE
Jean Paul Mouliat Pelat (Sep 87-Jul 89)
Ibra Sène (Jan 87-Aug 87)
Fred Mutika (Sep 87-OCt 87)
Ibrahima Diallo (Nov 87-Dec 87)
Badara Samb (Jan 88-0et 90)
Ablaye Yam (Mar 88-0ct 90)
Aminata Simaga (Mar 89-Jul 89)
Marie Emanuelle Ezan (Sep 89-OCt 90)
LABORATORY ASSISTANT
Frank Giry (Bioforee)
Tofène Ndiaye
SUPERVISORS
Ernest Faye
Pape Niokhor Diouf
FIELD WORKERS
Saliou Diouf
Ngor Sine
Samba Diatte
Bassirou Fall
Samba Diouf
Latyr Faye
Djib Diouf
El Hadj Diouf
Waly Diafate
OUsmane Faye
Abdou Diouf
Raphael Dogue
Moussa Sarr
DRIVERS
ousseynou Ndiaye
El Assane Faye
Etienne Ndong
OTHER NIAKHAR STAFF
Khady Sene
Marie Bakhoum
Pierre Tine
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Darou
Diokoul
Kalome Ndofane
Ngalagne Kop
Ngane Fissel
Ngayokheme
Sass Ndiafadji
Sob
Bary Ndondol
Datel
Lambaneme
Mbinondar
Mboyene
Ndokh
Ngangarlame
Nghonine
Poudaye
Toucar
Dame
Diohine
Gadiak
Godel
Khassous
Kothioh
Leme
Logdir
Keme
Kocane Ngouye
Ngardiame
Poultok Diohine
ANNEX 6
LIST OF VILLAGES OF THE STUDY AREA
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ANNEX 7
LABORATORY PROCEDURES
All samples were analyzed at the MRC laboratory in Fajarah, The Gambia.
The laboratory uses international standards for antibody assaye which have been
standardized against the WHO international reference preparation for measles
antibody.
The test used to measure decay of antibodies or change in antibody levels
following measles or exposure to measles was the measles hemagglutination
inhibition test (HAl). IgM and IgG measles antibodies were not tested separately
for previous experience using either HAl or ELISA methods to quantify these
classes of antibody have not proved helpful in differentiating primary vaccine
failure (i.e. no antibody response after vaccination) from secondary vaccine
failure (infection following a decline in antibody response after vaccination).
A micromethod was used. Sera obtained by fingerprick were taken into a
serum separator tube (Microtainer, Becton Dickinson), spun at 6000 9 for 3
minutes to separate serum from red cells and stored at - 16°C until used. Serum
was decomplemented in the microtainer tube at 56"C for 1/2 hour and thereafter
absorbed overnight in another tube with 1/3 volume of packed green monkey cells.
25 l of serum was diluted in an equal volume of phosphate Buffered saline (PBS)
containing 1% Bovine serum albumin and 0.1% sodium azide in non-sterile
microtiter plates. 25 l of phosphate buffered saline containing 4
hemagglutination units of Tween either extracted measles hemagglutinin
(Behringwerke) is added to an equal volume of each dilution of serum and
incubated at 37"C for 3 hours then 25 l of a 0.5% suspension of green monkey
cells is added to each of the wells. After standing for 3 hours at room
temperature the plates are 1eft overnight at 4"C and read by eye in the morning.
The starting dilution was 1:2, which detects 125 m.i.u measles HAl/ml.
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ANNEX 8
EXCERPTS FROM CONTRACT
Article VI. Proiect Officer
Roger Bernier, Lauri Markowitz and Hector Traveso are hereby designated
CO-Project Officers for this contract. Roger Bernier will serve as the Principal
Co-project Officer and is responsible for guiding the technical aspects of the
project collaboratively with the CO-Project Officers. The Co-project Officers
shall not make any commitments or authorize any changes which effect the contract
price, terms or conditions: any such changes shall be referred to the Contracting
Officer for action.
(NB: after 1988, John Bennett served as Principal Co-project Officer).
Article VI. Proiect Director
Work and services will be conducted under the direction of Michel Garenne.
The TFCS reserves the right to approve any necessary successor to the Project
Director.
Article xx. Data
A copy of the data tape will be given to the Project Officer at complet ion
of the study. All information of whatever nature resulting from work being
performed with the data collected under this contract will be submitted to the
Project Director for written approval prior to publication or dissemination.
Article XXI. Blood samples
Blood samples taken during the course of the study will remain property
of the contractor. Blood samples that will not be used for the direct interest
of the study will be made available to other researchers for further studies.
The use of these blood samples will be restricted to those whose project of
research has been accepted in written by the Project Director. A special
provision of blood samples will be made for use by the Project Officers. Al1
information of whatever nature resulting from work being performed with the blood
samples collected under this contract will be submitted to the Project Director
for written approval prior to publication or dissemination.
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